Modulators of calcium release-activated calcium channel

ABSTRACT

Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.

This application is a continuation of U.S. patent application Ser. No.15/635,268, filed Jun. 28, 2017, which is a continuation U.S. patentapplication Ser. No. 14/539,470, filed Nov. 12, 2014, now U.S. Pat. No.9,758,514, which is a continuation of U.S. patent application Ser. No.13/722,523, filed Dec. 20, 2012, now U.S. Pat. No. 8,921,364, which is acontinuation of U.S. patent application Ser. No. 12/899,416, filed Oct.6, 2010, now U.S. Pat. No. 8,377,970, which claims the benefit of IndianProvisional Patent Application Nos. 2439/CHE/2009 dated 8 Oct. 2009;2636/CHE/2009 dated 30 Oct. 2009; 158/CHE/2010 dated 25 Jan. 2010;1513/CHE/2010 dated 2 Jun. 2010; and 1514/CHE/2010 dated 2 Jun. 2010;and U.S. Provisional Patent Application No. 61/265,540 dated 1 Dec.2009, each of which is hereby incorporated by reference.

FIELD OF THE INVENTION

The present invention relates to calcium release-activated calcium(CRAC) channel inhibitors of formula I and pharmaceutically acceptablesalts thereof, methods for preparing them, pharmaceutical compositionscontaining them, and methods of treatment with them.

BACKGROUND OF THE INVENTION

The regulation of intracellular calcium is a key element in thetransduction of signals into and within cells. Cellular responses togrowth factors, neurotransmitters, hormones and a variety of othersignal molecules are initiated through calcium-dependent processes. Theimportance of calcium ion as a second messenger is emphasised by manydifferent mechanisms which work together to maintain calciumhomeostasis. Changes in intracellular free calcium ion concentrationrepresent the most wide-spread and important signalling event forregulating a plethora of cellular responses. A widespread route forcalcium ion entry into the cell is through store-operated channels(SOCs), i.e. many cell types employ store-operated calcium ion entry astheir principal pathway for calcium ion influx. This mechanism isengaged following calcium ion release from stores, where the depletedstores lead to activation of calcium release-activated calcium (CRAC)channels.

CRAC channels, a subfamily of store-operated channels, are activated bythe release of calcium from intracellular stores, particularly from theendoplasmic reticulum (ER). These channels are key factors in theregulation of a wide range of cellular function, including musclecontraction, protein and fluid secretion and control over cell growthand proliferation and hence play an essential role in various diseasessuch as immune disorders and allergic responses. Among severalbiophysically distinct store-operated currents the best characterizedand most calcium ion selective one is the CRAC current. Thus, CRACchannels mediate essential functions from secretion to gene expressionand cell growth and form a network essential for the activation ofimmune cells that establish the adaptive immune response. Recently twoproteins, stromal interaction molecule (STIM1) and CRAC Modulator 1(CRACM1 or Orai1), have been identified as the essential components thatfully reconstitute and amplify CRAC currents in heterologous expressionsystems with a similar biophysical fingerprint. In mammals, there existseveral homologs of these proteins: STIM1 and STIM2 in the endoplasmicreticulum and CRACM1, CRACM2, and CRACM3 in the plasma membrane.

CRAC currents were initially discovered in lymphocytes and mast cells,and at the same time have been characterized in various cell lines suchas S2 drosophila, DT40 B cells, hepatocytes, dendritic, megakaryotic,and Madin-Darby canine kidney cells. In lymphocytes and in mast cells,activation through antigen or Fc receptors initiates the release ofcalcium ion from intracellular stores caused by the second messengerinositol (1,4,5)-triphosphate (Ins(1,4,5)P₃), which in turn leads tocalcium ion influx through CRAC channels in the plasma membrane.Store-operated Ca²⁺ currents characterized in smooth muscle, A431epidermal cells, endothelial cells from various tissues, and prostatecancer cell lines show altered biophysical characteristics suggesting adistinct molecular origin.

For example, calcium ion influx across the cell membrane is important inlymphocyte activation and adaptive immune responses. [Ca²⁺]-oscillationstriggered through stimulation of the TCR (T-cell antigen receptor) havebeen demonstrated to be prominent, and appear to involve only a singlecalcium ion influx pathway, the store-operated CRAC channel. See, e.g.,Lewis “Calcium signalling mechanisms in T lymphocytes,” Annu. Rev.Immunol. 19, (2001), 497-521; Feske et al. “Ca⁺⁺ calcineurin signallingin cells of the immune system,” Biochem. Biophys. Res. Commun. 311,(2003), 1117-1132; Hogan et al. “Transcriptional regulation by calcium,calcineurin, and NFAT,” Genes Dev. 17, (2003) 2205-2232.

It is well established now that intracellular calcium plays an importantrole in various cellular functions, and that its concentration isregulated by calcium ion influx through calcium channels on the cellmembrane. Calcium ion channels, which are located in the nervous,endocrine, cardiovascular, and skeletal systems and are modulated bymembrane potential, are called voltage-operated Ca²⁺ (VOC) channels.These channels are classified into L, N, P, Q, R, and T subtypes.Excessive Ca²⁺ influx through the VOC channels causes hypertension andbrain dysfunction. In contrast, calcium ion channels on inflammatorycells, including lymphocytes, mast cells, and neutrophils, can beactivated regardless of their membrane potential. This type of calciumion channel has been reported to act in the crisis and exacerbation ofinflammation and autoimmune diseases. In the T cells, it has beenreported that the early stages of activation consist of pre- andpost-Ca²⁺ events. The stimulation of T cell receptors induces pre-Ca²⁺events, including the generation of IP3, followed by the release of Ca²⁺from the endoplasmic reticulum (ER). In post-Ca²⁺ events, depletion ofCa²⁺ in the ER induces the activation of CRAC channels, and capacitativeCa²⁺ influx through the CRAC channel sustains high intracellular Ca²⁺concentration ([Ca²⁺]i). This prolonged high [Ca²⁺]i activates cytosolicsignal transduction to produce lipid mediators (e.g., LTD₄), cytokines[e.g., interleukin-2 (IL-2)], and matrix metalloproteinases, whichparticipate in the pathogenesis of inflammation and autoimmune diseases.

These facts suggest that CRAC channel modulators can be useful for thetreatment of diseases caused by the activation of inflammatory cellswithout side effects observed in steroids. Since VOC channel modulatorswould cause adverse events in the nervous and cardiovascular systems, itmay be necessary for CRAC channel modulators to exhibit sufficientselectivity over VOC channels if they are to be used asanti-inflammatory drugs.

Accordingly, CRAC channel modulators have been said to be useful intreatment, prevention and/or amelioration of diseases or disordersassociated with calcium release-activated calcium channel including, butnot limited to, inflammation, glomerulonephritis, uveitis, hepaticdiseases or disorders, renal diseases or disorders, chronic obstructivepulmonary disease, rheumatoid arthritis, inflammatory bowel disease,vasculitis, dermatitis, osteoarthritis, inflammatory muscle disease,allergic rhinitis, vaginitis, interstitial cystitis, scleroderma,osteoporosis, eczema, allogeneic or xenogeneic transplantation, graftrejection, graft-versus-host disease, lupus erythematosus, type Idiabetes, pulmonary fibrosis, dermatomyositis, thyroiditis, myastheniagravis, autoimmune hemolytic anemia, cystic fibrosis, chronic relapsinghepatitis, primary biliary cirrhosis, allergic conjunctivitis, hepatitisand atopic dermatitis, asthma, Sjogren's syndrome, cancer and otherproliferative diseases, and autoimmune diseases or disorders, See, e.g.,International Publication Nos. WO 2005/009954, WO 2005/009539, WO2005/009954, WO 2006/034402, WO 2006/081389, WO 2006/081391, WO2007/087429, WO 2007/087427, WO 2007087441, WO 200/7087442, WO2007/087443, WO 2007/089904, WO 2007109362, WO 2007/112093, WO2008/039520, WO 2008/063504, WO 2008/103310, WO 2009/017818, WO2009/017819, WO 2009/017831, WO 2010/039238, WO 2010/039237, WO2010/039236, WO 2009/089305 and WO 2009/038775, and US Publication Nos.:US 2006/0173006 and US 2007/0249051.

CRAC channel inhibitors which have been identified include SK&F 96365(1), Econazole (2) and L-651582 (3).

However, these molecules lack sufficient potency and selectivity overVOC channels and hence are not suitable for therapeutic use.

Recent publications by Taiji et al. (European Journal of Pharmacology,560, 225-233, 2007) and Yasurio Yonetoky et al. (Bio. & Med. Chem., 16,9457-9466, 2008) describe a selective CRAC channel inhibitor codedYM-58483 that is capable of inhibiting T cell function and proposed tobe of some benefit in the treatment of inflammatory diseases includingbronchial asthma.

Yasurio Yonetoky et al. disclose YM-58483 to be selective for CRACchannels over the voltage operated channels (VOC) with a selective indexof 31.

Other CRAC channel modulators disclosed include various biaryl and/orheterocyclic carboxanilide compounds including for example PCT or USpatent applications assigned to Synta Pharmaceuticals viz. WO2005/009954, WO 2005/009539, WO 2005/009954, WO 2006/034402, WO2006/081389, WO 2006/081391, WO 2007/087429, WO 2007/087427, WO2007087441, WO 200/7087442, WO 2007/087443, WO 2007/089904, WO2007109362, WO 2007/112093, WO 2008/039520, WO 2008/063504, WO2008/103310, WO 2009/017818, WO 2009/017819, WO 2009/017831, WO2010/039238, WO 2010/039237, WO 2010/039236, WO 2009/089305 and WO2009/038775, US 2006/0173006 and US 2007/0249051.

Other patent publications relating to CRAC channel modulators includeapplications by Astellas, Queens Medical Centre, Calcimedica and othersviz., WO 2007/121186, WO 2006/050214, WO 2007/139926, WO 2008/148108,U.S. Pat. No. 7,452,675, US 2009/023177, WO 2007/139926, U.S. Pat. No.6,696,267, U.S. Pat. No. 6,348,480, WO 2008/106731, US 2008/0293092, WO2010/048559, WO 2010/027875, WO2010/025295, WO 2010/034011,WO2010/034003, WO 2009/076454, WO 2009/035818, US 2010/0152241, US2010/0087415, US 2009/0311720 and WO 2004/078995.

Further review and literature disclosure in the area of CRAC channelsincludes Isabella Derler et al., Expert Opinion in Drug Discovery, 3(7),787-800, 2008; Yousang G et al., Cell Calcium, 42, 145-156, 2007;Yasurio Yonetoky et. al., Bio. & Med. Chem., 14, 4750-4760, 2006; andYasurio Yonetoky et. al., Bio. & Med. Chem., 14, 5370-5383, 2006. All ofthese patents and/or patent applications and literature disclosures areincorporated herein by reference in their entirety for all purposes.

Cancer is a major public health problem in India, the U.S. and manyother parts of the world. Currently, 1 in 4 deaths in India is due tocancer. Lung cancer is the leading cause of cancer deaths worldwidebecause of its high incidence and mortality, with 5-year survivalestimates of ˜10% for non-small cell lung cancer (NSCLC). It has beenreported that further investigations on the mechanisms of tumorigenesisand chemoresistance of lung cancer are needed to improve the survivalrate (Jemal A, et al., Cancer Statistics, CA Cancer. J. Clin., 56,106-130, 2006). There are four major types of NSCLC, namely,adenocarcinoma, squamous cell carcinoma, bronchoalveolar carcinoma, andlarge cell carcinoma. Adenocarcinoma and squamous cell carcinoma are themost common types of NSCLC based on cellular morphology (Travis et al.,Lung Cancer Principles and Practice, Lippincott-Raven, N.Y., 361-395,1996). Adenocarcinomas are characterized by a more peripheral locationin the lung and often have a mutation in the K-ras oncogene (Gazdar etal., Anticancer Res., 14, 261-267, 1994). Squamous cell carcinomas aretypically more centrally located and frequently carry p53 gene mutations(Niklinska et al., Folia Histochem. Cytobiol., 39, 147-148, 2001).

The majority of NSCLCs are characterized by the presence of the rasmutation thereby rendering the patient relatively insensitive totreatment by known kinase inhibitors. As a result, current treatments oflung cancer are generally limited to cytotoxic drugs, surgery, andradiation therapy. There is a need for treatments which have fewer sideeffects and more specifically target the cancer cells, are lessinvasive, and improve the prognosis of patients.

The identification of lung tumor-initiating cells and associated markersmay be useful for optimization of therapeutic approaches and forpredictive and prognostic information in lung cancer patients.Accordingly, a need remains for new methods of predicting, evaluatingand treating patients afflicted with lung cancer.

There still remains an unmet and dire need for small molecule modulatorshaving specificity towards Stim1 and/or Orai1 in order to regulateand/or modulate activity of CRAC channels, particularly for thetreatment of diseases and disorders associated with the CRAC.

SUMMARY OF THE INVENTION

The present invention relates to compounds of formula (I), methods fortheir preparation, pharmaceutical compositions containing them, andmethods of treatment with them.

In particular, compounds of formula (I) and their pharmaceuticallyacceptable salts thereof are calcium release-activated calcium channelmodulators useful in the treatment, prevention, inhibition and/oramelioration of diseases or disorders associated with calciumrelease-activated calcium channel.

In one aspect, the present invention relates to a compound of formula(I):

or a tautomer thereof, prodrug thereof, N-oxide thereof,pharmaceutically acceptable ester thereof or pharmaceutically acceptablesalt thereof,wherein

Ring Hy represents

Ring Hy is optionally substituted with R′″;

R¹ and R² are the same or different and are independently selected fromCH₃, CH₂F, CHF₂, CF₃, substituted or unsubstituted C₍₃₋₅₎ cycloalkyl,CH₂—OR^(a), CH₂—NR^(a)R^(b), CN and COOH with the proviso that:

a) both R¹ and R² at the same time do not represent CF₃,

b) both R¹ and R² at the same time do not represent CH₃,

c) when R¹ is CF₃ then R² is not CH₃ and

d) when R¹ is CH₃ then R² is not CF₃;

Ring Ar represents:

T, U, V and W are the same or different and are independently selectedfrom CR^(a) and N;

Z¹, Z² and Z³ are the same or different and are independently selectedfrom CR^(a), CR^(a)R^(b), O, S and —NR^(a), with the proviso that atleast one of Z¹, Z² and Z³ represents O, S or —NR^(a);

L₁ and L₂ together represent —NH—C(═X)—, —NH—S(═O)_(q)—, —C(═X)NH—,—NH—CR′R″ or —S(═O)_(q)NH—;

A is absent or selected from —(CR′R″)—, O, S(═O)_(q), C(═X) and —NR^(a);

each occurrence of R′ and R″ are the same or different and areindependently selected from hydrogen, hydroxy, cyano, halogen, —OR^(a),—COOR^(a), —S(═O)_(q)—R^(a), —NR^(a)R^(b), —C(═X)—R^(a), substituted orunsubstituted C₍₁₋₆₎ alkyl group, substituted or unsubstituted C₍₁₋₆₎alkenyl, substituted or unsubstituted C₍₁₋₆₎ alkynyl, and substituted orunsubstituted C₍₃₋₅₎cycloalkyl, or R′ and R″, when directly bound to acommon atom, may be joined to form a substituted or unsubstitutedsaturated or unsaturated 3-6 member ring, which may optionally includeone or more heteroatoms which may be same or different and are selectedfrom O, NR^(a) and S;

R′″ is selected from hydrogen, hydroxy, cyano, halogen, —OR^(a),—COOR^(a), —S(═O)_(q)—R^(a), —NR^(a)R^(b), —C(═X)—R^(a), substituted orunsubstituted C₍₁₋₆₎ alkyl group, substituted or unsubstituted C₍₁₋₆₎alkenyl, substituted or unsubstituted C₍₁₋₆₎ alkynyl, and substituted orunsubstituted C₍₃₋₅₎cycloalkyl;

each occurrence of X is independently selected from O, S and —NR^(a);

Cy is selected from monocyclic substituted or unsubstituted cycloalkylgroup, monocyclic substituted or unsubstituted heterocyclyl, monocyclicsubstituted or unsubstituted aryl, and monocyclic substituted orunsubstituted heteroaryl;

each occurrence of R^(a) and R^(b) are the same or different and areindependently selected from hydrogen, nitro, hydroxy, cyano, halogen,—OR^(c), —S(═O)_(q)—R^(c), —NR^(c)R^(d), —C(═Y)—R, —CR^(c)R^(d)—C(═Y)—R,—CR^(c)R^(d)—Y—CR^(c)R^(d)—, —C(═Y)—NR^(c)R^(d)—,—NR^(c)R^(d)—C(═Y)—NR^(c)R^(d)—, —S(═O)_(q)—NR^(c)R^(d)—,—NR^(c)R^(d)—S(═O)_(q)—NR^(c)R^(d)—, —NR^(c)R^(d)—NR^(c)R^(d)—,substituted or unsubstituted alkyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted alkynyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl,substituted or unsubstituted cycloalkenyl, substituted or unsubstitutedheterocylyl, substituted or unsubstituted heterocyclylalkyl, substitutedor unsubstituted aryl, substituted or unsubstituted arylalkyl,substituted or unsubstituted heteroaryl, and substituted orunsubstituted heteroarylalkyl, or when R^(a) and R^(b) are directlybound to the same atom, they may be joined to form a substituted orunsubstituted saturated or unsaturated 3-10 membered ring, which mayoptionally include one or more heteroatoms which may be same ordifferent and are selected from O, NR^(c) and S;

each occurrence of R^(c) and R^(d) may be same or different and areindependently selected from hydrogen, nitro, hydroxy, cyano, halogen,substituted or unsubstituted alkyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted alkynyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted cycloalkylakyl,substituted or unsubstituted cycloalkenyl, substituted or unsubstitutedheterocyclic group, substituted or unsubstituted heterocyclylalkyl, orwhen two R^(c) and/or R^(d) substitutents are directly bound to the sameatom, they may be joined to form a substituted or unsubstitutedsaturated or unsaturated 3-10 membered ring, which may optionallyinclude one or more heteroatoms which are the same or different and areselected from O, NH and S;

each occurrence of Y is selected from O, S and —NR^(a); and

each occurrence of q independently represents an integer 0, 1 or 2;

with Proviso (e) that the compound of formula (I) is not:

-   N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-(difluoromethyl)-5-methyl-1H-pyrazole-3-carboxamide;-   N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl-4-nitro-1H-pyrazole-5-carboxamide;-   N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(1-ethyl-5-methyl-1H-pyrazol-4-yl)-5-isoxazolecarboxamide;-   N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4,5-dihydro-3-(2-methoxyphenyl)-5-isoxazolecarboxamide;-   N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-[4-(1,1-dimethylethyl)phenyl]-cyclopropanecarboxamide;-   N-[4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-pyridine    carboxamide;-   N-[4-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-pyridine    carboxamide; or-   N-benzyl-6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridazin-3-amine.

In one preferred embodiment, R¹ is cyclopropyl.

In one preferred embodiment, R² is CF₃.

According to one preferred embodiment, Hy is

Further preferred is a compound of formula (I) wherein Hy is

Further preferred is a compound of formula (I) wherein Hy is

According to one preferred embodiment, Ar is

Further preferred is a compound of formula (I) wherein Ar is

Further preferred is a compound of formula (I) wherein Ar is

According to one preferred embodiment, L₁ and L₂ together represent—NH—C(═O)—, —NH—S(═O)_(q)—, —C(═O)NH— or —NH—CH₂—.

According to one preferred embodiment, A is absent or selected from—(CR′R″)—, O, S(═O)_(q), C(═X) and —NR^(a). More preferably, A is —CH₂—,—CHMe- or —(CR′R″)—, where R′ and R″ are joined to form a substituted orunsubstituted saturated or unsaturated 3-6 member ring, which mayoptionally include one or more heteroatoms which are the same ordifferent and are selected from O, NR^(a) (such as NH) and S;

Further preferred is a compound of formula (I) wherein A is—CH₂—

Further preferred is a compound of formula (I) wherein A is—CH₂—, —CHMe—,

Further preferred is a compound of formula (I) wherein A is absent.

Further preferred is a compound of formula (I) wherein A is —CH₂—.

According to one preferred embodiment, Cy is

Further preferred is a compound of formula (I) wherein Cy is

Further preferred is a compound of formula (I) wherein Cy is

Further preferred is a compound of formula (I) wherein Cy is

Yet another embodiment is a compound having the formula (IA):

or a tautomer thereof, prodrug thereof, N-oxide thereof,pharmaceutically acceptable ester thereof, or pharmaceuticallyacceptable salt thereof, wherein the variables (e.g., R′″, R¹, R², T, U,V, W, L₁, L₂, A and Cy) are defined as described above in relation toformula (I), with the proviso that the compound of formula (IA) is notany of the compounds in Proviso ((a-e) defined above.

Further preferred is a compound of formula (IA-I)

or a tautomer thereof, prodrug thereof, N-oxide thereof,pharmaceutically acceptable ester thereof, or pharmaceuticallyacceptable salt thereof, wherein the variables (e.g., R′″, R¹, R² T, U,V, W, A and Cy) are defined as described above in relation to formula(I), with the proviso that the compound of formula (IA) is not any ofthe compounds in Proviso (a-e) defined above.

Further preferred is a compound of formula (IA-I)

or a tautomer thereof, prodrug thereof, N-oxide thereof,pharmaceutically acceptable ester thereof, or pharmaceuticallyacceptable salt thereof, wherein

R¹ and R² are the same or different and are independently selected fromCH₂F, CHF₂, CF₃ and cyclopropyl; with the proviso that

a) both R¹ and R² at the same time do not represent CF₃,;

R′″ is hydrogen or halogen;

T, U, V, W are independently CR^(a) or N;

R^(a) is hydrogen or halogen;

A is absent; and

Cy is selected from monocyclic substituted or unsubstituted aryl ormonocyclic substituted or unsubstituted heteroaryl,

with the proviso that the compound of formula (IA) is not any of thecompounds in Proviso (e) defined above.

Further preferred is a compound of formula (IA-I) wherein both R¹ and R²represent cyclopropyl.

Further preferred is a compound of formula (IA-I) wherein one of R¹ andR² is CF₃ and the other is cyclopropyl.

Further preferred is a compound of formula (IA-I) wherein R¹ iscyclopropyl and R² is CF₃.

Further preferred is a compound of formula (IA-I) wherein T, U, V, W areCH, CF or N.

Further preferred is a compound of formula (IA-I) wherein T is CF or Nand each of U, V and W is CH.

Further preferred is a compound of formula (IA-I) wherein each of T andV is CF or N and each of U and W is CH.

Further preferred is a compound of formula (IA-I) wherein A is absent

Further preferred is a compound of formula (IA-I) wherein Cy is selectedfrom

Further preferred is a compound of formula (IA-I) wherein Cy is

Yet another embodiment is a compound having the formula (IA-III)

or a tautomer, prodrug, N-oxide, pharmaceutically acceptable ester, orpharmaceutically acceptable salt thereof,

wherein

R¹ and R² are the same or different and are independently selected fromCH₂F, CHF₂, CF₃, Cyclopropyl with the proviso that both R¹ and R² at thesame time do not represent CF₃;

T and V are the same or different and are independently selected from CFand N;

Each of U and V is CR^(a);

L₁ and L₂ together represent —NH—C(═X)—, —NH—S(═O)_(q)—, —C(═X)NH—, or—S(═O)_(q)NH— or —NH—CR′R″—;

A is absent or selected from —(CR′R″)— and —NR^(a);

each occurrence of R′ and R″ are the same or different and areindependently selected from hydrogen or substituted or unsubstitutedC₍₁₋₆₎ alkyl group or R′ and R″ may be joined to form a substituted orunsubstituted saturated or unsaturated 3-6 membered ring, which mayoptionally include one or more heteroatoms which may be same ordifferent and are selected from O, NR^(a) and S;

R′″ is selected from the group consisting of hydrogen, or halogen

each occurrence of X is independently selected from O, S and —NR^(a);

Cy is selected from monocyclic substituted or unsubstitutedheterocyclyl, monocyclic substituted or unsubstituted aryl, andmonocyclic substituted or unsubstituted heteroaryl.

each occurrence of R^(a) and R^(b) are the same or different and areindependently selected from hydrogen, nitro, hydroxy, cyano, halogen,—OR^(c), —S(═O)_(q)—R^(c), —NR^(c)R^(d), —C(═Y)—R,—CR^(c)R^(d)—C(═Y)—R^(c), —CR^(c)R^(d)—Y—CR^(c)R^(d)—,—C(═Y)—NR^(c)R^(d)—, —NR^(c)R^(d)—C(═Y)—NR^(c)R^(d)—, —S(═O),—NR^(c)R^(d)—, —NR^(c)R^(d)—S(═O)_(q)—NR^(c)R^(d)—,—NR^(c)R^(d)—NR^(c)R^(d)—, substituted or unsubstituted alkyl,substituted or unsubstituted alkenyl, substituted or unsubstitutedalkynyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl,substituted or unsubstituted heterocylyl, substituted or unsubstitutedheterocyclylalkyl, substituted or unsubstituted aryl, substituted orunsubstituted arylalkyl, substituted or unsubstituted heteroaryl, andsubstituted or unsubstituted heteroarylalkyl, or when R^(a) and R^(b)substitutent are directly bound to the same atom, they may be joined toform a substituted or unsubstituted saturated or unsaturated 3-10 memberring, which may optionally include one or more heteroatoms which may besame or different and are selected from O, NR^(c) and S;

each occurrence of R^(c) and R^(d) may be same or different and areindependently selected from the group consisting of hydrogen, nitro,hydroxy, cyano, halogen, substituted or unsubstituted alkyl, substitutedor unsubstituted alkenyl, substituted or unsubstituted alkynyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedcycloalkylakyl, substituted or unsubstituted cycloalkenyl, substitutedor unsubstituted heterocyclic group, substituted or unsubstitutedheterocyclylalkyl, or when two R^(c) and/or R^(d) substitutents aredirectly bound to the same atom, they may be joined to form asubstituted or unsubstituted saturated or unsaturated 3-10 member ring,which may optionally include one or more heteroatoms which are the sameor different and are selected from O, NH and S;

each occurrence of Y is selected from O, S and —NR^(a); and

each occurrence of q independently represents 0, 1 or 2.

Further preferred is a compound of formula (IA-III) wherein both R¹ andR² represent cyclopropyl.

Further preferred is a compound of formula (IA-III) wherein one of R¹and R² is CF₃ and the other is cyclopropyl.

Further preferred is a compound of formula (IA-III) wherein one of R¹and R² is CF₃ and the other is CH₂F, CHF₂.

Further preferred is a compound of formula (IA-III) wherein R¹ iscyclopropyl and R² is CF₃.

Further preferred is a compound of formula (IA-III) wherein T is CF orN.

Further preferred is a compound of formula (IA-III) wherein U, V, W areCH, CF or N.

Further preferred is a compound of formula (IA-III) wherein L₁ and L₂together represent —NH—C(═O)—, C(═O)NH— or —NH—CH₂—;

Further preferred is a compound of formula (IA-III) wherein A is absent,—NH— or —CH₂—.

Further preferred is a compound of formula (IA-III) wherein Cy isselected from

Further preferred is a compound of formula (IA-III) wherein Cy isselected from

Representative compounds of the present invention include thosespecified below and in Table 1 and pharmaceutically acceptable saltsthereof. The present invention should not be construed to be limited tothem.

-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-4-methylthiazole-5-carboxamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2,4-dimethylthiazole-5-carboxamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-5-methylisoxazole-4-carboxamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-3,5-dimethylisoxazole-4-carboxamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]benzamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-methylbenzamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2,6-difluorobenzamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2,3-difluorobenzamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl-3-(methylsulfonyl)benzamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-4-(methylsulfonyl)benzamide-   2-chloro-N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-5-(methylthio)benzamide-   2-chloro-N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl)-5-(methylsulfonyl)benzamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]nicotinamide    hydrochloride-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]isonicotinamide    hydrochloride-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-3-fluoroisonicotinamide-   3,5-dichloro-N-(4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl)isonicotinamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-4-methylpyrimidine-5-carboxamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-phenylacetamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(4-fluorophenyl)acetamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-1-phenylcyclopropanecarboxamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(pyridin-2-yl)    acetamide hydrochloride-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(pyridin-3-yl)acetamide    hydrochloride-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(pyridin-4-yl)acetamide    hydrochloride-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(piperazin-1-yl)acetamide    hydrochloride-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-morpholinoacetamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]benzenesulfonamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-4-methylthiazole-5-carboxamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-3,5-dimethylisoxazole-4-carboxamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-2-methylbenzamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-2,3-difluorobenzamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-2,6-difluorobenzamide-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]nicotinamide    hydrochloride-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]isonicotinamide    hydrochloride-   N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-4-methylpyrimidine-5-carboxamide-   N-[4-(4-chloro-3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide-   N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamide    hydrochloride-   N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-4-methylthiazole-5-carboxamide    hydrochloride-   N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2,4-dimethylthiazole-5-carboxamide-   N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-3,5-dimethylisoxazole-4-carboxamide-   6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-N-o-tolylnicotinamide-   N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-fluorobenzamide-   N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2,3-difluorobenzamide    hydrochloride-   N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2,6-difluorobenzamide    hydrochloride-   N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]nicotinamide    dihydrochloride-   N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]isonicotinamide    dihydrochloride-   N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-3-fluoroisonicotinamide-   3,5-dichloro-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}isonicotinamide-   3,5-dichloro-N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]isonicotinamide    hydrochloride-   N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-4-methylpyrimidine-5-carboxamide    hydrochloride-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methyl-1,2,3-thiadiazole-5-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-N,4-dimethylthiazole-5-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2,4-dimethylthiazole-5-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-5-methylisoxazole-4-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,5-dimethylisoxazole-4-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-1-methyl-1H-imidazole-2-carboxamide-   N-{4-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methyl-1H-imidazole-5-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-methylbenzamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2,3-difluorobenzamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2,6-difluorobenzamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-(methylsulfonyl)benzamide-   2-chloro-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-5-(methylthio)benzamide-   2-chloro-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-5-(methylsulfonyl)benzamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}pyridine-4-carboxamide    hydrochloride-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-fluoro    isonicotinamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methylpyrimidine-5-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2,4-dimethyl    pyrimidine-5-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(4-fluorophenyl)acetamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(pyridin-2-yl)acetamide    hydrochloride-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(pyridin-3-yl)acetamide    hydrochloride-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(pyridin-4-yl)acetamide    hydrochloride-   4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-[(4-methylthiazol-5-yl)methyl]aniline-   1-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-(4-methyl-1,2,3-thiadiazol-5-yl)urea-   1-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-(4-methylthiazol-5-yl)urea-   1-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazo-1-yl]phenyl}-3-(4-methylpyrimidin-5-yl)urea-   4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-methylthiazol-5-yl)benzamide-   4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,6-difluorophenyl)benzamide-   N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide-   N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(pyridin-2-yl)acetamide    hydrochloride-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methyl-1,2,3-thiadiazole-5-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methylthiazole-5-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-5-methylisoxazole-4-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-3,5-dimethylisoxazole-4-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2-methylbenzamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2,3-difluorobenzamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2,6-difluorobenzamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}nicotinamide    hydrochloride-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}isonicotinamide    hydrochloride-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1l-yl]-3-fluorophenyl}-3-fluoroisonicotinamide    3,5-dichloro-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}isonicotinamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methylpyrimidine-5-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-N,4-dimethylpyrimidine-5-carboxamide-   N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methyl-1,2,3-thiadiazole-5-carboxamide-   N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2-(pyridin-2-yl)acetamide    hydrochloride-   1-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-3-(4-methylpyrimidin-5-yl)urea-   N-{4-[5)-cyclopropyl-3-(trifluromethyl)-1H-pyrazol-1-yl]3-flurophenyl}-2,6-dichloro    benzamide-   4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)-3-fluorobenzamide-   4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,6-difluorophenyl)-3-fluorobenzamide-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-4-methyl-1,2,3-thiadiazole-5-carboxamide-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-4-methylthiazole-5-carboxamide    hydrochloride-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3,5-dimethylisoxazole-4-carboxamide-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2-methylbenzamide-   2-chloro-N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}benzamide    hydrochloride-   N-(6-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-fluorobenzamide-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2,3-difluorobenzamide-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2,6-difluorobenzamide-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}picolinamide-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-methylpicolinamide-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}nicotinamide    hydrochloride-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2-methylnicotinamide    hydrochloride-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}isonicotinamide    hydrochloride-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide-   3,5-dichloro-N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}isonicotinamide-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-4-methylpyrimidine-5-carboxamide-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2-(pyridin-2-yl)acetamide    hydrochloride-   N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2-(pyridin-4-yl)acetamide    hydrochloride-   N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methylpyrimidine-5-carboxamide-   1-{6-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-4    methylthiazol-5-yl)urea-   6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)    nicotinamide-   6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,6-difluorophenyl)    nicotinamide-   N-{6-[4-chloro-5-cyclopropyl-3-trifluoromethyl-1H-pyrazol-1-yl]pyridin-3-yl}-4-methylthiazole-5-carboxamide-   N-{2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-5-yl}-2,6-difluorobenzamide-   N-{4-[5-(fluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide-   N-{4-[5-(difluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide-   3,5-dichloro-N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]isonicotinamide-   N-(2-chloro-6-fluorophenyl)-4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorobenzamide-   N-{2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-5-yl}-4-methylthiazole-5-carboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-difluorophenyl}-4-methylpyrimidine-5-carboxamide-   {4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-1-phenylcyclobutanecarboxamide-   N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methyloxazole-5-carboxamide-   N-{2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-5-yl}-4-methylpyrimidine-5-carboxamide-   4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluoro-N-(4-methylpyrimidin-5-yl)benzamide    or-   N-{4-[3-cyclopropyl-5-(difluoromethyl)-1H-pyrazo    l-yl]-3-fluorophenyl}-2,6-difluorobenzamide and    N-{4-[5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2,6-difluorobenzamide    or a tautomer, prodrug, N-oxide, pharmaceutically acceptable ester,    or pharmaceutically acceptable salt thereof.

TABLE 1  1

 2

 3

 4

 5

 6

 7

 8

 9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100 

101 

102 

103 

104 

105 

106 

107 

108 

109 

110 

111 

112 

113 

114 

115 

116 

117 

118 

119 

120 

121 

122 

123 

124 

125 

126 

127 

128 

129 

130 

131 

132 

133 

134 

135 

The compounds of the present invention (e.g., compounds of formulas I,IA, IA-I, and/or IA-III including their pharmaceutically acceptableesters and salts) are useful for the treatment, prevention, inhibition,and/or amelioration of diseases and disorders associated with calciumrelease-activated calcium (CRAC) channel.

Another embodiment of the present invention is a method for treating adisease or disorder via modulation of CRAC channels by administering toa patient in need of such treatment an effective amount of a compound ofthe present invention (e.g., a compound of formula I, IA, IA-I, and/orIA-III as defined above).

Yet another embodiment of the present invention is a method for treatinga disease or disorder via modulation of CRAC channels by administeringto a patient in need of such treatment an effective amount of a compoundof the present invention (e.g., a compound of formula I, IA, IA-I,and/or IA-III as defined above), in combination (simultaneously orsequentially) with at least one other anti-inflammatory agent.

The compounds of the present invention may inhibit store operatedcalcium entry, interrupt the assembly of SOCE units, alter thefunctional interactions of proteins that form store operated calciumchannel complexes, and alter the functional interactions of STIM1 withOrai1. These compounds are SOC channel pore blockers, and are CRACchannel pore blockers.

The compounds described herein modulate intracellular calcium and areused in the treatment of diseases, disorders or conditions wheremodulation of intracellular calcium has a beneficial effect. In oneembodiment, the compounds described herein inhibit store operatedcalcium entry. In one embodiment, the compounds of the present inventioncapable of modulating intracellular calcium levels interrupt theassembly of SOCE units. In another embodiment, the compounds of thepresent invention capable of modulating intracellular calcium levelsalter the functional interactions of proteins that form store operatedcalcium channel complexes. In one embodiment, the compounds of thepresent invention capable of modulating intracellular calcium levelsalter the functional interactions of STIM1 with Orai1. In otherembodiments, the compounds of the present invention capable ofmodulating intracellular calcium levels are SOC channel pore blockers.In other embodiments, the compounds of the present invention capable ofmodulating intracellular calcium levels are CRAC channel pore blockers.

In one aspect, the compounds of the present invention capable ofmodulating intracellular calcium levels inhibit the electrophysiologicalcurrent (I_(SOC)) directly associated with activated SOC channels. Inone aspect, compounds capable of modulating intracellular calcium levelsinhibit the electrophysiological current (I_(CRAC)) directly associatedwith activated CRAC channels.

The compounds of the present invention are useful in the treatment ofdiseases, conditions or disorders that benefit from modulation ofintracellular calcium, including, but not limited to, an immunesystem-related disease (e.g., an autoimmune disease), a disease ordisorder involving inflammation (e.g., asthma, chronic obstructivepulmonary disease, rheumatoid arthritis, inflammatory bowel disease,glomerulonephritis, neuroinflammatory diseases, multiple sclerosis,uveitis and disorders of the immune system), cancer or otherproliferative disease, hepatic diseases or disorders, and renal diseasesor disorders. In one embodiment, the compounds described herein are usedas immunosuppresants to prevent (or inhibit) transplant graftrejections, allogeneic or xenogeneic transplantation rejection (organ,bone marrow, stem cells, other cells and tissues), and/orgraft-versus—host disease. For instance, the compounds of the presentinvention can be used to prevent (or inhibit) transplant graftrejections result from tissue or organ transplants. The compounds of thepresent invention can also be used to prevent (or inhibit)graft-versus-host disease resulting from bone marrow or stem celltransplantation.

More particularly, the compounds of formula I, IA, IA-I, and/or IA-IIIare useful in the treatment of a variety of inflammatory diseasesincluding, but not limited to, inflammation, glomerulonephritis,uveitis, hepatic diseases or disorders, renal diseases or disorders,chronic obstructive pulmonary disease, rheumatoid arthritis,inflammatory bowel disease, vasculitis, dermatitis, osteoarthritis,inflammatory muscle disease, allergic rhinitis, vaginitis, interstitialcystitis, scleroderma, osteoporosis, eczema, allogeneic or xenogeneictransplantation, graft rejection, graft-versus-host disease, lupuserythematosus, type I diabetes, pulmonary fibrosis, dermatomyositis,thyroiditis, myasthenia gravis, autoimmune hemolytic anemia, cysticfibrosis, chronic relapsing hepatitis, primary biliary cirrhosis,allergic conjunctivitis, hepatitis and atopic dermatitis, asthma andSjogren's syndrome

The compounds described herein modulate an activity of, modulate aninteraction of, or bind to, or interact with at least one portion of aprotein in the store operated calcium channel complex. In oneembodiment, the compounds described herein modulate an activity of,modulate an interaction of, or bind to, or interact with at least oneportion of a protein in the calcium release activated calcium channelcomplex. In one embodiment, the compounds described herein reduce thelevel of functional store operated calcium channel complexes. In anotherembodiment, the compounds described herein reduce the level of activatedstore operated calcium channel complexes. In a further embodiment, thestore operated calcium channel complexes are calcium release activatedcalcium channel complexes.

The compounds of the present invention which are capable of modulatingintracellular calcium levels for treatment of a disease or disorder,when administered to a subject having a disease or disorder, effectivelyreduce, ameliorate or eliminate a symptom or manifestation of thedisease, condition or disorder. In other embodiments, the compoundsdescribed herein are administered to a subject predisposed to a disease,condition or disorder that does not yet manifest a symptom of thedisease, condition or disorder, and prevents or delays development ofthe symptoms. In further embodiments, the compound of the presentinvention has such effects alone or in combination with other agents, orfunctions to enhance a therapeutic effect of another agent.

Due to the key role of calcium in the regulation of cellularproliferation in general, calcium channel inhibitors could act asreversible cytostatic agents which may be useful in the treatment of anydisease process which features abnormal cellular proliferation, e.g.,benign prostatic hyperplasia, familial adenomatosis polyposis,neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis,psoriasis, glomerulonephritis, restenosis following angioplasty orvascular surgery, hypertrophic scar formation, inflammatory boweldisease, transplantation rejection, endotoxic shock, and fungalinfections.

The compounds of the present invention, as modulators of apoptosis, areuseful in the treatment of cancer (including, but not limited to, thosetypes mentioned herein above), viral infections (including, but notlimited, to herpevirus, poxvirus, Epstein-Barr virus, Sindbis virus andadenovirus), prevention of AIDS development in HIV-infected individuals,autoimmune diseases (including, but not limited, to systemic lupus,erythematosus, autoimmune mediated glomerulonephritis, rheumatoidarthritis, psoriasis, inflammatory bowel disease, and autoimmunediabetes mellitus), neurodegenerative disorders (including, but notlimited to, Alzheimer's disease, AIDS-related dementia, Parkinson'sdisease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinalmuscular atrophy and cerebellar degeneration), myelodysplasticsyndromes, aplastic anemia, ischemic injury associated with myocardialinfarctions, stroke and reperfusion injury, arrhythmia, atherosclerosis,toxin-induced or alcohol related liver diseases, hematological diseases(including but not limited to chronic anemia and aplastic anemia),degenerative diseases of the musculoskeletal system (including, but notlimited to, osteoporosis and arthritis) aspirin-sensitiverhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases andcancer pain.

The compounds of present invention can modulate the level of cellularRNA and DNA synthesis. These agents are therefore useful in thetreatment of viral infections (including, but not limited to, HIV, humanpapilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbisvirus and adenovirus).

The compounds of the present invention are useful in the chemopreventionof cancer. Chemoprevention is defined as inhibiting the development ofinvasive cancer by either blocking the initiating mutagenic event or byblocking the progression of pre-malignant cells that have alreadysuffered an insult or inhibiting tumor relapse. The compounds are alsouseful in inhibiting tumor angiogenesis and metastasis.

The compounds of the present invention are also useful in combination(administered together or sequentially) with known anti-cancertreatments such as radiation therapy or with cytostatic or cytotoxic oranticancer agents, such as for example, but not limited to, DNAinteractive agents, such as cisplatin or doxorubicin; topoisomerase IIinhibitors, such as etoposide; topoisomerase I inhibitors such as CPT-11or topotecan; tubulin interacting agents, such as paclitaxel, docetaxelor the epothilones (for example, ixabepilone), either naturallyoccurring or synthetic; hormonal agents, such as tamoxifen; thymidilatesynthase inhibitors, such as 5-fluorouracil; and anti-metabolites, suchas methotrexate, other tyrosine kinase inhibitors such as Iressa andOSI-774; angiogenesis inhibitors; EGF inhibitors; VEGF inhibitors; CDKinhibitors; SRC inhibitors; c-Kit inhibitors; Her1/2 inhibitors andmonoclonal antibodies directed against growth factor receptors such aserbitux (EGF) and herceptin (Her2) and other protein kinase modulatorsas well.

The invention further provides a pharmaceutical composition comprisingone or more compounds of formula I, IA, IA-I, and/or IA-III and apharmaceutically acceptable carrier.

Yet another embodiment of the invention is a dosage form comprising oneor more compounds of the present invention, optionally with apharmaceutically acceptable carrier. The dosage form can be, forexample, a solid oral dosage form such as a tablet or capsule.

DETAIL DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood in the field to whichthe claimed subject matter belongs. In the event that there is aplurality of definitions for terms herein, those in this sectionprevail.

It is to be understood that the foregoing general description and thefollowing detailed description are exemplary and explanatory only andare not restrictive of any subject matter claimed. In this application,the use of the singular includes the plural unless specifically statedotherwise. It must be noted that, as used in the specification and theappended claims, the singular forms “a,” “an” and “the” include pluralreferents unless the context clearly dictates otherwise. In thisapplication, the use of “or” means “and/or” unless stated otherwise.Furthermore, use of the term “including” as well as other forms, such as“include”, “includes,” and “included,” is not limiting.

Definition of standard chemistry and molecular biology terms are foundin reference works, including but not limited to, Carey and Sundberg“ADVANCED ORGANIC CHEMISTRY 4^(th) edition” Vols. A (2000) and B (2001),Plenum Press, New York and “MOLECULAR BIOLOGY OF THE CELL 5^(th)edition” (2007), Garland Science, New York. Unless otherwise indicated,conventional methods of mass spectroscopy, NMR, HPLC, protein chemistry,biochemistry, recombinant DNA techniques and pharmacology, arecontemplated within the scope of the embodiments disclosed herein.

Unless specific definitions are provided, the nomenclature employed inconnection with, and the laboratory procedures and techniques of,analytical chemistry, and medicinal and pharmaceutical chemistrydescribed herein are those generally used. In some embodiments, standardtechniques are used for chemical analyses, pharmaceutical preparation,formulation, and delivery, and treatment of patients. In otherembodiments, standard techniques are used for recombinant DNA,oligonucleotide synthesis, and tissue culture and transformation (e.g.,electroporation, lipofection). In finer embodiments, reactions andpurification techniques are performed e.g., using kits of manufacturer'sspecifications or as described herein. The foregoing techniques andprocedures are generally performed by conventional methods and asdescribed in various general and more specific references that are citedand discussed throughout the present specification.

As used herein the following definitions shall apply unless otherwiseindicated. Further many of the groups defined herein can be optionallysubstituted. The listing of substituents in the definition is exemplaryand is not to be construed to limit the substituents defined elsewherein the specification.

The term ‘alkyl’ refers to a straight or branched hydrocarbon chainradical consisting solely of carbon and hydrogen atoms, containing nounsaturation, having from one to eight carbon atoms, and which isattached to the rest of the molecule by a single bond, e.g., methyl,ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, and1,1-dimethylethyl (t-butyl).

The term substituted or unsubstituted (C₁₋₆) alkyl refers to an alkylgroup as defined above having up to 6 carbon atoms.

The term “alkenyl” refers to an aliphatic hydrocarbon group containing acarbon-carbon double bond and which may be a straight or branched orbranched chain having about 2 to about 10 carbon atoms, e.g., ethenyl,1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl,1-butenyl, and 2-butenyl.

The term substituted or unsubstituted (C₁₋₆)alkenyl refers to an alkeynlgroup as defined above having up to 6 carbon atoms.

The term “alkynyl” refers to a straight or branched chain hydrocarbylradical having at least one carbon-carbon triple bond, and having in therange of about 2 up to 12 carbon atoms (with radicals having in therange of about 2 to 10 carbon atoms presently being preferred) e.g.,ethynyl, propynyl, and butnyl.

The term substituted or unsubstituted (C₁₋₆) alkynyl refers to analkynyl group as defined above having up to 6 carbon atoms.

The term “alkoxy” denotes an alkyl group as defined above attached viaan oxygen linkage to the rest of the molecule. Representative examplesof those groups are —OCH₃ and —OC₂H₅.

The term “cycloalkyl” denotes a non-aromatic mono or multicyclic ringsystem of about 3 to 12 carbon atoms such as cyclopropyl, cyclobutyl,cyclopentyl, and cyclohexyl. Non-limiting examples of multicycliccycloalkyl groups include perhydronapththyl, adamantly, norbornyl groups(bridged cyclic group), or spirobicyclic groups e.g. spiro (4,4)non-2-yl.

The term “cycloalkylalkyl” refers to a cyclic ring-containing radicalcontaining in the range of about 3 up to 8 carbon atoms directlyattached to an alkyl group which is then attached to the main structureat any carbon in the alkyl group that results in the creation of astable structure such as cyclopropylmethyl, cyclobuyylethyl, andcyclopentylethyl.

The term “cycloalkenyl” refers to a cyclic ring-containing radicalcontaining in the range of about 3 up to 8 carbon atoms with at leastone carbon-carbon double bond such as cyclopropenyl, cyclobutenyl, andcyclopentenyl.

The term “aryl” refers to an aromatic radical having in the range of 6up to 20 carbon atoms such as phenyl, naphthyl, tetrahydronapthyl,indanyl, and biphenyl.

The term “arylalkyl” refers to an aryl group as defined above directlybonded to an alkyl group as defined above, e.g., —CH₂C₆H₅, and—C₂H₅C₆H₅.

The term “heterocyclic ring” refers to a non-aromatic 3 to 15 memberring radical which, consists of carbon atoms and at least one heteroatomselected from the group consisting of nitrogen, phosphorus, oxygen andsulfur. For purposes of this invention, the heterocyclic ring radicalmay be a mono-, bi-, tri- or tetracyclic ring system, which may includefused, bridged or spiro ring systems, and the nitrogen, phosphorus,carbon, oxygen or sulfur atoms in the heterocyclic ring radical may beoptionally oxidized to various oxidation states. In addition, thenitrogen atom may be optionally quaternized. The heterocyclic ringradical may be attached to the main structure at any heteroatom orcarbon atom that results in the creation of a stable structure.

The term “heteroaryl” refers to an optionally substituted 5-14 memberaromatic ring having one or more heteroatoms selected from N, O, and Sas ring atoms. The heteroaryl may be a mono-, bi- or tricyclic ringsystem. Examples of such heteroaryl ring radicals includes but are notlimited to oxazolyl, thiazolyl imidazolyl, pyrrolyl, furanyl, pyridinyl,pyrimidinyl, pyrazinyl, benzofuranyl, indolyl, benzothiazolyl,benzoxazolyl, carbazolyl, quinolyl and isoquinolyl. The heteroaryl ringradical may be attached to the main structure at any heteroatom orcarbon atom that results in the creation of a stable structure.

Examples of such “heterocyclic ring” or “heteroaryl” radicals include,but are not limited to, azetidinyl, acridinyl, benzodioxolyl,benzodioxanyl, benzofurnyl, carbazolyl, cinnolinyl, dioxolanyl,indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl,phenothiazinyl, phenoxazinyl, phthalazinyl, pyridyl, pteridinyl,purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl,tetrazoyl, imidazolyl, tetrahydroisouinolyl, piperidinyl, piperazinyl,2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl,azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazinyl, pyrimidinyl,pyridazinyl, oxazolyl, oxazolinyl, oxasolidinyl, triazolyl, indanyl,isoxazolyl, isoxasolidinyl, morpholinyl, thiazolyl, thiazolinyl,thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl,isoindolyl, indolinyl, isoindolinyl, octahydroindolyl,octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl,benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl,benzooxazolyl, furyl, tetrahydrofurtyl, tetrahydropyranyl, thienyl,benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide thiamorpholinylsulfone, dioxaphospholanyl oxadiazolyl, chromanyl, isochromanyl and thelike.

The term “heteroarylalkyl” refers to a heteroaryl ring radical asdefined above directly bonded to an alkyl group. The heteroarylalkylradical may be attached to the main structure at any carbon atom fromthe alkyl group that results in the creation of a stable structure.

The term “heterocyclylalkyl” refers to a heterocylic ring radical asdefined above directly bonded to an alkyl group. The heterocyclylalkylradical may be attached to the main structure at carbon atom in thealkyl group that results in the creation of a stable structure.

The term “substituted” unless otherwise specified refers to substitutionwith any one or any combination of the following substituents: hydrogen,hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio(═S),substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy,substituted or unsubstituted alkenyl, substituted or unsubstitutedalkynyl, substituted or unsubstituted aryl, substituted or unsubstitutedarylalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted cycloalkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heteroaryl, substituted heterocyclylalkylring, substituted or unsubstituted heteroarylalkyl, substituted orunsubstituted heterocyclic ring, substituted or unsubstituted guanidine,—COOR^(x), —C(O)R^(x), —C(S)R^(x), —C(O)NR^(x)R^(y), —C(O)NR^(x)R^(y),—NR^(y)R^(z), —NR^(x)CONR^(y)R^(z), —N(R^(x))SOR^(y), —N(R^(x))SO₂R^(y),—(═N—N(R^(x))R^(y)), —NR^(x)C(O)OR^(y), —NR^(x)R^(y), —NR^(x)C(O)R^(y)—,—NR^(x)C(S)R^(y)—NR^(x)C(S)NR^(y)R^(z), —SONR^(x)R^(y)—, —SO₂NR^(x)R^(y)—, —OR^(x), —OR^(x)C(O)NR^(y)R^(z), —OR^(x)C(O)OR^(y)—,—OC(O)R^(x), —OC(O)NR^(x)R^(y), — R^(x)NR^(y)C(O)R^(z), —R^(x)OR^(y),—R^(x)C(O)OR^(y), —R^(x)C(O)NR^(y)R^(z), —R^(x)C(O)R^(x),—R^(x)OC(O)R^(y), —SR^(x), —SOR^(x), —SO₂R^(x), and —ONO₂, whereinR^(x), R^(y) and R^(z) in each of the above groups can be hydrogen atom,substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy,substituted or unsubstituted alkenyl, substituted or unsubstitutedalkynyl, substituted or unsubstituted aryl, substituted or unsubstitutedarylalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted cycloalkenyl, substituted or unsubstituted amino,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, substituted heterocyclylalkyl ring, substituted orunsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclicring, or any two of R^(x), R^(y) and R^(z) may be joined to form asubstituted or unsubstituted saturated or unsaturated 3-10 member ring,which may optionally include heteroatoms which may be same or differentand are selected from O, NR^(x) or S. The substituents in theaforementioned “substituted” groups cannot be further substituted. Forexample, when the substituent on “substituted alkyl” is “substitutedaryl”, the substituent on “substituted aryl” cannot be “substitutedalkenyl”. Substitution or the combination of substituents envisioned bythis invention are preferably those resulting in the formation of astable compound.

The term “halogen” or “halo” refers to radicals of fluorine, chlorine,bromine and iodine.

The term “protecting group” or “PG” refers to a substituent that isemployed to block or protect a particular functionality. Otherfunctional groups on the compound may remain reactive. For example, an“amino-protecting group” is a substituent attached to an amino groupthat blocks or protects the amino functionality in the compound.Suitable amino-protecting groups include, but are not limited to,acetyl, trifluoroacetyl, tert-butoxycarbonyl (BOC), benzyloxycarbonyl(CBz) and 9-fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a“hydroxy-protecting group” refers to a substituent of a hydroxy groupthat blocks or protects the hydroxy functionality. Suitablehydroxy-protecting groups include, but are not limited to, acetyl andsilyl. A “carboxy-protecting group” refers to a substituent of thecarboxy group that blocks or protects the carboxy functionality.Suitable carboxy-protecting groups include, but are not limited to,—CH₂CH₂SO₂Ph, cyanoethyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-toluenesulfonyl)ethyl,2-(p-nitrophenylsulfenyl)ethyl, 2-dipheny-1-phosphino)-ethyl andnitroethyl. For a general description of protecting groups and theiruse, see T. W. Greene, Protective Groups in Organic Synthesis, JohnWiley & Sons, New York, 1991.

The term “stereoisomer” refers to compounds, which have identicalchemical composition, but differ with regard to arrangement of the atomsand the groups in space. These include enantiomers, diastereomers,geometrical isomers, atropisomer or conformational isomers.

All the stereoisomers of compounds described herein are within the scopeof this invention. Racemic mixtures are also encompassed within thescope of this invention. Therefore, single stereochemical isomers aswell enantiomeric, diastereoisomeric and geometric (or conformational)mixtures of the present compounds fall within the scope of theinvention.

The term “tautomers” refers to compounds, which are characterized byrelatively easy interconversion of isomeric forms in equilibrium. Theseisomers are intended to be covered by this invention.

The term “prodrug” refers to compounds, which are an inactive precursorof a compound, converted into its active form in the body by normalmetabolic processes.

The term “ester” refers to compounds, which are formed by reactionbetween an acid and an alcohol with elimination of water. An ester canbe represented by the formula RCOOR′, where R is the base compound andR′ is the ester moiety (e.g., an ethyl group).

Additionally the instant invention also includes the compounds whichdiffer only in the presence of one or more isotopically enriched atomsfor example replacement of hydrogen with deuterium and the like.

Pharmaceutically acceptable salts forming part of this invention includesalts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu,Zn, and Mn; salts of organic bases such as N,N′-diacetylethylenediamine,glucamine, triethylamine, choline, hydroxide, dicyclohexylamine,metformin, benzylamine, trialkylamine, and thiamine; chiral bases suchas alkylphenylamine, glycinol, and phenyl glycinol; salts of naturalamino acids such as glycine, alanine, valine, leucine, isoleucine,norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxyproline, histidine, omithine, lysine, arginine, and serine; quaternaryammonium salts of the compounds of invention with alkyl halides or alkylsulphates such as MeI and (Me)₂SO₄; non-natural amino acids such asD-isomers or substituted amino acids; guanidine or substituted guanidinewherein the substituents are selected from nitro, amino, alkyl, alkenyl,alkynyl, ammonium or substituted ammonium salts and aluminum salts.Salts may include acid addition salts where appropriate which aresulphates, nitrates, phosphates, perchlorates, borates, hydrohalides,acetates, tartrates, maleates, citrates, fumarates, succinates,palmoates, methanesulphonates, benzoates, salicylates,benzenesulfonates, ascorbates, glycerophosphates, and ketoglutarates.

The term “subject” or “patient” encompasses mammals and non-mammals.Examples of mammals include, but are not limited to, any member of theMammalian class: humans, non-human primates such as chimpanzees, andother apes and monkey species; farm animals such as cattle, horses,sheep, goats, and swine; domestic animals such as rabbits, dogs, andcats; and laboratory animals including rodents, such as rats, mice andguinea pigs. Examples of non-mammals include, but are not limited to,birds, and fish. In one embodiment of the methods and compositionsprovided herein, the mammal is a human.

The terms “treat,” “treating” or “treatment,” as used herein, includealleviating, abating or ameliorating a disease, disorder or conditionsymptoms, preventing additional symptoms, ameliorating or preventing theunderlying causes of symptoms, inhibiting the disease, disorder orcondition, e.g., arresting the development of the disease, disorder orcondition, relieving the disease, disorder or condition, causingregression of the disease, disorder or condition, relieving a conditioncaused by the disease, disorder or condition, or stopping the symptomsof the disease, disorder or condition either prophylactically and/ortherapeutically.

As used herein, the term “target protein” refers to a protein or aportion of a protein capable of being bound by, or interacting with acompound described herein, such as a compound capable of modulating aSTIM protein and/or an Orai protein. In certain embodiments, a targetprotein is a STIM protein. In other embodiments, a target protein is anOrai protein, and in yet other embodiments, the compound targets bothSTIM and Orai proteins.

The term “STIM protein” refers to any protein situated in theendoplasmic reticular or plasma membrane which activates an increase inrate of calcium flow into a cell by a CRAC channel. (STIM refers to astromal interaction molecule.) As used herein, “STIM protein” includesbut is not limited to, mammalian STIM-1, such as human and rodent (e.g.,mouse) STIM-1, Drosophila melanogaster D-STIM, C. elegans C-STIM,Anopheles gambiae STIM and mammalian STIM-2, such as human and rodent(e.g., mouse) STIM-2. As described herein, such proteins have beenidentified as being involved in, participating in and/or providing forstore-operated calcium entry or modulation thereof, cytoplasmic calciumbuffering and/or modulation of calcium levels in or movement of calciuminto, within or out of intracellular calcium stores (e.g., endoplasmicreticulum).

It will be appreciated by “activate” or “activation” it is meant thecapacity of a STIM protein to up-regulate, stimulate, enhance orotherwise facilitate calcium flow into a cell by a CRAC channel. It isenvisaged that cross-talk between the STIM protein and the CRAC channelmay occur by either a direct or indirect molecular interaction.Suitably, the STIM protein is a transmembrane protein which isassociated with, or in close proximity to, a CRAC channel.

The term “fragment” or “derivative” when referring to a protein (e.g.STIM, Orai) means proteins or polypeptides which retain essentially thesame biological function or activity in at least one assay as the nativeprotein(s). For example, the fragment or derivative of the referencedprotein preferably maintains at least about 50% of the activity of thenative protein, at least 75%, or at least about 95% of the activity ofthe native protein, as determined, e.g., by a calcium influx assay.

As used herein, “amelioration” refers to an improvement in a disease orcondition or at least a partial relief of symptoms associated with adisease or condition. As used herein, amelioration of the symptoms of aparticular disease, disorder or condition by administration of aparticular compound or pharmaceutical composition refers to anylessening of severity, delay in onset, slowing of progression, orshortening of duration, whether permanent or temporary, lasting ortransient that are attributed to or associated with administration ofthe compound or composition.

The term “modulate,” as used herein, means to interact with a targetprotein either directly or indirectly so as to alter the activity of thetarget protein, including, by way of example only, to inhibit theactivity of the target, or to limit or reduce the activity of thetarget.

As used herein, the term “modulator” refers to a compound that alters anactivity of a target (e.g., a target protein). For example, in someembodiments, a modulator causes an increase or decrease in the magnitudeof a certain activity of a target compared to the magnitude of theactivity in the absence of the modulator. In certain embodiments, amodulator is an inhibitor, which decreases the magnitude of one or moreactivities of a target. In certain embodiments, an inhibitor completelyprevents one or more activities of a target.

As used herein, “modulation” with reference to intracellular calciumrefers to any alteration or adjustment in intracellular calciumincluding but not limited to alteration of calcium concentration in thecytoplasm and/or intracellular calcium storage organelles, e.g.,endoplasmic reticulum, or alteration of the kinetics of calcium fluxesinto, out of and within cells. In aspect, modulation refers toreduction.

The terms “inhibits”, “inhibiting”, or “inhibitor” of SOC channelactivity or CRAC channel activity, as used herein, refer to inhibitionof store operated calcium channel activity or calcium release activatedcalcium channel activity.

The term “acceptable” with respect to a formulation, composition oringredient, as used herein, means having no persistent detrimentaleffect on the general health of the subject being treated.

The term “pharmaceutically acceptable,” molecular entities andcompositions that are physiologically tolerable and do not typicallyproduce an allergic or similar untoward reaction, such as gastric upset,and dizziness, when administered to a human. Preferably, as used herein,the term “pharmaceutically acceptable” means approved by a regulatoryagency of the federal or a state government or listed in the U.S.Pharmacopeia or other generally recognized pharmacopeia for use inanimals, and more particularly in humans.

The term “pharmaceutical composition” refers to a mixture of a compoundof the present invention with other chemical components, such ascarriers, stabilizers, diluents, dispersing agents, suspending agents,thickening agents, and/or excipients.

The compounds and pharmaceutical compositions of the present inventioncan be administered by various routes of administration including, butnot limited to, intravenous, oral, aerosol, parenteral, ophthalmic,pulmonary and topical administration.

The terms “effective amount” or “therapeutically effective amount,” asused herein, refer to a sufficient amount of an agent or a compoundbeing administered which will relieve to some extent one or more of thesymptoms of the disease or condition being treated. The result isreduction and/or alleviation of the signs, symptoms, or causes of adisease, or any other desired alteration of a biological system. Forexample, an “effective amount” for therapeutic uses is the amount of acompound of the present invention required to provide a clinicallysignificant decrease in disease symptoms. In some embodiments, anappropriate “effective” amount in any individual case is determinedusing techniques, such as a dose escalation study.

The terms “enhance” or “enhancing,” as used herein, means to increase orprolong either in potency or duration a desired effect. Thus, in regardto enhancing the effect of therapeutic agents, the term “enhancing”refers to the ability to increase or prolong, either in potency orduration, the effect of other therapeutic agents on a system. An“enhancing-effective amount,” as used herein, refers to an amountadequate to enhance the effect of another therapeutic agent in a desiredsystem.

The term “carrier,” as used herein, refers to relatively nontoxicchemical compounds or agents that facilitate the incorporation of acompound into cells or tissues.

The term “diluent” refers to chemical compounds that are used to dilutethe compound of interest prior to delivery. In some embodiments,diluents are used to stabilize compounds because they provide a morestable environment. Salts dissolved in buffered solutions (which alsoprovide pH control or maintenance) are utilized as diluents, including,but not limited to a phosphate buffered saline solution.

As used herein, “intracellular calcium” refers to calcium located in acell without specification of a particular cellular location. Incontrast, “cytosolic” or “cytoplasmic” with reference to calcium refersto calcium located in the cell cytoplasm.

As used herein, an effect on intracellular calcium is any alteration ofany aspect of intracellular calcium, including but not limited to, analteration in intracellular calcium levels and location and movement ofcalcium into, out of or within a cell or intracellular calcium store ororganelle. For example, in some embodiments, an effect on intracellularcalcium is an alteration of the properties, such as, for example, thekinetics, sensitivities, rate, amplitude, and electrophysiologicalcharacteristics, of calcium flux or movement that occurs in a cell orportion thereof. In some embodiments, an effect on intracellular calciumis an alteration in any intracellular calcium-modulating process,including, store-operated calcium entry, cytosolic calcium buffering,and calcium levels in or movement of calcium into, out of or within anintracellular calcium store. Any of these aspects are assessed in avariety of ways including, but not limited to, evaluation of calcium orother ion (particularly cation) levels, movement of calcium or other ion(particularly cation), fluctuations in calcium or other ion(particularly cation) levels, kinetics of calcium or other ion(particularly cation) fluxes and/or transport of calcium or other ion(particularly cation) through a membrane. An alteration is any suchchange that is statistically significant. Thus, for example, in someembodiments, if intracellular calcium in a test cell and a control cellis said to differ, such differences are a statistically significantdifference.

Modulation of intracellular calcium is any alteration or adjustment inintracellular calcium including but not limited to alteration of calciumconcentration or level in the cytoplasm and/or intracellular calciumstorage organelles, e.g., endoplasmic reticulum, alteration in themovement of calcium into, out of and within a cell or intracellularcalcium store or organelle, alteration in the location of calcium withina cell, and alteration of the kinetics, or other properties, of calciumfluxes into, out of and within cells. In some embodiments, intracellularcalcium modulation involves alteration or adjustment, e.g. reduction orinhibition, of store-operated calcium entry, cytosolic calciumbuffering, calcium levels in or movement of calcium into, out of orwithin an intracellular calcium store or organelle, and/or basal orresting cytosolic calcium levels. The modulation of intracellularcalcium involves an alteration or adjustment in receptor-mediated ion(e.g., calcium) movement, second messenger-operated ion (e.g., calcium)movement, calcium influx into or efflux out of a cell, and/or ion (e.g.,calcium) uptake into or release from intracellular compartments,including, for example, endosomes and lysosomes.

As used herein, “involved in”, with respect to the relationship betweena protein and an aspect of intracellular calcium or intracellularcalcium regulation means that when expression or activity of the proteinin a cell is reduced, altered or eliminated, there is a concomitant orassociated reduction, alteration or elimination of one or more aspectsof intracellular calcium or intracellular calcium regulation. Such analteration or reduction in expression or activity occurs by virtue of analteration of expression of a gene encoding the protein or by alteringthe levels of the protein. A protein involved in an aspect ofintracellular calcium, such as, for example, store-operated calciumentry, thus, are one that provides for or participates in an aspect ofintracellular calcium or intracellular calcium regulation. For example,a protein that provides for store-operated calcium entry are a STIMprotein and/or an Orai protein.

As used herein, a protein that is a component of a calcium channel is aprotein that participates in multi-protein complex that forms thechannel.

As used herein, “cation entry” or “calcium entry” into a cell refers toentry of cations, such as calcium, into an intracellular location, suchas the cytoplasm of a cell or into the lumen of an intracellularorganelle or storage site. Thus, in some embodiments, cation entry is,for example, the movement of cations into the cell cytoplasm from theextracellular medium or from an intracellular organelle or storage site,or the movement of cations into an intracellular organelle or storagesite from the cytoplasm or extracellular medium. Movement of calciuminto the cytoplasm from an intracellular organelle or storage site isalso referred to as “calcium release” from the organelle or storagesite.

As used herein, “cell response” refers to any cellular response thatresults from ion movement into or out of a cell or within a cell. Insome embodiments, the cell response is associated with any cellularactivity that is dependent, at least in part, on ions such as, forexample, calcium. Such activities optionally include, for example,cellular activation, gene expression, endocytosis, exocytosis, cellulartrafficking and apoptotic cell death.

As used herein, “immune cells” include cells of the immune system andcells that perform a function or activity in an immune response, suchas, but not limited to, T-cells, B-cells, lymphocytes, macrophages,dendritic cells, neutrophils, eosinophils, basophils, mast cells, plasmacells, white blood cells, antigen presenting cells and natural killercells.

As used herein, “cytokine” or “cytokines” refers to small solubleproteins secreted by cells that in some embodiments, alter the behavioror properties of the secreting cell or another cell. Cytokines bind tocytokine receptors and trigger a behavior or property within the cell,for example, cell proliferation, death or differentiation. Exemplarycytokines include, but are not limited to, interleukins (e.g., IL-2,IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13,IL-15, IL-16, IL-17, IL-18, IL-1.alpha., IL-1.beta., and IL-1 RA),granulocyte colony stimulating factor (G-CSF), granulocyte-macrophagecolony stimulating factor (GM-CSF), oncostatin M, erythropoietin,leukemia inhibitory factor (LIF), interferons, B7.1 (also known asCD80), B7.2 (also known as B70, CD86), TNF family members (TNF-.alpha.,TNF-.beta., LT-.beta., CD40 ligand, Fas ligand, CD27 ligand, CD30ligand, 4-1BBL, Trail), and MIF.

“Store operated calcium entry” or “SOCE” refers to the mechanism bywhich release of calcium ions from intracellular stores is coordinatedwith ion influx across the plasma membrane.

Cellular calcium homeostasis is a result of the summation of regulatorysystems involved in the control of intracellular calcium levels andmovements. Cellular calcium homeostasis is achieved, at least in part,by calcium binding and by movement of calcium into and out of the cellacross the plasma membrane and within the cell by movement of calciumacross membranes of intracellular organelles including, for example, theendoplasmic reticulum, sarcoplasmic reticulum, mitochondria andendocytic organelles including endosomes and lysosomes.

Movement of calcium across cellular membranes is carried out byspecialized proteins. For example, calcium from the extracellular spaceenters the cell through various calcium channels and a sodium/calciumexchanger and is actively extruded from the cell by calcium pumps andsodium/calcium exchangers. Calcium is also released from internal storesthrough inositol trisphosphate or ryanodine receptors and is likelytaken up by these organelles by means of calcium pumps.

Calcium enters cells by any of several general classes of channels,including but not limited to, voltage-operated calcium (VOC) channels,store-operated calcium (SOC) channels, and sodium/calcium exchangersoperating in reverse mode. VOC channels are activated by membranedepolarization and are found in excitable cells like nerve and muscleand are for the most part not found in nonexcitable cells. Under someconditions, Ca²⁺ also enters cells via Na⁺—Ca²⁺ exchangers operating inreverse mode.

Endocytosis provides another process by which cells take up calcium fromthe extracellular medium through endosomes. In addition, some cells,e.g., exocrine cells, release calcium via exocytosis.

Cytosolic calcium concentration is tightly regulated with resting levelsusually estimated at approximately 0.1 .mu.M in mammalian cells, whereasthe extracellular calcium concentration is typically about 2 mM. Thistight regulation facilitates transduction of signals into and withincells through transient calcium flux across the plasma membrane andmembranes of intracellular organelles. There is a multiplicity ofintracellular calcium transport and buffer systems in cells that serveto shape intracellular calcium signals and maintain the low restingcytoplasmic calcium concentration. In cells at rest, the principalcomponents involved in maintaining basal calcium levels are calciumpumps and leaks in the endoplasmic reticulum and plasma membrane.Disturbance of resting cytosolic calcium levels effects transmission ofsuch signals and give rise to defects in a number of cellular processes.For example, cell proliferation involves a prolonged calcium signallingsequence. Other cellular processes include, but are not limited to,secretion, signalling, and fertilization, involve calcium signalling.

Cell-surface receptors that activate phospholipase C(PLC) createcytosolic Ca²⁺ signals from intra- and extra-cellular sources. Aninitial transient rise of [Ca²⁺]i (intracellular calcium concentration)results from the release of Ca²⁺ from the endoplasmic reticulum (ER),which is triggered by the PLC product, inositol-1,4,5-trisphosphate(P₃), opening IP₃ receptors in the ER (Streb et al. Nature, 306, 67-69,1983). A subsequent phase of sustained Ca²⁺ entry across the plasmamembrane then ensues, through specialized store operated calcium (SOC)channels (in the case of immune cells the SOC channels are calciumrelease-activated calcium (CRAC) channels) in the plasma membrane.Store-operated Ca²⁺ entry (SOCE) is the process in which the emptying ofCa²⁺ stores itself activates Ca²⁺ channels in the plasma membrane tohelp refill the stores (Putney, Cell Calcium, 7, 1-12, 1986; Parekh etal, Physiol. Rev. 757-810; 2005). SOCE does more than simply provideCa²⁺ for refilling stores, but itself generates sustained Ca²⁺ signalsthat control such essential functions as gene expression, cellmetabolism and exocytosis (Parekh and Putney, Physiol. Rev. 85, 757-810(2005).

In lymphocytes and mast cells, activation of antigen or Fc receptorscauses the release of Ca²⁺ from intracellular stores, which in turnleads to Ca²⁺ influx through CRAC channels in the plasma membrane. Thesubsequent rise in intracellular Ca²⁺ activates calcineurin, aphosphatase that regulates the transcription factor NFAT. In restingcells, NFAT is phosphorylated and resides in the cytoplasm, but whendephosphorylated by calcineurin, NFAT translocates to the nucleus andactivates different genetic programmes depending on stimulationconditions and cell type. In response to infections and duringtransplant rejection, NFAT partners with the transcription factor AP-1(Fos-Jun) in the nucleus of “effector” T cells, thereby transactivatingcytokine genes, genes that regulate T cell proliferation and other genesthat orchestrate an active immune response (Rao et al., Annu RevImmunol, 1997; 15:707-47). In contrast, in T cells recognizing selfantigens, NFAT is activated in the absence of AP-1, and activates atranscriptional programme otherwise known as “anergy” that suppressesautoimmune responses (Macian et al., Transcriptional mechanismsunderlying lymphocyte tolerance. Cell, 2002 Jun. 14; 109(6):719-31). Ina subclass of T cells, known as regulatory T cells which suppressautoimmunity mediated by self-reactive effector T cells, NFAT partnerswith the transcription factor FOXP3 to activate genes responsible forsuppressor function (Wu et al., Cell, 2006 Jul. 28; 126(2):375-87;Rudensky A Y, Gavin M, Zheng Y. Cell. 2006 Jul. 28; 126(2):253-256).

The endoplasmic reticulum (ER) carries out a variety processes. The ERhas a role as both an agonist-sensitive Ca²⁺ store and sink, proteinfolding/processing takes place within its lumen. Here, numerousCa²⁺-dependent chaperone proteins ensure that newly synthesized proteinsare folded correctly and sent off to the appropriate destination. The ERis also involved in vesicle trafficking, release of stress signals,regulation of cholesterol metabolism, and apoptosis. Many of theseprocesses require intraluminal Ca²⁺, and protein misfolding, ER stressresponses, and apoptosis are all likely induced by depleting the ER ofCa²⁺ for prolonged periods of time. Because of its role as a source ofCa²⁺, it is clear that ER Ca²⁺ content must fall after stimulation.However, to preserve the functional integrity of the ER, it is vitalthat the Ca²⁺ content does not fall too low or is maintained at a lowlevel. Replenishment of the ER with Ca²⁺ is therefore a central processto all eukaryotic cells. Because a fall in ER Ca²⁺ content activatesstore-operated Ca²⁺ channels in the plasma membrane, a major function ofthis Ca²⁺ entry pathway is believed to be maintenance of ER Ca²⁺ levelsthat are necessary for proper protein synthesis and folding. However,store-operated Ca²⁺ channels have other important roles.

The understanding of store operated calcium entry was provided byelectrophysiological studies which established that the process ofemptying the stores activated a Ca²⁺ current in mast cells called Ca²⁺release-activated Ca²⁺ current or I_(CRAC). I_(CRAC) is non-voltageactivated, inwardly rectifying, and remarkably selective for Ca²⁺. It isfound in several cell types mainly of hemopoietic origin. I_(CRAC) isnot the only store-operated current, and it is now apparent thatstore-operated influx encompasses a family of Ca²⁺-permeable channels,with different properties in different cell types. I_(CRAC) was thefirst store-operated Ca²⁺ current to be described and remains a popularmodel for studying store-operated influx.

Effects of compounds or agents on intracellular calcium can be monitoredusing various screening/identification methods which provide for adirect or indirect evaluation or measurement of cellular (includingcytosolic and intracellular organelle or compartment) calcium and/ormovement of ions into, within or out of a cell, organelle, calcium storeor portions thereof (e.g., a membrane). A variety of methods can be usedfor evaluating calcium levels and ion movements or flux. The particularmethod used and the conditions employed would depend on whether aparticular aspect of intracellular calcium is being monitored orassessed. For example, in some aspects, reagents and conditions may beused for specifically evaluating store-operated calcium entry, restingcytosolic calcium levels, calcium buffering and calcium levels anduptake by or release from intracellular organelles and calcium stores.Alternately, the effect of a compound or agent on intracellular calciumcan be monitored or assessed using, for example, a cell, anintracellular organelle or calcium storage compartment, a membrane(including, e.g., a detached membrane patch or a lipid bilayer) or acell-free assay system (e.g., outside-out membrane vesicle). Generally,some aspect of intracellular calcium is monitored or assessed in thepresence of test agent and compared to a control, e.g., intracellularcalcium in the absence of test agent.

Diseases, Disorders or Conditions

Clinical studies demonstrate that the CRAC channel is absolutelyrequired for the activation of genes underlying the T cell response toantigen. Sustained calcium entry is needed for lymphocyte activation andadaptive immune response. Calcium entry into lymphocytes occursprimarily through the CRAC channels. Increased calcium leads to NFATactivation and expression of cytokines required for immune response.Inhibiting the store operated calcium entry is an efficient way toprevent T cell activation.

Inhibition of CRAC channel activity with the compounds that modulateintracellular calcium levels provide a means for providingimmunosuppressive therapy as demonstrated by the elimination ofstore-operated calcium entry noted in patients with severe-combinedimmunodeficiency (SCID). T cells, fibroblasts, and in some cases Bcells, from patients with T cell immunodeficiency or SCID having aprincipal defect in T cell activation show a strong defect instore-operated calcium entry. SCID patients lack adaptive immuneresponse, but without any impairment or toxicity in major organs. TheSCID patient phenotype indicates that inhibition of CRAC channels is aneffective strategy for immunosuppression.

Diseases/Disorders Involving Inflammation and Diseases/Disorders Relatedto the Immune System

In some embodiments, diseases, disorders or conditions that are treatedor prevented using compounds disclosed herein that are capable ofmodulating intracellular calcium levels, compositions thereof, andmethods provided herein to identify compounds capable of modulatingintracellular calcium levels, include diseases, conditions or disordersinvolving inflammation and/or that are related to the immune system.These diseases include, but are not limited to, asthma, chronicobstructive pulmonary disease, rheumatoid arthritis, inflammatory boweldisease, glomerulonephritis, neuroinflammatory diseases such as multiplesclerosis, and disorders of the immune system.

The activation of neutrophils (PMN) by inflammatory mediators is partlyachieved by increasing cytosolic calcium concentration. Store-operatedcalcium influx in particular is thought to play an important role in PMNactivation. It has been shown that trauma increases PMN store-operatedcalcium influx and that prolonged elevations of cytosolic calciumconcentration due to enhanced store-operated calcium influx likelyalters stimulus-response coupling to chemotaxins and contribute to PMNdysfunction after injury. Modulation of PMN cytosolic calciumconcentration through store-operated calcium channels might therefore beuseful in regulating PMN-mediated inflammation and spare cardiovascularfunction after injury, shock or sepsis.

Calcium plays a critical role in lymphocyte activation. Activation oflymphocytes, e.g., by antigen stimulation, results in rapid increases inintracellular free calcium concentrations and activation oftranscription factors, including nuclear factor of activated T cells(NFAT), NF-.kappa.B, JNK1, MEF2 and CREB. NFAT is a key transcriptionalregulator of the IL-2 (and other cytokine) genes. A sustained elevationof intracellular calcium level is required to keep NFAT in atranscriptionally active state, and is dependent on store-operatedcalcium entry. Reduction or blocking of store-operated calcium entry inlymphocytes blocks calcium-dependent lymphocyte activation. Thus, insome embodiments, modulation of a STIM protein and/or an Orai protein,and particularly store-operated calcium entry (e.g., reduction in,elimination of store-operated calcium entry), in lymphocytes is a methodfor treating immune and immune-related disorders, including, forexample, chronic immune diseases/disorders, acute immunediseases/disorders, autoimmune and immunodeficiency diseases/disorders,diseases/disorders involving inflammation, organ transplant graftrejections and graft-versus-host disease and altered (e.g., hyperactive)immune responses. For example, in some embodiments treatment of anautoimmune disease/disorder involves reducing, blocking or eliminatingstore-operated calcium entry in lymphocytes.

Examples of immune disorders include, for example, psoriasis, rheumatoidarthritis, vasculitis, inflammatory bowel disease, dermatitis,osteoarthritis, asthma, inflammatory muscle disease, allergic rhinitis,vaginitis, interstitial cystitis, scleroderma, osteoporosis, eczema,allogeneic or xenogeneic transplantation (organ, bone marrow, stem cellsand other cells and tissues) graft rejection, graft-versus-host disease,lupus erythematosus, inflammatory disease, type I diabetes, pulmonaryfibrosis, dermatomyositis, Sjogren's syndrome, thyroiditis (e.g.,Hashimoto's and autoimmune thyroiditis), myasthenia gravis, autoimmunehemolytic anemia, multiple sclerosis, cystic fibrosis, chronic relapsinghepatitis, primary biliary cirrhosis, allergic conjunctivitis and atopicdermatitis.

In other embodiments, compounds disclosed herein that are capable ofmodulating intracellular calcium levels, compositions thereof, andmethods provided herein to identify compounds capable of modulatingintracellular calcium levels, are used in connection with treatment ofmalignancies, including, but not limited to, malignancies oflymphoreticular origin, bladder cancer, breast cancer, colon cancer,endometrial cancer, head and neck cancer, lung cancer, melanoma, ovariancancer, prostate cancer and rectal cancer. Store-operated calcium entryis thought to play an important role in cell proliferation in cancercells.

Inhibition of SOCE is sufficient to prevent tumor cell proliferation.The pyrazole derivative BTP-2, a direct I_(CRAC) blocker inhibits SOCEand proliferation in Jurkat cells and in colon cancer cells. Moreover,sustained SOCE requires mitochondrial Ca²⁺ uptake and that prevention ofmitochondrial Ca²⁺ uptake leads to SOCE inhibition. Stimulation ofJurkat cells induces sustained SOCE and activation of the Ca²⁺-dependentphosphatase calcineurin that dephosphorylates NFAT, promoting expressionof interleukin-2 and proliferation. In other embodiments, compoundscapable of modulating intracellular calcium levels inhibit SOCE and areused in the treatment of cancer or other proliferative diseases orconditions.

In some embodiments, diseases, disorders or conditions that are treatedor prevented using compounds disclosed herein that are capable ofmodulating intracellular calcium levels, compositions thereof, andmethods provided herein to identify compounds capable of modulatingintracellular calcium levels, include, for example, hepatic or liverdiseases and disorders. These diseases, conditions or disorders includebut are not limited to liver injury, for example, due totransplantation, hepatitis and cirrhosis.

Store-operated calcium entry has been implicated in chronic liverdisease as well as transplantation injury after cold preservation-warmdeoxygenation.

In some embodiments, diseases, conditions or disorders that are treatedor prevented using the compounds disclosed herein that are capable ofmodulating intracellular calcium levels, compositions thereof, andmethods provided herein to identify compounds capable of modulatingintracellular calcium levels, include kidney or renal diseases anddisorders. Mesangial cell hyperplasia is often a key feature of suchdiseases and disorders. In other embodiments, such diseases anddisorders are caused by immunological or other mechanisms of injury,including IgAN, membranoproliferative glomerulonephritis or lupusnephritis. Imbalances in the control of mesangial cell replication alsoappear to play a key role in the pathogenesis of progressive renalfailure. The turnover of mesangial cells in normal adult kidney is verylow with a renewal rate of less than 1%. A prominent feature ofglomerular/kidney diseases is mesangial hyperplasia due to elevatedproliferation rate or reduced cell loss of mesangial cells. Whenmesangial cell proliferation is induced without cell loss, for exampledue to mitogenic stimulation, mesangioproliferative glomerulonephritisdoes result. Data have indicated that regulators of mesangial cellgrowth, particularly growth factors, are thought to act by regulatingstore-operated calcium channels. In yet other embodiments, modulators ofstore-operated calcium influx aids in the treatment of glomerulardiseases by inhibiting mesangial cell proliferation.

In one aspect, compounds described herein modulate intracellularcalcium, such as but not limited to, modulation (e.g. reduction orinhibition) of SOC channel activity, such as inhibition of CRAC channelactivity (e.g. inhibition of I_(CRAC), inhibition of SOCE), in an immunesystem cell (e.g., a lymphocyte, white blood cell, T cell, B cell), afibroblast (or a cell derived from a fibroblast), or an epidermal,dermal or skin cell (e.g., a keratinocyte). In some embodiments, thestep of modulating one or more proteins involved in modulatingintracellular calcium (e.g. a STIM protein and/or Orai protein)involves, for example, reducing the level, expression of, an activityof, function of and/or molecular interactions of a protein. Forinstance, if a cell exhibits an increase in calcium levels or lack ofregulation of an aspect of intracellular calcium modulation, e.g.,store-operated calcium entry, then in other embodiments, modulatinginvolves reducing the level of, expression of, an activity or functionof, or a molecular interaction of a protein, e.g. a STIM protein and/orOrai protein.

The following general methodology described herein provides the mannerand process of making and using the compound of the present inventionand are illustrative rather than limiting. Further modification ofprovided methodology and additionally new methods may also be devised inorder to achieve and serve the purpose of the invention. Accordingly, itshould be understood that there may be other embodiments which fallwithin the spirit and scope of the invention as defined by thespecification hereto.

General Method of Preparation of Compound of Formula (I)

The compounds of the present invention may be prepared by the followingprocesses. Unless otherwise indicated, all the variables when used inthe below formulae are to be understood to present those groupsdescribed above in relation to formula (IA). These methods can similarlybe applied to other compounds of formula (I) (e.g, I, IA, IA-I, and/orIA-III).

Scheme 1 provides a general process for synthesis of a compound offormula (IA) wherein L₁ & L₂ together are —NH—CO—, R′″ is hydrogen orhalogen, and all other variables R, R¹, R², T, U, V, W, A and Cy are asdescribed above in relation to formula (IA)

A compound of formula 1 can be reacted with a compound of formula 2(e.g., phenyl hydrazine) to form a compound of formula 3. The compoundof formula 3 can then be nitrated, e.g., using a mixture of concentratedH₂SO₄ and concentrated HNO₃ to form a compound of formula 4. Reductionof the compound of formula 4, such as with FeCl₃ and hydrazine in thepresence of activated charcoal, yields the corresponding amine compoundof formula 5a wherein R′″ is Hydrogen. Alternately halogenation followedby reduction of the compound of formula 4, yields the correspondingamine compound of formula 5b wherein R′″ is Halogen. The compound offormula 5a or 5b can be coupled with various other intermediates in thepresence of a suitable coupling reagent to provide a compound of formula(IA). The compound of formula 5a or 5b can be coupled with i. Cy-A-COOHusing one or more amide coupling reagents such as(benzotriazol-1-yloxy)tris(dimethylamino)phosphoniumhexafluoro phosphate(BOP reagent) or N-(3-dimethylaminopropyl)-N′-ethylcarbodiimidehydrochloride (EDC); ii. with acid chlorides of formula Cy-A-COCl; oriii. isocyanates of formula Cy-NCO where A is NH.

Scheme 2 provides a general process for synthesis of a compound offormula (IA) wherein L₁ & L₂ together i —NH—CO—, R′″ is hydrogen orhalogen and all other variables R, R¹, R², T, U, V, W, A and Cy arethose described above in relation to formula (IA).

Step-1: A ketone of formula a can be condensed with an ester of formulab in the presence of a base such as a metal alkoxide, e.g., sodiumethoxide, to give a diketone of formula 1.

Step-2: The compound of formula 1 can be converted to a pyrazolecompound of formula 2a by reacting it with hydrazine. The compound offormula 2a can be reacted with a compound of formula 2b wherein L_(g) isa leaving group (such as a halogen) in the presence of a suitable basesuch as an alkali metal carbonate, e.g., Cs₂CO₃, to give a compound offormula 4, which can be subjected to a similar sequence oftransformations as described above in scheme 1 to afford a compound offormula IA.

Scheme 2A provides a general process for synthesis of a compound offormula (IA) wherein L₁ & L₂ together is —CO—NH—, R′″ is hydrogen orHalogen and all other variables R, R¹, R², T, U, V, W, A and Cy arethose described above in relation to formula (IA).

The compound of formula 2a can be reacted with a compound of formula 2cwherein L_(g) is a leaving group (such as a halogen) in the presence ofa suitable base such as an alkali metal carbonate, e.g., Cs₂CO₃, to givea compound of formula 4a, which can then be hydrolysed to to give acompound of formula 5c. The compound of formula 5c can be coupled withCy-A-NH₂ using one or more amide coupling reagents such as(benzotriazol-1-yloxy)tris(dimethylamino)phosphoniunhexafluoro phosphate(BOP reagent) or N-(3-dimethylaminopropyl)-N′-ethylcarbodiimidehydrochloride (EDC).

Similar methodologies with certain modifications as known to thoseskilled in the art can be used to synthesize compounds of formula I, IA,IA-I, and/or IA-III wherein the variables are to be understood topresent those groups described above in relation to formula I, IA, IA-I,and/or IA-III using suitable intermediates and reagents.

EXPERIMENTAL

The following abbreviations are used throughout this disclosure: EDC.HCl[N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride], HOBt[Hydroxybenzotriazole], TEA (triethylamine), DMF (dimethyl formamide),AcOEt (ethyl acetate), DCM (dichloromethane), DMSO (dimethyl sulfoxide,THF (tetrahydrofuran). Unless otherwise mentioned, work-up impliesdistribution of reaction mixture between the aqueous and organic phasesindicated within parentheses, separation and drying over Na₂SO₄ of theorganic layer and evaporating the solvent to afford a residue. Unlessotherwise stated, purification implies column chromatography usingsilica gel as the stationary phase and a mixture of petroleum ether(boiling at 60-80° C.) and ethyl acetate or dichloromethane and methanolof suitable polarity as the mobile phases. RT (or rt)implies ambienttemperature (˜25-28° C.).

Intermediate 1: 1,3-dicyclopropylpropane-1,3-dione

Sodium ethoxide (8 g, 117.64 mmol) was added to a solution ofcyclopropyl methyl ketone (5 g, 59.4 mmol) and methyl cyclopropanecarboxylate (12 ml, 118.9 mmol) in DMSO (30 mL). The resulting mixturewas heated at 60° C. overnight and then cooled to 0° C. After quenchingthe reaction with 6N HCl, work-up (H₂O/AcOEt) gave the title compound asa brown liquid which was used without any purification. ¹H-NMR (δ ppm,CDCl₃, 400 MHz): 16.05 (bs, 0.6H), 5.72 (s, 0.6H) 3.78 (s, 0.8H),2.08-2.0 (m, 0.8H), 1.62-1.53 (m, 1.2H), 1.12-1.05 (m, 4H), 0.97-0.83(m, 4H). MS (m/z): 153.2 [M+H]⁺.

Intermediate 2: 1-cyclopropyl-4,4,4-trifluorobutane-1,3-dione

A procedure similar to that described for intermediate 1 was followed.From cyclopropyl methyl ketone (10 g, 119 mmol), ethyl2,2,2-trifluoroacetate (29 ml, 237 mmol), DMSO (60 mL) and sodiumethoxide (16.1 g, 237 mmol), the title compound (15 g) was obtained as abrown liquid and was used in the next step without purification. ¹H-NMR(δ ppm, CDCl₃, 400 MHz): 5.65 (s, 2H), 2.16-2.04 (m, 1H), 1.18-1.12 (m,2H), 0.98-0.94 (m, 2H).

Intermediate 3: 4,4,4-trifluoro-1-(furan-2-yl)butane-1,3-dione

A procedure similar to that described for intermediate 1 was followed.From 1-(furan-2-yl)ethanone (5 g, 45.4 mmol), ethyl2,2,2-trifluoroacetate (12.9 g, 90.8 mmol), DMSO (30 mL) and sodiumethoxide (6.2 g, 90.8 mmol), the title compound was obtained as a brownliquid quantitatively and was used without purification. ¹H-NMR (δ ppm,DMSO-d₆, 400 M Hz): 9.10 (bs, 1H), 8.15 (s, 1H), 7.96 (d, J 1, 1H),6.85-6.81 (m, 1H), 6.70 (s, 1H).

Intermediate 4: 3,5-dicyclopropyl-1H-pyrazole

Intermediate 1 (5.3 g, 35 mmol) and hydrazine hydrate (1.8 mL, 38.3mmol) in ethanol (20 mL) were refluxed overnight. Work-up (H₂O/AcOEt)after cooling the mixture to ambient temperature gave the title compoundas a brown solid. M.P.: 161-164° C. ¹H-NMR (δ ppm, CDCl₃, 400 MHz): 15.2(bs, 1H), 5.65 (s, 1H), 2.16-2.09 (m, 2H), 1.18-1.14 (m, 4H), 0.98-0.94(m, 4H). MS (m/z): 149.04 [M+H]⁺.

Intermediate 5: 5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazole

Intermediate 2 (0.120 g, 0.66 mmol) and hydrazine hydrate (0.04 mL, 0.72mmol) were dissolved in ethanol (6 mL) and refluxed overnight. Work-up(H₂O/AcOEt) after cooling the mixture to RT gave the title compound as abrown solid (0.114 g).

Intermediate 6: 5-(furan-2-yl)-1-phenyl-3-(trifluoromethyl)-1H-pyrazole

A procedure similar to that described for intermediate 4 was followed.From intermediate 3 (4 g, 19.4 mmol) and phenyl hydrazine (2.31 g, 21.3mmol), title compound obtained as a white solid. ¹H-NMR (δ ppm, CDCl₃,400 MHz): 7.52-7.48 (m, 3H), 7.46-7.40 (m, 3H), 6.91 (s, 1H), 6.36-6.33(m, 1H), 5.96 (d, J 7.4, 1H).

Intermediate 7: 1-phenyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxylicacid

Intermediate 6 (2.84 g, 10.2 mmol) was dissolved in acetone (120 ml) andKMnO₄ (11.2 gms, 71.45 mmol in 135 ml water) solution was added to it.This mixture was heated at 60° C. for 3h and then cooled to rt. Thenisopropyl alcohol was added to the reaction mixture and stirred at rtovernight. The reaction mixture filtered through celite and filtrate wasevaporated on high vacuum. The residue was dissolved in 1N NaOH andwashed with petether. Aqueous layer was acidified with 2N HCl solutionto obtain the solid. Solid was filtered and dried on high vacuum toobtain the title compound (2.3 g) as a white solid. ¹H-NMR (δ ppm,CDCl₃, 400 MHz): 7.57-7.42 (m, 5H), 7.30 (s, 1H).

Intermediate 8: methyl1-phenyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxylate

Intermediate 7 (1.55 g, 6.0 mmol) was dissolved in MeOH (15 ml), cooledto 0° C. and thionyl chloride (1.3 ml, 18.2 mmol) was added. Reactionmixture was heated to 60° C. for overnight. Work up (AcOEt: H₂O)followed by evaporation on high vacuum obtained the title compound as anyellow solid. ¹H-NMR (δ ppm, CDCl₃, 400 MHz): 7.51-7.47 (m, 3H),7.46-7.41 (m, 2H), 7.50 (s, 1H), 3.82 (s, 3H).

Intermediate 9: 3,5-dicyclopropyl-1-(4-nitrophenyl)-1H-pyrazole

A solution of intermediate 4 (2.0 g, 13.5 mmol) and Cs₂CO₃ (5.51 g, 40.5mmol) in DMSO (15 mL) was heated at 160° C. under nitrogen for 0.5 h. Tothe mixture, 4-chloro-1-nitro benzene (6.38 g, 40.5 mmol) was added andstirred at the same temperature for 4 h. Work-up (H₂O/AcOEt) andpurification afforded the title compound (0.8 g). ¹H-NMR (δ ppm, CDCl₃,400 MHz): 8.32 (d, J 9.0, 2H), 7.92 (d, J 9.0, 2H), 5.76 (s, 1H),1.97-1.91 (m, 1H), 1.86-1.80 (m, 1H), 1.09-1.04 (m, 2H), 0.98-0.94 (m,2H), 0.83-0.75 (m, 4H).

Intermediate 10:3,5-dicyclopropyl-1-(2-fluoro-4-nitrophenyl)-1H-pyrazole

A solution of intermediate 4 (2.0 g, 13.5 mmol) and K₂CO₃ (5.5 g, 40.6mmol) in DMSO (20 mL) were heated at 120° C. under nitrogen for 0.5 h.To this mixture, 3,4-difluoro-1-nitrobenzene (2.15 g, 13.5 mmol) wasadded and stirred at the same temperature for 2 h. Work-up (H₂O/AcOEt)and purification afforded the title compound as an yellow solid (3.16g). ¹H-NMR (δ ppm, CDCl₃, 400 MHz): 8.19-8.12 (m, 2H), 7.78 (t, J 7.9,1H), 5.70 (s, 1H), 2.10-2.00 (m, 1H), 1.68-1.58 (m, 1H), 1.08-0.92 (m,4H), 0.82-0.74 (m, 2H), 0.72-0.65 (m, 2H).

Intermediate 11: 2-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-5-nitropyridine

A solution of intermediate 4 (8.0 g, 54.05 mmol) and K₂CO₃ (27.96 g,202.6 mmol) in DMSO (60 mL) was heated at 110° C. under nitrogen for 0.5h. To the mixture, 2-chloro-5-nitro pyridine (12.8 g, 80.75 mmol) wasadded and stirred at the same temperature for 2 h. Work-up (H₂O/AcOEt)and purification afforded the title compound (3.03 g). ¹H-NMR (δ ppm,CDCl₃, 400 MHz): 9.24 (d, J 2.6, 1H), 8.51 (dd, J 2.6, 9.9, 1H), 8.10(d, J 9.2, 1H), 5.72 (s, 1H), 2.90-2.75 (m, 1H), 1.99-1.90 (m, 1H),1.06-0.93 (m, 4H), 0.82-0.64 (m, 4H).

Intermediate 12: ethyl 6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)nicotinate

A solution of intermediate 4 (2.0 g, 13.5 mmol) and K₂CO₃ (5.6 g, 40.5mmol) in DMSO (15 mL) was heated at 120° C. under nitrogen for 0.5 h. Tothe mixture, ethyl-6-chloronicotinate (3.8 g, 20.3 mmol) was added andstirred at 160° C. for 4 h. Work-up (H₂O/AcOEt) and purificationafforded the title compound (0.26 g). ¹H-NMR (δ ppm, CDCl₃, 400 MHz):8.95-8.90 (m, 1H), 8.38 (dd, J 2.2, 8.7, 1H), 7.91 (d, J 8.7, 1H), 5.93(s, 1H), 4.35 (q, J 4.12, 2H), 2.88-2.78 (m, 1H), 1.91-1.83 (m, 1H),1.33 (t, J 7.1, 3H), 0.99-0.85 (m, 4H), 0.62-0.55 (m, 4H). MS (m/z):298.3 ([M+H]⁺).

Intermediate 13:5-cyclopropyl-1-(4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazole

A procedure similar to that followed for intermediate 9 was employed.From intermediate 5 (1.0 g, 5.67 mmol), Cs₂CO₃ (5.5 g, 16.9 mmol), DMSO(4 mL) and 4-chloro-1-nitro benzene (1.93 g, 14.1 mmol) was obtained thetitle compound (0.7 g). ¹H-NMR (δ ppm, CDCl₃, 400 MHz): 8.38 (d, J 7.08,2H), 7.92 (d, J 7.08, 2H), 6.32 (s, 1H), 1.89-1.82 (m, 1H), 1.19-1.11(m, 2H), 0.89-0.85 (m, 2H), MS (m/s): 298.15 [M+H]⁺.

Intermediate 14:5-cyclopropyl-1-(2-fluoro-4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazole

A solution of intermediate 5 (6.3 g, 35 mmol) and K₂CO₃ (14.6 g, 105mmol) in DMSO (20 mL) was heated at 120° C. under nitrogen for 30 mins.To this mixture, 1,2-difluoro nitrobenzene (5.68 g, 35 mmol) was addedand stirred at the same temperature for 2 h. Work-up (H₂CO/AcOEt) andpurification afforded the title compound (7.52 g). ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 8.49 (dd, J 2.4, 9.9, 1H), 8.47-8.27 (m, 1H),8.04-8.02 (m, 1H), 6.73 (s, 1H), 1.76-1.68 (m, 1H), 0.99-0.90 (m, 2H),0.84-0.74 (m, 2H).

Intermediate 15:5-cyclopropyl-1-(2,6-difluoro-4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazole

Intermediate 5 (1 g, 5.7 mmol) and 3,4,5-trifluoronitrobenzene (1 g 5.7mmol) were dissolved in THF and added sodium hydride (274 mg, 11.3mmol). Mixture was refluxed for 2h and reaction mixture cooled to rt andquenched with water. Work-up (H₂O/AcOEt) gave the desired product as ayellow gummy liquid. ¹H-NMR (δ ppm, CDCl₃, 400 MHz): 8.05-8.01 (m, 2H),6.31 (s, 1H), 1.60-1.50 (m, 1H), 1.00-0.91 (m, 2H), 0.80-0.71 (m, 2H).

Intermediate 16:2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-5-nitropyridine

A solution of intermediate 5 (1.0 g, 5.67 mmol) and K₂CO₃ (2.35 g, 17.03mmol) in DMSO (10 mL) was heated at 90° C. under nitrogen for 30 mins.To the mixture, 2-chloro-5-nitro pyridine (1.35 g, 8.5 mmol) was addedand stirred at the same temperature for 2 h. Work-up (H₂O/AcOEt) andpurification afforded the title compound (0.30 g). ¹H-NMR (δ ppm, CDCl₃,400 MHz): 9.33 (d, J 2.5, 1H), 8.62 (dd, J 2.8, 9.0, 1H), 8.19 (d, J9.0, 1H), 6.29 (s, 1H), 2.92-2.83 (m, 1H), 1.60-1.50 (m, 2H), 0.79-0.70(m, 2H).

Intermediate 17:2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-5-nitropyrimidine

Intermediate 5 (500 mg, 2.84 mmol) and 2-chloro-4-nitropyrimidine (452mg, 2.84 mmol) were dissolved in THF and cooled to 0° C. To this mixturesodium hydride (136 mg, 5.7 mmol) was added slowly and reaction mixturewas heated to reflux. After one hour reaction mixture cooled to rt andquenched with water. Work up (H₂O/AcOEt) and purification gave thedesired product (455 mg) as a white solid. ¹H-NMR (δ ppm, CDCl₃, 400MHz): 9.58 (s, 2H), 6.37 (s, 1H), 2.82-2.74 (m, 1H), 1.18-1.10 (m, 2H),0.82-0.75 (m, 2H).

Intermediate 18: methyl1-(4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxylate

Intermediate 8 (2 g, 7.4 mmol) was dissolved in acetic acid (15 ml),cooled to 0° C. and added nitration mixture (6 ml HNO₃ and 6 ml H₂SO₄)drop-wise. Reaction mixture was heated to 60° C. for overnight. Work up(AcOEt: H₂O) and purification on silicagel (60-120 mesh silicagel) usingEA and pet ether (3: 97) as eluent afforded the title compound (850 mg)as a white solid. ¹H-NMR (δ ppm, CDCl₃, 400 MHz): 8.37 (d, J 9, 2H),7.68 (d, J 9, 2H), 7.31 (s, 1H), 3.87 (s, 3H).

Intermediate 19:[1-(4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]methanol

Intermediate 18 (0.662 g, 2.1 mmol) dissolved in a mixture of THF (5 ml)and MeOH (5 ml) and added sodium borohydride (79 mg, 2.1 mmol). Colourof the reaction mixture changed to pink and then two drops of wateradded to it. Reaction mixture allowed to stir at rt for 1 h and at thisstage colour changed to pink to pale yellow. Reaction mixture wasallowed to stir further overnight. Work up (AcOEt/H₂O) and evaporationof organic layer on vacuum afforded the title compound (558 mg) as awhite solid. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 8.42 (d, J 8.9, 2H), 8.01(d, J 8.9, 2H), 7.01 (s, 1H), 5.77 (t, J 5.4, 1H), 4.63 (d, J 5.4, 2H).

Intermediate 20:1-(4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carbaldehyde

Oxalyl chloride (0.32 ml, 3.8 mmol) was dissolved in DCM, cooled to −78°C. and added DMSO (0.5 ml 7.6 mmol) and stirred for 30 mins. To thisintermediate 19 (550 mg, 1.9 mmol) was added, stirred at −78° C. for 20mins and added triethyl amine (1.06 ml, 7.6 mmol). Reaction mixturewarmed to 0° C. and then slowly heated to rt. Work up (H₂O/AcOEt)afforded the title compound (375 mg). 9.85 (s, 1H), 8.41 (d, J 8.6, 2H),7.99 (d, J 8.5, 2H), 7.84 (s, 1H).

Intermediate 21:5-(fluoromethyl)-1-(4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazole

Intermediate 19 (0.5 g, 1.75 mmol) was dissolved in DCM (10 ml) andreaction mixture cooled to 0° C. To this (Diethylamino)sulphurtrifluoride (0.46 ml, 3.5 mmol) was added drop-wise and allowed thereaction mixture to stir at rt for 30 mins. After completion of thereaction, reaction mixture diluted with DCM and washed with water. DCMremoved on rotavapour to obtain the crude. Crude was purified by columnchromatography using EA and petether (7: 97) as eluent to afford thetitle compound (0.41 g) as an yellow solid. ¹H-NMR (δ ppm, CDCl₃, 400MHz): 8.42 (d, J 9, 2H), 7.86 (d, J 9, 2H), 6.94 (d, J 3.4, 1H), 5.42(d, J 48.4, 2H).

Intermediate 22:5-(difluoromethyl)-1-(4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazole

Intermediate 20 (500 mg, 1.75 mmol) was dissolved in DCM, cooled to 0°C. and added (Diethylamino) sulphur trifluoride (0.46 ml, 3.5 mmol).This mixture was stirred at ambient temperature for 30 mins. Water addedto reaction mixture and DCM layer separated was dried on anhydrousNa₂SO₄ and DCM was removed on rotavapour to obtain the crude.Purification (60-120 mesh silica gel) [EA:Petether (60:40)] afforded thetitle compound as an yellow solid. ¹H-NMR (δ ppm, CDCl₃, 400 MHz): 8.42(d, J 9.1, 2H), 7.79 (d, J 9.1, 2H), 7.06 (s, 1H), 6.73 (t, J 53, 1H).

Intermediate 23:4-chloro-3,5-dicyclopropyl-1-(2-fluoro-4-nitrophenyl)-1H-pyrazole

Intermediate 10 (1.15 g, 3.40 mmol) was dissolved in DMF and to thisN-Chlorosuccinimide (0.64 g, 4.8 mmol) was added at 0° C. Then reactionwas allowed to stir at rt for 2h. After completion of the reaction, workup (EtOAc) and purification afforded the title compound (0.575 g).¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 8.18-8.09 (m, 2H), 7.64 (t, J 8.3,1H), 1.98-1.90 (m, 1H), 1.82-1.72 (m, 1H), 0.90-0.80 (m, 4H), 0.68-0.60(m, 4H).

Intermediate 24:4-chloro-5-cyclopropyl-1-(4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazole

Intermediate 13 (1 g, 3.36 mmol) was dissolved in DMF and to thisN-Chlorosuccinimide (0.54 g, 4.0 mmol) was added at 0° C. Then reactionwas allowed to stir at rt for 2h. After completion of the reaction, workup (EtOAc) afforded the title compound (0.802 mg). ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 8.39 (d, J 9, 2H), 7.82 (d, J 9, 2H), 1.91-1.80 (m,1H), 1.10-1.00 (m, 2H), 0.80-0.72 (m, 2H).

Intermediate 25:5-cyclopropyl-1-(2-fluoro-4-nitrophenyl)-3-(trifluoromethyl)-1H-pyrazole

Intermediate 14 (1.05 g, 3.40 mmol) was dissolved in DMF and to thisN-Chlorosuccinimide (0.545 g, 4.08 mmol) was added at 0° C. Thenreaction was allowed to stir at rt for 2h. After completion of thereaction, work up (EtOAc) and purification afforded the title compound(1 g). ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 8.23-8.16 (m, 2H), 7.72 (t, J7.5, 1H), 1.82-1.70 (m, 1H), 0.99-0.82 (m, 2H), 0.74-0.65 (m, 2H).

Intermediate 26:2-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-5-nitropyridine

Intermediate 16 (1.5 g, 5.0 mmol) was dissolved in DMF and to thisN-Chlorosuccinimide (0.8 g, 6 mmol) was added at 0° C. Then reaction wasallowed to stir at rt for 2h. After completion of the reaction, work up(EtOAc) and purification afforded the title compound (0.802 g). ¹H-NMR(δ ppm, DMSO-d₆, 400 MHz): 9.34 (d, J 2.5, 1H), 8.65 (dd, J 2.5, 9, 1H),8.09 (d, J 9, 1H), 2.48-2.38 (m, 1H), 1.13-1.03 (m, 2H), 0.90-0.82 (m,2H).

Intermediate 27: 4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)aniline

Iron powder (0.88 g, 15.8 mmol) and ammonium chloride (17 mg, 0.3 mmol)were added to a solution of intermediate 9 (0.85 g, 3.15 mmol) inEtOH/H₂O (2:1, 15 mL) and the mixture refluxed for half an hour. Themixture was filtered through celite and celite washed with ethanol.Work-up (H₂O/AcOEt) after concentration of the combined layers affordedtitle compound as a yellow solid (0.68 g). ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 7.11 (d, J 8.6, 2H), 6.61 (d, J 8.6, 2H), 5.65 (s, 1H), 5.24 (s,2H), 1.81-1.74 (m, 1H), 1.67-1.60 (m, 1H), 0.86-0.77 (m, 4H), 0.61-0.56(m, 4H). MS (m/z): 240.3 [M+H]⁺.

Intermediate 28: 4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluoroaniline

Iron powder (1.86 g, 34.8 mmol) and ammonium chloride (30 mg, 0.7 mmol)were added to a solution of intermediate 10 (2 g, 7.0 mmol) in EtOH/H₂O(2:1, 30 mL) and the mixture refluxed for one hour. The mixture wasfiltered through celite and celite washed with ethanol. Work-up(H₂O/AcOEt) and concentration of the combined layers afforded titlecompound as a yellow solid (1.34 g).

Intermediate 29:4-(4-chloro-3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluoroaniline

Iron powder (0.48 g, 8.9 mmol) and ammonium chloride (9 mg, 0.17 mmol)were added to a solution of intermediate 23 (0.57 g, 1.8 mmol) inEtOH/H₂O (2:1, 7.5 mL) and the mixture refluxed for one hour. Themixture was filtered through celite and celite washed with ethanol.Work-up (H₂O/AcOEt) after concentration of the combined layers affordedintermediate 29 as a yellow solid (0.46 g). ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 7.02 (t, J 8.6, 1H), 6.45-6.38 (m, 2H), 5.74 (s, 2H), 1.85-1.76 (m1H), 1.61-1.52 (m, 1H), 0.90-0.82 (m, 2H), 0.78-0.70 (m, 4H), 0.69-0.60(m, 2H). MS (m/z): 291.98 [M+H]⁺.

Intermediate 30: 6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-amine

Iron powder (0.79 g, 14.17 mmol) and ammonium chloride (15 mg, 0.28mmol) were added to a solution of intermediate 11 (0.77 g, 2.86 mmol) inEtOH/H₂O (2:1, 15 mL) and the mixture refluxed for one hour. The mixturewas filtered through celite and celite washed with ethanol. Work-up(H₂O/AcOEt) after concentration of the combined layers affordedintermediate 30 as a yellow solid (0.570 g). ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 7.75 (d, J 2.5, 1H), 7.27 (d, J 8.6, 1H), 7.06 (dd, J 2.7, 8.6,1H), 5.67 (s, 1H), 5.43 (s, 2H), 2.39-2.27 (m, 1H), 1.88-1.74 (m, 1H),0.90-0.72 (m, 4H), 0.69-0.50 (m, 4H).

Intermediate 31:4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]aniline

A procedure similar to that employed for intermediate 27 was followed.From intermediate 13 (0.69 g, 2.32 mmol), EtOH-H₂O (2:1, 12 mL), Fe(0.64 g, 15.8 mmol) and NH₄C (0.012 mg, 0.22 mmol), the title compoundwas obtained as yellow solid (0.49 g). ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz):7.19 (d, J 8.64, 2H), 6.65 (d, J 8.64, 2H), 6.47 (s, 1H), 5.46 (s, 2H),1.75-1.69 (m, 1H), 0.94-0.89 (m, 2H), 0.77-0.73 (m, 2H). MS (m/z): 268.1[M+H]⁺.

Intermediate 32:4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]aniline

Iron powder (0.67 g, 12.05 mmol) and ammonium chloride (25 mg, 4.8 mmol)were added to a solution of intermediate 24 (0.800 g, 2.41 mmol) inEtOH/H₂O (2:1, 15 mL) and the mixture refluxed for one hour. The mixturewas filtered through celite and celite washed with ethanol. Work-up(H₂O/AcOEt) and concentration of the combined layers affordedintermediate 32 as a yellow solid (0.720 g). ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 7.19 (d, J 8.6, 2H), 6.63 (d, J 8.6, 2H), 5.51 (s, 2H), 1.89-1.80(m, 1H), 0.88-0.80 (m, 2H), 0.65-0.61 (m, 2H).

Intermediate 33:4-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluoroaniline

Iron powder (4.75 g, 85.1 mmol) and ammonium chloride (90 mg, 1.7 mmol)were added to a solution of intermediate 14 (5 g, 17.00 mmol) inEtOH/H₂O (2:1, 45 mL) and the mixture refluxed for one hour. The mixturewas filtered through celite and celite washed with ethanol. Work-up(H₂O/AcOEt) after concentration of the combined layers afforded titledcompound as a yellow solid (4.3 g). ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz):7.16 (t, J 8.5, 1H), 6.50-6.45 (m, 3H), 5.86 (s, 2H), 1.60-1.51 (m, 1H),0.91-0.82 (m, 2H), 0.76-0.69 (m, 2H).

Intermediate 34:4-(4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)-3-fluoroaniline

Iron powder (0.8 g, 56 mmol) and ammonium chloride (300 mg, 5.8 mmol)were added to a solution of intermediate 26 (1.0 g, 2.88 mmol) inEtOH/H₂O (2:1, 15 mL) and the mixture refluxed for one hour. The mixturewas filtered through celite and celite washed with ethanol. Work-up(H₂O/AcOEt) and concentration of the combined layers affordedintermediate 34 as a pale-yellow solid (0.87 g). ¹H-NMR (δ ppm, DMSO-d₆,400 MHz): 7.19 (t, J 8.6, 1H), 6.50-6.45 (m, 2H), 5.91 (s, 2H),1.72-1.62 (m, 1H), 0.87-0.79 (m, 2H), 0.76-0.67 (m, 2H).

Intermediate 35:4-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)-3,5-difluoroaniline

Iron powder (1.14 g, 20.5 mmol) and ammonium chloride (21 mg 0.41 mmol)were added to a solution of intermediate 15 (1.36 g, 4.1 mmol) inEtOH/H₂O (2:1, 30 mL) and the mixture refluxed for one hour. The mixturewas filtered through celite and celite washed with ethanol. Work-up(H₂O/AcOEt) and concentration of the combined layers afforded titlecompound (680 mg) as a yellow solid. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz):6.54 (s, 1H), 6.37 (d, J 10.6, 21H), 6.24 (s, 2H), 1.59-1.49 (m, 1H),0.92-0.84 (m, 2H), 0.74-0.66 (m, 2H). MS (m/z): 304.06 ([M+H]⁺).

Intermediate 36:6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-amine

Iron powder (0.279 g, 5.00 mmol) and ammonium chloride (5 mg, 0.09 mmol)were added to a solution of intermediate 16 (0.77 g, 2.86 mmol) inEtOH/H₂O (2:1, 9 mL) and the mixture refluxed for one hour. The mixturewas filtered through celite and celite washed with ethanol. Work-up(H₂O/AcOEt) after concentration of the combined layers affordedintermediate 36 as a yellow solid (0.239 g). ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 7.84 (d, J 2.6, 1H), 7.33 (d, J 8.6, 1H), 7.12 (dd, J 2.6, 8.6,1H), 6.49 (s, 1H), 5.69 (s, 2H), 2.45-2.36 (m, 1H), 0.90-0.81 (m, 2H),0.74-0.65 (m, 2H). MS (m/z): 269.2 [M+H]⁺.

Intermediate 37:6-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-amine

Iron powder (1.56 g, 28.0 mmol) and ammonium chloride (600 mg, 11.2mmol) were added to a solution of intermediate 26 (1.7 g, 5.60 mmol) inEtOH/H₂O (2:1, 15 mL) and the mixture refluxed for one hour. The mixturewas filtered through celite and celite washed with ethanol. Work-up(H₂O/AcOEt) and concentration of the combined layers affordedintermediate 37 as a yellow solid (1.1 g). ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 8.04 (s, 1H), 7.39 (d, J 8.2, 1H), 7.20 (d, J 8, 1H), 4.26 (s,2H), 2.10-1.99 (m, 1H), 1.96-1.85 (m, 2H), 1.84-1.70 (m, 2H).

Intermediate 38:2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-5-amine

Iron powder (466 mg, 1.67 mmol) and ammonium chloride (8 mg, 0.17 mmol)were added to a solution of intermediate 17 (0.41 g, 1.41 mmol) inEtOH/H₂O (2:1, 7.5 mL) and the mixture refluxed for one hour. Themixture was filtered through celite and celite washed with ethanol.Work-up (H₂O/AcOEt) and concentration of the combined layers affordedintermediate 38 (0.35 g) as a yellow solid. ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 8.20 (s, 2H), 6.52 (s, 1H), 5.99 (s, 2H), 2.22-2.12 (m, 1H),1.00-0.85 (m, 2H), 0.80-0.68 (m, 2H). MS (m/z): 267.73 ([M−H]⁻).

Intermediate 39:4-[5-(fluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]aniline

Iron powder (434 mg, 7.78 mmol) and ammonium chloride (8 mg, 0.15 mmol)were added to a solution of intermediate 21 (450 mg, 1.56 mmol) inEtOH/H₂O (2:1, 15 mL) and the mixture refluxed for one hour. The mixturewas filtered through celite and celite washed with ethanol. Work-up(H₂O/AcOEt) and concentration of the combined layers afforded titlecompound (335 mg) as a yellow solid (460 mg). ¹H-NMR (δ ppm, DMSO-d₆,400 MHz): 7.16 (d, J 8.6, 2H), 7.12 (d, J 2.8, 1H), 6.65 (d, J 8.6, 2H),5.5 (s, 2H), 5.4 (d, J 48.3, 2H).

Intermediate 40:4-[5-(difluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]aniline

Iron powder (0.39 g, 7.78 mmol) and ammonium chloride (90 mg, 1.7 mmol)were added to a solution of intermediate 22 (0.41 g, 1.41 mmol) inEtOH/H₂O (2:1, 7.5 mL) and the mixture refluxed for one hour. Themixture was filtered through celite and celite washed with ethanol.Work-up (H₂O/AcOEt) and concentration of the combined layers affordedintermediate 40 (0.35 g) as a yellow solid. ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 7.29 (s, 1H), 7.16 (d, J 8.7, 2H), 7.10 (t, J 53, 1H), 6.64 (d, J8.7, 2H), 5.60 (s, 2H).

Intermediate 41:2-chloro-N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]acetamide

Chloroacetyl chloride (0.2 mL, 2.39 mmol) was added to a solution ofintermediate 27 (600 mg, 2.24 mmol) in dichloromethane (DCM) at 0° C.The mixture was stirred for 15 mins. Work-up (H₂O/DCM) gave theintermediate 41 which was used in the next step without furtherpurification.

Intermediate 42:2-chloro-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}acetamide

Chloroacetyl chloride (0.05 mL, 0.62 mmol) was added to a solution ofintermediate 31 (150 mg, 0.561 mmol) in dichloromethane (DCM) at 0° C.The mixture was stirred for 15 mins. Work-up (H₂O/DCM) gave the titledcompound, which was used in the next step without further purification.

Intermediate 43:2-chloro-N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}acetamide

Chloroacetyl chloride (0.16 mL, 2.00 mmol) was added to a solution ofintermediate 36 (500 mg, 1.86 mmol) in dichloromethane (DCM) at 0° C.The mixture was stirred for 15 mins. Work-up (H₂O/DCM) gave theintermediate 43 which was used in the next step without furtherpurification.

Intermediate 44:5-cyclopropyl-1-(4-iodophenyl)-3-(trifluoromethyl)-1H-pyrazole

To the intermediate 31 (2 g, 7.49 mmol) in 5 ml water was added Conc.HCl (5 ml) and cooled to 0° C. To this sodium nitrite solution (1 g, 15mmol) was added slowly and stirred for 15 mins at 0° C. To this mixturepotassium iodide solution (2.5 g, 15 mmol), was added at sametemperature and stirred the reaction mixture at rt. Work-up (H₂O/AcOEt)and purification gave the desired product as a yellow liquid. ¹H-NMR (δppm, CDCl₃, 400 MHz): 7.92 (d, J 8.6, 2H), 7.47 (d, J 8.6, 2H), 6.65 (s,1H), 1.90-1.80 (m, 1H), 1.00-0.90 (m, 2H), 0.85-0.77 (m, 2H).

Intermediate 45:5-cyclopropyl-1-(2-fluoro-4-iodophenyl)-3-(trifluoromethyl)-1H-pyrazole

To the intermediate 33 (1.9 g, 7.20 mmol) in 5 ml water was added Cone.HCl (5 ml) and cooled to 0° C. To this sodium nitrite solution (1 g, 15mmol) was added slowly and stirred for 15 mins at 0° C. To this mixturepotassium iodide solution (2.5 g, 15 mmol) was added at same temperatureand stirred the reaction mixture at rt. Work-up (H₂O/AcOEt) andpurification gave the desired product as a yellow colour liquid. ¹H-NMR(δ ppm, DMSO-d₆, 400 MHz): 8.01 (dd, J 1.7, 9.5, 1H), 7.79 (dd, J 1.7,8.4, 1H), 7.45 (t, J 8.1, 1H), 6.63 (s, 1H), 1.64-1.56 (m, 1H),0.92-0.84 (m, 2H), 0.79-0.71 (m, 2H).

Intermediate 46: 6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)nicotinic acid

To a solution of intermediate 12 (300 mg, 1 mmol) in THF:H₂O (1:1) addedPotassium hydroxide (83 mg, 1.5 mmol) and refluxed for 5 h. Aftercompletion of the reaction, reaction mixture was acidified with 2N HCland worked up (H₂O/AcOEt) to afford the title compound (240 mg). ¹H-NMR(δ ppm, DMSO-d₆, 400 MHz): 13.3 (bs, 1H), 8.90 (d, J 2.0, 1H), 8.35 (dd,J 2.2, 8.6, 1H), 7.89 (d, J 8.6, 1H), 5.93 (s, 1H), 2.90-2.80 (m, 1H),1.90-1.80 (m, 1H), 1.00-0.82 (m, 4H), 0.75-0.62 (m, 4H).

Intermediate 47:4-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzoic acid

Magnesium (32 mg, 1.32 mmol) and a pinch of iodine suspended in etherunder inert atmosphere. To this small amount of methyl iodide was addedand refluxed the reaction mixture to start Grignard formation. At thisstage intermediate 44 (500 mg, 1.32 mmol) was added and continued thereaction under reflux condition. After complete consumption of thestarting material, reaction mixture cooled to rt and added dry icepieces into it followed by con. HCl. Solid that formed was filtered anddried on high vacuum to obtain the title compound (100 mg) as a yellowsolid. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 13.2 (bs, 1H), 8.11 (d, J 8.6,2H), 7.82 (d, J 8.6, 2H), 6.7 (s, 1H), 1.99-1.90 (m, 1H), 1.04-0.94 (m,2H), 0.88-0.80 (m, 2H).

Intermediate 48:4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorobenzoicacid

Magnesium (143 mg, 6 mmol) and a pinch of iodine suspended in etherunder inert atmosphere. To this small amount of methyl iodide was addedand refluxed the reaction mixture to start Grignard formation. At thisstage intermediate 45 (790 mg, 2 mmol) was added and continued thereaction under reflux condition. After complete consumption of thestarting material, reaction mixture cooled to rt and added dry icepieces into it followed by 2N HCl. Solid that formed was filtered anddried on high vacuum to obtain the title compound (160 mg) as anoff-white solid. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 13.6 (bs, 1H),7.97-7.92 (m, 2H), 7.84-7.78 (m, 1H), 6.68 (s, 1H), 1.69-1.61 (m, 1H),0.94-0.87 (m, 2H), 0.80-0.74 (m, 2H).

Intermediate 49: Ethyl6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]nicotinate

A solution of intermediate 5 (0.84 g, 4.7 mmol) and K₂CO₃ (1.9 g, 14.1mmol) in DMSO (10 mL) was heated at 80° C. under nitrogen for 0.5 h. Tothe mixture, ethyl-6-chloronicotinate (3.8 g, 20.3 mmol) was added andstirred at 80° C. for 4 h. Work-up (H₂O/AcOEt) and purification affordedthe title compound (0.26 g). ¹H-NMR (δ ppm, CDCl₃, 400 MHz): 9.11 (d, J1, 1H), 8.44 (d, J 2.2, 8.6, 1H), 8.00 (d, J 8.6, 1H), 6.25 (s, 1H),4.45 (q, J 7.1, 2H), 2.91-2.80 (m, 1H), 1.43 (t, J 7.1, 3H), 1.11-1.01(m, 2H), 0.79-0.70 (m, 2H).

Intermediate 50:6-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)nicotinic acid

To a solution of intermediate 49 (600 mg, 1.8 mmol) in MeOH:H₂O (2:1)added sodium hydroxide (221 mg, 5.4 mmol) and refluxed for 2 h. Aftercompletion of the reaction, reaction mixture was acidified with 2N HCland worked up (H₂O/AcOEt) to afford the pure compound (452 mg). ¹H-NMR(δ ppm, DMSO-d₆, 400 MHz): 9.18 (d, J 2.0, 1H), 8.50 (dd, J 2.2, 8.6,1H), 8.07 (d, J 8.6, 1H), 6.27 (s, 1H), 2.92-2.82 (m, 1H), 1.14-1.04 (m,2H), 0.78-0.71 (m, 2H).

Intermediate 51: ethyl 2-[(dimethylamino)methylene]-3-oxobutanoate

Ethyl acetoacetate (15 g, 115 mmol) and N,N-Dimethylformamide dimethylAcetal (13.7 g, 115 mmol) stirred at rt for overnight. After completionof the reaction, reaction mixture distilled on rotavapour to obtain thecrude. Crude was purified by column chromatography over 60-120 meshsilica gel using EtOAc and petether (10:90) as eluent to obtain thetitle compound (20 g).

Intermediate 52: ethyl 4-methylpyrimidine-5-carboxylate

Intermediate 51 (9.7 g, 52.4 mmol) and Formamidine acetate (5.4 g, 52.4mmol), were dissolved in EtOH and added NaOEt (3.6 g, 52.4 mmol). Thismixture was refluxed for 6h. After that, ethanol removed on rotavapourfollowed by work-up (AcOEt/H₂O) to obtain the crude. Crude was purifiedby column chromatography using 60-120 mesh silicagel and AcOEt andPetether (25:75) as eluent to obtain the title compound (2.7 g).

Intermediate: 53: 4-methylpyrimidine-5-carboxylic acid

Intermediate 52 (2.6 g, 15.64 mmol) dissolved in sodium hydroxidesolution (1.88 g, 47 mmol in 4 ml water) and refluxed. The reactionmixture was cooled to rt and acidified with con HCl to obtain the solid.Solid that obtained was filtered and dried to obtain the title compound(1.5 g) as an yellow solid. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 13.5 (bs,1H), 9.14 (s, 1H), 9.05 (s, 1H), 2.71 (s, 3H).

Intermediate 54: ethyl 2,4-dimethylpyrimidine-5-carboxylate

Intermediate 51 (17.6 g, 95 mmol) and acetamidine hydrochloride (17.6 g,95 mmol), were dissolved in EtOH and added NaOEt (6.5 g, 95 mmol). Thismixture was refluxed for 4h. After that, ethanol removed on rotavapourfollowed by work-up (AcOEt/H₂O) to obtain the crude. Crude was purifiedby column chromatography using 60-120 mesh silicagel and AcOEt andPetether (25:75) as eluent to obtain the title compound (7.3 g).

Intermediate 55: 2,4-dimethylpyrimidine-5-carboxylic acid

Intermediate 54 (7.3 g, 40.5 mmol) dissolved in sodium hydroxidesolution (4.86 g, 121.6 mmol in 10 ml water) and refluxed. The reactionmixture was cooled to rt and acidified with con HCl to obtain the solid.Solid that obtained was filtered and dried to obtain the title compoundquantitatively as an yellow solid. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz):13.5 (bs, 1H), 8.93 (s, 1H), 2.66 (s, 3H), 2.60 (s, 3H).

Intermediate 56: ethyl 4-methylthiazole-5-carboxylate

4-methylthiazole-5-carboxylic acid was dissolved in DCM, cooled to 0°C., added oxalyl chloride (7.6 ml, 88 mmol) and DMF (2 drops). Reactionmixture was stirred for 30 mins and DCM was removed on rotavapour.Residue was dissolved in MeOH at 0° C. and stirred for 30 mins at rt.MeOH was removed on rotavapour and crude was worked up (AcOEt/H₂O) toobtain the title compound (4.1 g) as a white solid. ¹H-NMR (δ ppm,CDCl₃, 400 MHz): 8.83 (s, 1H), 4.35 (q, J 7.2, 2H), 2.78 (s, 3H), 1.37(t, J 7.2, 3H).

Intermediate 57: (4-methylthiazol-5-yl)methanol

Intermediate 56 (262 mg, 1.6 mmol) was dissolved in MeOH and addedsodium borohydride (126 mg, 3.2 mmol) and stirred the reaction mixtureat rt for overnight. MeOH was removed on rotavapour and residue wasworked up (AcOEt/H₂CO) to obtain the title compound (183 mg) as a whitesolid. ¹H-NMR (δ ppm, CDCl₃, 400 MHz): 8.67 (s, 1H), 4.82 (s, 2H), 2.44(s, 3H).

Intermediate 58: 4-methylthiazole-5-carbaldehyde

Oxalyl chloride (0.8 ml, 9.8 mmol) was dissolved in DCM, cooled to −78°C. and added DMSO (1.39 ml 19.6 mmol) and stirred for 30 mins. To thisintermediate 57 (630 mg, 4.9 mmol) was added, stirred at −78° C. for 20mins and added triethyl amine (2.7 ml, 7.6 mmol). Reaction mixturewarmed to 0° C. and then slowly heated to rt. Work up (H₂O/AcOEt)afforded the title compound (408 mg) as a yellow solid. 10.13 (s, 1H),9.37 (s, 1H), 2.71 (s, 3H).

Intermediate 59: 4-methylthiazol-5-amine

4-Methylthiazole-5-carboxylic acid (1 g, 7 mmol) was dissolved inacetone (50 mL) and cooled to 0° C. To this mixture triethyl amine (0.84g, 8.3 mmol) was added and after 5 mins ethylchloroformate (0.9 g, 8.3mmol) was added slowly. This mixture stirred at rt for 1 h and thenSodium azide solution (0.9 g, 13.8 mmol in 5 ml H₂O) was added to it at0° C. The reaction mixture was stirred for half an hour at rt, acetonewas removed and residue was extracted with ether. Ether removed onrotavapour to obtain the crude. Crude was dissolved in 1,4-dioxane,added Conc. H₂SO₄ and refluxed for 1h. The reaction mixture cooled tort, pH adjusted to 9 with aq NaOH and extracted with EtOAc to obtain thetitle compound (0.24 g) as a brown solid. ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 7.98 (s, 1H), 5.13 (s, 2H), 2.11 (s, 3H).

Intermediate 60: 1-phenylcyclobutanecarbonitrile

Sodium hydride (1.54 g, 64.1 mmol) dissolved in DMF (15 ml) and cooledto 0° C. Phenyl acetonitrile (3 g, 25.6 mmol) and 1,3-dibromopropane(5.2 g, 25.6 mmol) were dissolved in DMF (15 ml) and added to abovemixture drop-wise at 0° C. This mixture was heated to rt and continuedstirring for 2h. Work up (H₂O/Toluene) afforded the title compound (2.61g) as crude, which was used in the next without further purification.

Intermediate 61: 1-phenylcyclobutanecarboxylic acid

Intermediate 60 (2.6 g, 16.54 mmol) was dissolved in ethyleneglycol andadded potassium hydroxide (5.6 g, 99.2 mmol). This mixture was heated to160° C. for 2h. After two hours reaction mixture was cooled to rt andtoluene and water were added. Aqueous layer separated and acidified withHCl and pH adjusted to 4. Aqueous layer extracted with ethyl acetate andethyl acetate layer was dried on anhydrous sodium sulphate. Ethylacetate removed on rotavapour to obtain the title compound (930 mg) as awhite solid.

Intermediate 62: (Z)-1-cyclopropyl-4,4-difluoro-3-hydroxybut-2-en-1-one

Hexamethyldisilazane (1 g, 6.2 mmol) and diethylether were taken in RBFand cooled to −78° C. under nitrogen atmosphere. n-BuLi (7.7 ml) wasadded and stirred for 15 mins. Cyclopropyl methyl ketone (0.66 ml, 6.8mmol) was added and stirred at −78° C. for 45 mins. At this stage methyl2,2-difluoroacetate (1.62 ml, 18.58 mmol) was added and brought thereaction mixture to rt and allowed to stir for overnight. Reactionmixture quenched with water, ether layer separated and aqueous layer wasacidified with 1N HCl. Aqueous layer extracted with diethyl ether andether was dried over anhydrous Na₂SO₄. Diethyl ether was removed onrotavapour to obtain the title compound (390 mg) which was used in thenext step without further purification. ¹H-NMR (δ ppm, CDCl₃, 400 MHz):6.08 (s, 1H), 5.95 (t, J 54.2, 1H), 1.84-1.76 (m, 1H), 1.34-1.29 (m,2H), 1.10-1.03 (m, 2H).

Intermediate 63: 5-cyclopropyl-3-(difluoromethyl)-1H-pyrazole

Intermediate 62 (390 mg, 2.4 mmol) dissolved in ethanol (2 ml), addedhydrazine hydrate (0.13 ml, 2.65 mmol) and HCl (0.18 ml). This mixturewas refluxed for 3 h. After 3 h, ethanol was removed on rotavapour andwork up (H₂O/AcOEt) afforded the title compound (290 mg) which was usedin the next step without further purification. ¹H-NMR (5 ppm, CDCl₃, 400MHz): 12.96 (s, 1H), 6.84 (t, J 54.8, 1H), 6.15 (s, 1H), 1.95-1.87 (m,1H), 0.99-0.91 (m, 2H), 0.74-0.66 (m, 2H).

Intermediate 64: Mixture of3-cyclopropyl-5-(difluoromethyl)-1-(2-fluoro-4-nitrophenyl)-1H-pyrazoleand5-cyclopropyl-3-(difluoromethyl)-1-(2-fluoro-4-nitrophenyl)-1H-pyrazole

Intermediate 63 (100 mg, 0.63 mmol), Cs₂CO₃ (622 mg, 1.9 mmol), acetone(5 mL) were mixed and heated to reflux. After 30 mins,1,2-difluoro-4-benzene (253 mg, 1.59 mmol) was added and continued thereaction for 1 h. Work up (H₂O/AcOEt) followed by purification using60-120 mesh silica gel and EtOAc and Petether (3:97) as eluent affordedthe title compound (65 mg), ¹H-NMR (6 ppm, CDCl₃, 400 MHz): 8.23-8.10(m, 2H), 7.78-7.72 (m, 1H), 6.71 (t, J 54.8, 0.37H), 6.66 (t, J 54.8,0.63H), 6.43 (s, 0.37H), 6.25 (s, 0.63H), 2.05-1.95 (m, 0.37H),1.70-1.61 (m, 0.63H), 1.04-0.94 (m, 2H), 0.86-0.80 (m, 0.74H), 0.77-0.71(m, 1.26H).

Intermediate 65: Mixture of4-(3-cyclopropyl-5-(difluoromethyl)-1H-pyrazol-1-yl)-3-fluoroaniline and4-(5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-yl)-3-fluoroaniline

Iron powder (120 mg, 2.31 mmol) and ammonium chloride (2 mg, 0.046 mmol)were added to a solution of intermediate 64 (130 mg, 0.46 mmol) inEtOH/H₂O (2:1, 1.65 mL) and the mixture refluxed for half an hour. Themixture was filtered through celite and celite washed with ethanol.Work-up (H₂O/AcOEt) and concentration of the combined layers affordedtitle compound as a yellow solid (90 mg). ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 7.12 (t, J 8.5, 0.63H), 7.08-7.03 (m, 0.37H), 6.90 (t, J 54.8,0.63H), 6.84 (t, J 54.8, 0.37H), 6.50-6.38 (m, 2.37H), 6.25 (s, 0.63H),5.81 (s, 2H), 1.95-1.86 (m, 0.37H), 1.57-1.48 (m, 0.63H), 0.90-0.82 (m,2H), 0.71-0.64 (m, 2H).

General Procedure for Amide Formation:

Procedure-1: A solution of an appropriate aniline (1 eq.), the requisiteacid (1.1 eq.), EDC.HCl (1.2 eq.), HOBt (0.5 eq.) and TEA (3 eq.) in DMFwas stirred at RT overnight. Work-up (H₂O/AcOEt) and purification gavethe desired product.

Procedure-2: Acid (1 eq.) was dissolved in DCM, cooled to 0° C., addedoxalyl chloride (3 eq.) and three drops of DMF. The reaction mixture wasstirred at room temperature for 30 mins and DCM was removed onrotavapour to obtain the acid chloride. Amine was dissolved in DCM underN₂ atmosphere and added Pyridine (1.3 eq). To this mixture acid chloridein DCM was added and allowed to stir at room temperature until amine wastotally consumed. Work-up (H₂O/AcOEt) and purification gave the desiredproduct.

The following compounds were prepared using these procedures:

Example 1N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide

Following the general procedure-1, the title compound (60 mg) wasprepared from 4-methyl-1,2,3-thiadiazole-5-carboxylic acid (86 mg, 0.60mmol) and intermediate 27 (120 mg, 0.50 mmol) as a white solid. M.P.:117-120° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.86 (s, 1H), 7.79 (d, J8.8, 2H), 7.59 (d, J 8.8, 2H), 5.81 (s, 1H), 2.81 (s, 3H), 1.84-1.77 (m,2H), 0.92-0.90 (m, 2H), 0.89-0.81 (m, 2H), 0.68-0.61 (m, 4H). MS (m/z):363.96 [M−H]⁻.

Example 2N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-4-methylthiazole-5-carboxamide

Following the general procedure-1, the title compound (102 mg) wasprepared from 4-methylthiazole-5-carboxylic acid (78 mg, 0.54 mmol) andintermediate 27 (120 mg, 0.50 mmol) as an off-white solid. M. P.110-114° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.37 (s, 1H), 9.13 (s,1H), 7.78 (d, J 8.7, 2H), 7.55 (d, J 8.7, 2H), 5.79 (s, 1H), 2.61 (s,3H), 1.89-1.71 (m, 2H), 0.94-0.80 (m, 4H), 0.69-0.60 (m, 4H). MS (m/z):363.11 [M−H]⁻.

Example 3N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2,4-dimethylthiazole-5-carboxamide

Following the general procedure-1, the title compound (87 mg) wasprepared from 2,4-dimethylthiazole-5-carboxylic acid (94 mg, 0.59 mmol)and intermediate 27 (120 mg, 0.50 mmol) as an off-white solid. M. P.98-114° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.22 (s, 1H), 7.76 (d, J8.4, 2H), 7.52 (d, J 8.4, 2H), 5.79 (s, 1H), 2.66 (s, 3H), 2.54 (s, 3H),1.88-1.73 (m, 2H), 0.95-0.82 (m, 4H), 0.69-0.61 (m, 4H). MS (m/z):379.20 [M+H]⁺.

Example 4N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-5-methylisoxazole-4-carboxamide

Following the general procedure-2, the title compound (55 mg) wasprepared from 5-methylisoxazole-4-carbonyl chloride (79 mg) andintermediate 27 as a white solid. M. P. 153-158° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 10.17 (s, 1H), 9.06 (s, 1H), 7.79 (d, J 7.6, 2H),7.56 (d, J 7.6, 2H), 5.80 (s, 1H), 2.68 (s, 3H), 1.84-1.78 (m, 2H),0.91-0.70 (m, 4H), 0.69-0.55 (m, 4H). MS (m/z): 347.08 [M−H]⁻.

Example 5N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-3,5-dimethylisoxazole-4-carboxamide

Following the general procedure-1, the title compound (147 mg) wasprepared from 3,5-dimethylisoxazole-4-carboxylic acid (155 mg, 1 mmol)and intermediate 27 (150 mg, 0.62 mmol) as a yellow solid. M.P.:115-119° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.18 (s, 1H), 7.76 (d, J8.7, 2H), 7.55 (d, J 8.7, 2H), 5.79 (s, 1H), 2.55 (s, 3H), 2.33 (s, 3H),1.88-1.73 (m, 2H), 0.94-0.80 (m, 4H), 0.70-0.61 (m, 4H). MS (m/z):363.27 [M+H]⁺.

Example 6 N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]benzamide

Following the general procedure-2, title compound (90 mg) was preparedfrom benzoyl chloride (64 mg, 0.45 mmols) and intermediate 27 (100 mg,0.41 mmols) as a pale yellow solid. M. P. 133-138.5° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 10.39 (s, 1H), 7.96 (d, J 7.1, 2H), 7.91 (d, J 9.0,2H), 7.61-7.51 (m, 5H), 5.79 (s, 1H), 1.85-1.76 (m, 2H), 0.93-0.81 (m,4H), 0.68-0.61 (m, 4H). MS (m/z): 341.9 [M−H]⁻.

Example 7N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-methylbenzamide

Following the general procedure-1, the title compound (130 mg) wasprepared from intermediate 27 (200 mg, 0.84 mmol) and o-toluic acid (182mg, 1.34 mmol) as an yellow solid. M.P.: 127.5-129.8° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 10.44 (s, 1H), 7.85 (d, J 8.8, 2H), 7.57 (d, J 8.7,1H), 7.53 (d, J 8.8, 2H), 7.47 (d, J 7.5, 1H), 7.42-7.37 (m, 1H),7.33-7.27 (m, 2H), 2.38 (s, 3H), 1.90-1.73 (m, 2H), 0.93-0.80 (m, 4H),0.69-0.61 (m, 4H). MS (m/z): 358.03 [M+H]⁺.

Example 8N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2,6-difluorobenzamide

The title compound (77 mg) was prepared from 2,6-difluorobenzoic acidand intermediate 27 (120 mg, 0.50 mmol) as a white solid. M. P. 158-163°C. ¹H-NMR (8 ppm, DMSO-d₆, 400 MHz): 10.93 (s, 1H), 7.79 (d, J 8.8, 2H),7.63-7.56 (m, 3H), 7.25 (t, J 8.0, 2H), 1.85-1.80 (m, 2H), 0.89-0.85 (m,2H), 0.84-0.81 (m, 2H), 0.68-0.61 (m, 4H). MS (m/z): 378.4 [M−H]⁻.

Example 9N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2,3-difluorobenzamide

Following the general procedure-1, the title compound (120 mg) wasprepared from 2,3-difluorobenzoic acid and intermediate 27 (95 mg, 0.60mmol) as a white solid. M. P. 135-142° C. ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 10.69 (s, 1H), 7.81 (d, J 8.8, 2H), 7.65-7.61 (m, 1H), 7.57 (d, J8.8, 2H), 7.51-7.48 (m, 1H), 7.37-7.32 (m, 1H), 1.87-1.75 (m, 2H),0.93-0.85 (m, 2H), 0.84-0.81 (m, 2H), 0.68-0.61 (m, 4H). MS (m/z):380.26 [M+H]⁺.

Example 10N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl-3-(methylsulfonyl)benzamide

Following the general procedure-2, the title compound (63 mg) wasprepared from 3-(methylsulfonyl)benzoyl chloride (100 mg, 0.45 mmol) andintermediate 27 (120 mg, 0.50 mmol) as a pale yellow solid. M. P.203-208° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.66 (s, 1H), 8.48 (s,1H), 8.30 (d, J 7.5, 1H), 8.14 (d, J 7.5, 1H), 7.89 (d, J 8.8, 2H), 7.83(t, J 7.8, 1H), 7.59 (d, J 8.8, 2H), 5.80 (s, 1H), 3.29 (s, 31H),1.88-1.75 (m, 2H), 0.96-0.81 (m, 4H), 0.69-0.60 (m, 4H). MS (m/z):422.29 [M+H]⁺.

Example 11N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-4-(methylsulfonyl)benzamide

Following the general procedure-2, the title compound (97 mg) wasprepared from 4-(methylsulfonyl)benzoyl chloride (100 mg, 0.46 mmol) andintermediate 27 (110 mg, 0.45 mmol) as an yellow solid. M. P. 171-176°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.64 (s, 1H), 8.18 (d, J 8.3, 2H),8.09 (d, J 8.3, 2H), 7.89 (d, J 8.8, 2H), 7.58 (d, J 8.8, 2H), 5.80 (s,1H), 3.29 (s, 3H), 1.92-1.85 (m, 2H), 0.90-0.81 (m, 4H), 0.68-0.61 (m,4H). MS (m/z): 422.29 [M+H]⁺.

Example 122-chloro-N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-5-(methylthio)benzamide

Following the general procedure-1, the title compound (24 mg) wasprepared from 2-chloro-5-(methylthio)benzoic acid (109 mg, 0.54 mmol)and intermediate 27 (120 mg, 0.45 mmol) as a pale yellow solid. M. P.168-173° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.66 (s, 1H), 7.82 (d, J8.8, 2H), 7.55 (d, J 8.8, 2H), 7.49-7.45 (m, 2H), 7.39-7.36 (m, 1H),5.79 (s, 1H), 2.52 (s, 3H), 1.87-1.74 (m, 2H), 0.93-0.88 (m, 2H),0.86-0.81 (m, 2H), 0.67-0.61 (m, 4H). MS (m/z): 422.03 [M−H]⁻.

Example 132-chloro-N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl)-5-(methylsulfonyl)benzamide

Following the general procedure-2, the title compound (58 mg) wasprepared from 2-chloro-5-(methylsulfonyl)benzoyl chloride (120 mg, 0.47mmol) and intermediate 27 (120 mg, 0.45 mmol) as a pale yellow solid. M.P. 60-65° C. ¹H-NMR (6 ppm, DMSO-d₆, 400 MHz): 10.85 (s, 1H), 8.16 (d, J2.1, 1H), 8.03 ((dd, J 2.0, 8.4, 1H), 7.88 (d, J 8.4, 1H) 7.81 (d, J8.8, 2H), 7.58 (d, J 8.8, 2H), 5.80 (s, 1H), 3.31 (s, 3H), 1.86-1.74 (m,2H), 0.95-0.82 (m, 4H), 0.70-0.59 (m, 4H). MS (m/z): 454.07 [M−H]⁻.

Example 14 N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]nicotinamidehydrochloride

Following the general procedure-1,N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]nicotinamide (220 mg) wasprepared from intermediate 27 (200 mg, 0.84 mmol) and isonicotinic acid(164 mg, 1.34 mmol) as an off-white solid and dissolved in THF.Saturated HCl in diethyl ether was added to this solution at 0° C. andstirred for 15 min. Solid that separated out was filtered and dried togive the title compound (190 mg) as an off-white solid. M.P.:230.2-232.9° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.97 (s, 1H), 9.34(s, 1H), 8.94 (d, J 3.6, 1H), 8.74 (bs, 1H), 7.93 (d, J 8.8, 3H), 7.60(d, J 8.8, 2H), 5.82 (s, 1H), 1.90-1.74 (m, 2H), 0.95-0.80 (m, 4H),0.70-0.60 (m, 4H). MS (m/z): 345.15 [M+H−HCl]⁺.

Example 15N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]isonicotinamidehydrochloride

Following the general procedure-1N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]isonicotinamide (40 mg)was prepared from isonicotinic acid (74 mg, 0.60 mmol) and intermediate27 (120 mg, 0.50 mmol) as a pale yellow solid and dissolved in THF.Saturated HCl in diethyl ether was added to this solution at 0° C. andstirred for 15 min. Solid that separated out was filtered and dried togive the title compound (47 mg) as an yellow solid. M. P. 232-238° C.¹H-NMR (5 ppm, DMSO-d₆, 400 MHz): 11.08 (s, 1H), 9.01 (d, J 6.0, 2H),8.30 (d, J 6.0, 2H), 7.94 (d, J 8.8, 2H), 7.61 (d, J 8.8, 2H), 5.83 (s,1H), 1.90-1.74 (m, 2H), 0.95-0.80 (m, 4H), 0.70-0.60 (m, 4H). MS (m/z):345.22 [M−H−HCl]⁻.

Example 16N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-3-fluoroisonicotinamide

Following the general procedure-1, the title compound (60 mg) wasprepared from intermediate 27 (200 mg, 0.84 mmol) and3-fluoroisonicotinic acid (188 mg, 1.3 mmol) as an off-white solid.M.P.: 135.2-139.3° C. ¹H-NMR (5 ppm, DMSO-d₆, 400 MHz): 10.84 (s, 1H),8.77 (s, 1H), 8.60 (d, J 4.7, 1H), 7.81 (d, J 8.9, 2H), 7.71 (t, J 5.4,1H), 7.59 (d, J 8.9, 2H), 5.80 (s, 1H), 1.90-1.73 (m, 2H), 0.95-0.79 (m,4H), 0.69-0.60 (m, 4H). MS (m/z): 363.14 [M+H]⁺.

Example 173,5-dichloro-N-(4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl)isonicotinamide

Following the general procedure-2, the title compound (168 mg) wasprepared from intermediate 27 (200 mg, 0.84 mmol) and3,6-dichloropyridine-4carboxylic acid (211 mg, 1 mmol) as a white solid.M.P.: 159-164° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.09 (s, 1H), 8.81(s, 2H), 7.76 (d, J 8.9, 2H) 7.60 (d, J 8.9, 2H), 5.80 (s, 1H),1.88-1.75 (m, 2H), 0.95-0.89 (m, 2H), 0.87-0.81 (m, 2H), 0.71-0.60 (m,4H). MS (m/z): 413.30 [M+H]⁺.

Example 18N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-4-methylpyrimidine-5-carboxamide

Following the general procedure-1, the title compound (129 mg) wasprepared from intermediate 27 (200 mg, 0.87 mmol) and4-methylpyrimidine-5-carboxylic acid (360 mg, 2.63 mmol) as a yellowsolid. M.P.: 89-95° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.75 (s, 1H),9.15 (s, 1H), 8.90 (s, 1H), 7.83 (d, J 8.8, 2H), 7.58 (d, J 8.8, 2H),5.80 (s, 1H), 2.59 (s, 3H), 1.90-1.78 (m, 2H), 0.99-0.82 (m, 4H),0.70-0.58 (m, 4H). MS (m/z): 359.99 [M+H]⁺.

Example 19N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-phenylacetamide

Following the general procedure-1, title compound (100 mg) was preparedfrom 2-phenylacetic acid (68 mg, 0.501 mmol) and intermediate 27 (100mg, 0.41 mmols) as a pale yellow solid. M. P. 133-138.5° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): 10.30 (s, 1H), 7.69 (d, J 8.8, 2H), 7.48 (d, J8.8, 2H), 7.35-7.30 (m, 4H), 7.26-7.22 (m, 1H), 5.77 (s, 1H), 3.65 (s,2H), 1.84-1.70 (m, 2H), 0.90-0.80 (m, 4H), 0.65-0.59 (m, 4H). MS (m/z):358.29 [M+H]⁺.

Example 20N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(4-fluorophenyl)acetamide

Following the general procedure-1, the title compound (120 mg) wasprepared from 2-(4-fluorophenyl)acetic acid (92 mg, 0.60 mmol) andintermediate 27 (120 mg, 0.60 mmol) as an off-white solid. M. P.141-148° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.30 (s, 1H), 7.68 (d, J8.8, 2H), 7.48 (d, J 8.8, 2H), 7.38-7.34 (m, 2H), 7.14 (t, J 8.9, 2H),5.77 (s, 2H), 1.84-1.70 (m, 2H), 0.89-0.80 (m, 4H), 0.65-0.59 (m, 4H).MS (m/z): 374.1 [M−H]⁻.

Example 21N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-1-phenylcyclopropanecarboxamide

Following the general procedure-2, the title compound (40 mg) wasprepared from 1-phenylcyclopropanecarbonyl chloride (82 mg, 0.45 mmol)and intermediate 27 (100 mg, 0.42 mmol) as a brown viscous liquid.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 9.24 (s, 1H), 7.65 (d, J 8.9, 2H),7.45 (d, J 8.9, 2H), 7.42-7.33 (m, 4H), 7.28 (d, J 7.0, 1H), 5.76 (s,1H), 1.83-1.79 (m, 1H), 1.75-1.70 (m, 1H), 1.46-1.41 (m, 2H), 1.31-1.10(m, 2H), 0.89-0.79 (m, 4H), 0.65-0.59 (m, 4H). MS (m/z): 384.27 [M+H]⁺.

Example 22N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(pyridin-2-yl)acetamidehydrochloride

Following the general procedure-1,N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(pyridin-2-yl)acetamide(85 mg) was prepared from 2-pyridylacetic acid (139 mg, 0.8 mmol) andintermediate 27 (120 mg, 0.5 mmol) as a pale yellow solid and dissolvedin THF. Saturated HCl in diethyl ether was added to this solution at 0°C. and stirred for 15 min. Solid that separated out was filtered anddried to give the title compound (75 mg) as a pale yellow solid. M. P.157-162° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.90 (s, 1H), 8.89 (d, J5.1, 1H), 8.53 (t, J 8.0, 1H), 8.05 (d, J 8.0, 1H), 7.95 (t, J 6.5, 1H),7.72 (d, J 8.8, 2H), 7.52 (d, J 8.8, 2H), 5.79 (s, 1H), 4.34 (s, 2H),1.87-1.70 (m, 2H), 0.95-0.81 (m, 4H), 0.67-0.59 (in, 4H). MS (m/z):359.29 [M+H-HCl]⁺.

Example 23N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(pyridin-3-yl)acetamidehydrochloride

Following the general procedure-1,N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(pyridin-3-yl)acetamide(86 mg) was prepared from 3-pyridylacetic acid (139 mg, 0.8 mmol) andintermediate 27 (120 mg, 0.5 mmol) as a pale yellow solid and dissolvedin THF. Saturated HCl in diethyl ether was added to this solution at 0°C. and stirred for 15 min. Solid that separated out was filtered anddried to give the title compound (75 mg) as a pale yellow solid. M. P.103-108° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.71 (s, 1H), 8.92 (s,1H), 8.84 (d, J 5.1, 1H), 8.55 (d, J 7.8, 1H), 8.06-8.01 (m, 1H), 7.72(d, J 8.8, 2H), 7.51 (d, J 8.8, 2H), 5.78 (s, 1H), 4.05 (s, 2H),1.85-1.69 (m, 2H), 0.91-0.79 (m, 4H), 0.68-0.58 (m, 4H). MS (m/z):393.05 [M−H]⁻.

Example 24N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(pyridin-4-yl)acetamidehydrochloride

Following the general procedure-1,N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(pyridin-4-yl)acetamide(89 mg) was prepared from 2-(pyridin-4-yl)acetic acid (104 mg, 0.60mmol) and intermediate 27 (120 mg, 0.50 mmol) as an off-white solid.This amide was dissolved in saturated HCl in diethyl ether at 0° C. andstirred for 15 min. Solid that separated out was filtered and dried togive the title compound (12 mg). M. P. 175-181° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 10.75 (s, 1H), 8.86 (d, J 6.2, 2H), 8.04 (d, J 5.8,2H), 7.71 (d, J 8.8, 2H), 7.51 (d, J 8.8, 2H), 5.78 (s, 1H), 4.12 (s,2H), 1.84-1.72 (m, 2H), 0.91-0.80 (m, 4H), 0.66-0.60 (m, 4H). MS (m/z):393.09 [M−H]⁻

Example 25N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-(piperazin-1-yl)acetamidehydrochloride

Intermediate 41 (150 mg, 0.475 mmol) and piperazine (40 mg, 0.464 mmol)were dissolved in DMF (3 mL) at 0° C. and Sodium Hydride (30 mg, 1.25mmol) was added to the reaction mixture. Then reaction was allowed tostir at ambient temperature overnight. Work-up (H₂O:AcOEt) followed bypurification on column afforded both mono and di substitutedpiperazines. They were separated by column chromatography. Monosubstituted piperazine was protected with di-tert-butyl dicarbonate (100mg, 0.46 mmol) in presence of tri ethyl amine (0.11 ml, 0.82 mmol) inDCM. Work up followed by purification afforded the tert-butyl4-(2-(4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenylamino)-2-oxoethyl)piperazine-1-carboxylate(98 mg). Saturated HCl in diethyl ether was added at 0° C. to it andstirred for 15 min. Solid that separated out was filtered and dried togive the title compound (40 mg) as an off-white solid. M. P. 218-226° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.99 (bs, 1H), 9.69 (bs, 2H), 7.74(d, J 8.7, 2H), 7.56 (d, J 8.7, 2H), 4.20 (bs, 21H), 3.54 (bs, 2H), 3.41(bs, 2H), 1.80-1.71 (m, 2H), 0.97-0.80 (m, 4H), 0.69-0.60 (m, 4H). MS(m/z): 393.05 [M+H−HCl]⁺.

Example 26N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]-2-morpholinoacetamide

Intermediate 41 (150 mg, 0.475 mmol) and morpholine (40 mg, 0.475 mmol)were dissolved in DMF (3 mL) at 0° C. and Sodium Hydride (30 mg, 1.25mmol) was added to the reaction mixture. Reaction was allowed to stir atambient temperature overnight. Work-up (H₂O:AcOEt) followed bypurification on column afforded the title compound as a white solid, M.P. 178-184° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 9.87 (s, 1H), 7.74 (d,J 8.7, 2H), 7.49 (d, J 8.7, 2H), 5.77 (s, 1H), 3.63 (t, J 4.2, 4H), 3.13(s, 2H), 2.48-2.45 (m, 4H), 1.89-1.69 (m, 2H), 0.92-0.81 (m, 4H),0.69-0.60 (m, 4H). MS (m/z): 367.32 [M+H]⁺.

Example 27N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)phenyl]benzenesulfonamide

Following the general procedure-2, title compound (90 mg) was preparedfrom benzene sulphonyl chloride (81 mg, 0.458 mmol) and intermediate 27(100 mg, 0.42 mmol) as a yellow solid. M. P 180-184.5° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 10.43 (s, 1H), 7.77 (d, J 7.2, 2H), 7.64-7.59 (m,1H), 7.58-7.52 (m, 2H), 7.43 (d, J 8.7, 2H), 7.17 (d, J 8.7, 2H), 5.75(s, 1H), 1.81-1.75 (m, 1H), 1.69-1.64 (m, 1H), 1.16-0.78 (m, 4H),0.62-0.57 (m, 4H). MS (m/z): 378.05 [M−H]⁻.

Example 28N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide

Following the general procedure-2, the title compound (34 mg) wasprepared from 4-methyl-1,2,3-thiadiazole-5-carbonyl chloride (90 mg,0.56 mmol) and intermediate 28 (120 mg, 0.47 mmol) as a white solid.M.P.: 148-152° C. ¹H-NMR (6 ppm, DMSO-d₆, 400 MHz): 11.07 (s, 1H), 7.83(d, J 10.8, 1H), 7.57-7.50 (m, 2H), 5.76 (s, 1H), 2.82 (s, 3H),1.87-1.79 (m, 1H), 1.56-1.48 (m, 1H), 0.89-0.77 (m, 4H), 0.66-0.54 (m,4H). MS (m/z): 384.28 [M+H]⁺.

Example 29N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-4-methylthiazole-5-carboxamide

Following the general procedure-1, the title compound (48 mg) wasprepared from 4-methylthiazole-5-carboxylic acid (106 mg, 0.75 mmol) andintermediate 28 (120 mg, 0.47 mmol) as a pale-yellow solid. M.P.:102-106° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.58 (s, 1H), 9.16 (s,1H), 7.83 (dd, J 2.2, 12.6, 1H), 7.57 (dd, J 1.9, 8.8, 1H), 7.48 (t, J8.6, 1H), 5.75 (s, 1H), 2.62 (s, 3H), 1.85-1.79 (m, 1H), 1.55-1.45 (m,1H), 0.90-0.77 (m, 4H), 0.68-0.55 (m, 4H). MS (m/z): 383.05 [M+H]⁺.

Example 30N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-3,5-dimethylisoxazole-4-carboxamide

Following the general procedure-2, the title compound (70 mg) wasprepared from intermediate 28 (200 mg, 0.78 mmol) and3,5-dimethylisoxazole-4-carboxylic acid (150 mg, 0.95 mmol) as apale-yellow solid. M.P.: 166-168° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz):10.40 (s, 1H), 7.84-7.81 (m, 1H), 7.52-7.46 (m, 2H), 5.74 (s, 1H), 2.58(s, 3H), 2.31 (s, 3H), 1.88-1.79 (m, 1H), 1.54-1.46 (m, 1H), 0.90-0.78(m, 4H), 0.64-0.55 (m, 4H). MS (m/z): 381.32 [M+H]⁺.

Example 31N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-2-methylbenzamide

Following the general procedure-2, the title compound (25 mg) wasprepared from intermediate 28 (200 mg, 0.78 mmol) and o-toluic acid (143mg, 0.93 mmol) as a yellow solid. M.P.: 105-107° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 10.67 (s, 1H), 7.92 (d, J 11.4, 1H), 7.59 (d, J 8,1H), 7.52-7.47 (m, 2H), 7.46-7.38 (m, 2H), 7.32 (d, J 7.4, 2H), 5.74 (s,1H), 2.39 (s, 3H), 1.90-1.80 (m, 1H), 1.59-1.50 (m, 1H), 0.90-0.78 (m,4H), 0.68-0.54 (m, 4H). MS (m/z): 375.86 [M+H]⁺.

Example 32N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-2,3-difluorobenzamide

Following the general procedure-1, the title compound (50 mg) wasprepared from intermediate 28 (200 mg, 0.77 mmol) and2,3-difluorobenzoic acid (196 mg, 1.24 mmol) as a pale-yellow solid.M.P.: 132-135° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.93 (s, 1H), 7.87(d, J 10.8, 1H), 7.65 (q, J 8.3, 1H), 7.59-7.48 (m, 3H), 7.41-7.34 (m,1H), 5.75 (s, 1H), 1.88-1.79 (m, 1H), 1.56-1.48 ((m, 1H), 0.90-0.78 (m,4H), 0.65-0.55 (m, 4H). MS (m/z): 396.16 [M−H]⁻.

Example 33N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-2,6-difluorobenzamide

Following the general procedure-1, the title compound (50 mg) wasprepared from intermediate 28 (200 mg, 0.78 mmol) and2,6-difluorobenzoic acid (196 mg, 1.2 mmol) as a yellow solid. M.P.:182.2-185.7° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.20 (s, 1H), 7.84(d, J 11.4, 1H), 7.68-7.59 (m, 1H), 7.59-7.50 (m, 2H), 7.28 (t, J 8,2H), 5.75 (s, 1H), 1.89-1.79 (m, 1H), 1.60-1.50 (m, 1H), 0.90-0.78 (m,4H), 0.66-0.58 (m, 4H). MS (m/z): 398.07 [M+H]⁺.

Example 34N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]nicotinamidehydrochloride

Following the general procedure-1,N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]nicotinamide(130 mg) was prepared from intermediate 28 (200 mg, 0.78 mmol) andnicotinic acid (153 mg, 1.2 mmol) as an off-white solid and dissolved inTHF. Saturated HCl in diethyl ether was added to this solution at 0° C.and stirred for 15 min. Solid that separated out was filtered and driedto give the title compound (70 mg) as a white solid. M.P.: 201.2-203.4°C., ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.04 (s, 1H), 9.26 (s, 1H), 8.87(d, J 4.8, 1H), 8.58 (d, J 4.8, 1H), 7.97 (d, J 12.8, 1H), 7.81 (d, J 5,1H), 7.71 (d, J 8.6, 1H), 7.52 (t, J 8.7, 1H), 5.76 (s, 1H), 1.90-1.80(m, 1H), 1.58-1.48 (m, 1H), 0.90-0.78 (m, 4H), 0.65-0.55 (m, 4H). MS(nm/z): 363.14 [M+H−HCl]⁺.

Example 35N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]isonicotinamidehydrochloride

Following the general procedure-1,N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]isonicotinamide(107 mg) was prepared from intermediate 28 (200 mg, 0.78 mmol) andisonicotinic acid (153 mg, 1.2 mmol) as a yellow solid and dissolved inTHF. Saturated HCl in diethyl ether was added to this solution at 0° C.and stirred for 15 min. Solid that separated out was filtered and driedto give the title compound (70 mg) as a pale-yellow solid. M.P.:201.2-203.4° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.83 (s, 1H), 8.81(d, J 5.9, 2H), 7.94 (dd, J 1.9, 12.6, 1H), 7.87 (d, J 5.9, 2H), 7.67(dd, J 1.4, 8.6, 1H), 7.51 (t, J 8.7, 1H), 5.76 (s, 1H), 1.88-1.78 (m,1H), 1.58-1.48 (m, 1H), 0.88-0.78 (m, 4H), 0.62-0.50 (m, 4H). MS (m/z):363.14 [M+H−HCl]⁺.

Example 36N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-4-methylpyrimidine-5-carboxamide

Following the general procedure-1, the title compound (44 mg) wasprepared from 4-methylpyrimidine-5-carboxylic acid (144 mg, 0.75 mmol)and intermediate 28 (120 mg, 0.47 mmol) as a pale-brown solid M.P.:123-125° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.00 (s, 1H), 9.16 (s,1H), 8.93 (s, 1H), 7.91-7.87 (m, 1H), 7.60-7.47 (m, 2H) 5.75 (s, 1H),2.6 (s, 3H), 1.90-1.78 (m, 1H), 1.66-1.56 (m, 1H), 0.90-0.78 (m, 4H),0.67-0.59 (m, 4H). MS (m/z): 377.86 [M+H]⁺.

Example 37N-[4-(4-chloro-3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]-4-methyl-1,2,3-thiadiazole-5-carboxamide

Following the general procedure-2, the title compound (43 mg) wasprepared from 4-methyl-1,2,3-thiadiazole-5-carbonyl chloride (80 mg,0.49 mmol) and intermediate 29 (120 mg, 0.41 mmol) as a white solid.M.P.: 153-156° C. ¹H-NMR (8 ppm, DMSO-d₆, 400 MHz): 11.09 (s, 1H), 7.84(d, J 12, 1H), 7.58-7.49 (m, 2H), 2.82 (s, 3H), 1.89-1.81 (m, 1H),1.69-1.61 (m, 1H), 0.92-0.85 (m, 2H), 0.82-0.72 (m, 4H), 0.64-0.55 (m,2H). MS (m/z): 415.57 [M−H]⁻.

Example 38N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-4-methyl-1,2,3-thiadiazole-5-carboxamidehydrochloride

Following the general procedure-1, the title compound (32 mg) wasprepared from 4-methyl-1,2,3-thiadiazole-5-carboxylic acid (80 mg, 0.47mmol) and intermediate 30 (120 mg, 0.40 mmol) as a white solid. M.P.:215-219° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.09 (s, 1H), 8.74 (d, J2.2, 1H), 8.24 (dd, J 2.4, 8.8, 1H), 7.77 (d, J 8.8, 1H), 5.83 (s, 1H),3.87 (s, 3H), 2.70-2.61 (m, 1H), 1.90-1.81 (m, 1H), 0.95-0.82 (m, 4H),0.70-0.58 (m, 4H). MS (m/z): 365.03 [M−H−HCl]⁻.

Example 39N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-4-methylthiazole-5-carboxamidehydrochloride

Following the general procedure-1,N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-4-methylthiazole-5-carboxamide(55 mg) was prepared from 4-methylthiazole-5-carboxylic acid (130 mg,0.83 mmol) and intermediate 30 (200 mg, 0.83 mmol) as a brown solid anddissolved in THF. Saturated HCl in diethyl ether was added to thissolution at 0° C. and stirred for 15 min. Solid that separated out wasfiltered and dried to give the title compound (50 mg) as an off-whitesolid. M. P. 93-98° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.57 (s, 1H),9.16 (s, 1H), 8.74 (s, 1H), 8.23 (dd, J 2.4, 8.9, 1H), 7.73 (d, J 8.9,1H), 5.82 (s, 1H), 2.70-2.60 (m, 4H), 1.88-1.80 (m, 1H), 0.93-0.81 (m,4H), 0.69-0.58 (m, 4H). MS (m/z): 366.36 [M+H−HCl]⁺.

Example 40N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2,4-dimethylthiazole-5-carboxamide

Following the general procedure-1, title compound (48 mg) was preparedfrom 2,4-dimethylthiazole-5-carboxylic acid (94 mg, 0.59 mmol) andintermediate 30 (120 mg, 0.49 mmol) as a pale yellow solid M. P.108-113° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.38 (s, 1H), 8.71 (d, J2.0, 1H), 8.20 (dd, J 2.0, 8.8, 1H), 7.71 (d, J 8.8, 1H), 5.81 (s, 1H),2.66 (s, 3H), 2.64-2.58 (m, 1H), 2.56 (s, 3H), 1.89-1.81 (m, 1H),0.92-0.84 (m, 4H), 0.67-0.59 (m, 4H). MS (m/z): 380.23 [M+H−HCl]⁺.

Example 41N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-3,5-dimethylisoxazole-4-carboxamide

Following the general procedure-1, the title compound (68 mg) wasprepared from 3,5-dimethylisoxazole-4-carboxylic acid (112 mg, 0.8 mmol)and intermediate 30 (120 mg, 0.5 mmol) as a pale-yellow solid M.P.:208-210° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.32 (s, 1H), 8.70 (d, J2.5, 8.8, 1H), 8.20 (dd, J 2.5, 8.8, 1H), 7.73 (d, J 8.8, 1H), 5.82 (s,1H), 2.67-2.59 (m, 1H), 2.57 (s, 3H), 2.34 (s, 3H), 1.90-1.81 (m, 1H),0.94-0.82 (m, 4H), 0.69-0.58 (m, 4H). MS (n/z): 361.74 [M−H]⁻.

Example 42 6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-N-o-tolylnicotinamide

Following the general procedure-2, the title compound (10 mg) wasprepared from o-toluidine (60 mg, 0.56 mmol) and intermediate 30 (177mg, 0.62 mmol) as a white solid. M.P.: 123-126° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 10.05 (s, 1H), 9.00 (s, 1H), 8.44 (d, J 8.2, 1H),7.92 (d, J 8.6, 1H), 7.36 (d, J 7.6, 2H), 7.28 (d, J 7.5, 1H), 7.26-7.19(m, 1H), 5.92 (s, 1H), 2.89-2.81 (m, 1H), 2.25 (s, 3H), 1.94-1.84 (m,1H), 1.00-0.87 (m, 4H), 0.74-0.62 (m, 4H). MS (m/z): 357.02 [M−H]⁻.

Example 43N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2-fluorobenzamide

Following the general procedure-1, the title compound (121 mg) wasprepared from 2-fluorobenzoic acid (111 mg, 0.8 mmol) and intermediate30 (120 mg, 0.5 mmol) as a pale-yellow solid M.P.: 121-126° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): 10.75 (s, 1H), 8.76 (d, J 2.4, 1H), 8.28 (dd, J2.6, 8.9, 1H), 7.79-7.70 (m, 2H), 7.65-7.54 (m, 1H), 7.42-7.30 (m, 2H),5.82 (s, 1H), 2.71-2.60 (m, 1H), 1.94-1.80 (m, 1H), 0.94-0.80 (m, 4H),0.72-0.59 (m, 4H). MS (m/z): 362.95 [M+H]⁺.

Example 44N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2,3-difluorobenzamidehydrochloride

Following the general procedure-1, title compound (68 mg) was preparedfrom 2,3-difluorobenzoic acid (126 mg, 0.5 mmol) and intermediate 30(120 mg, 0.5 mmol) as a pale yellow solid M. P. 172-177° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.84 (s, 1H),8.75 (d, J 1, 1H), 8.26 (dd, J 1, 8.8, 1H), 7.75 (d, J 8.8, 1H), 7.64(q, J 8.3, 1H), 7.53 (t, J 6.6, 1H), 7.35 (q, J 7.5, 1H), 5.82 (s, 1H),2.70-2.61 (m, 1H), 1.91-1.80 (m, 1H), 0.99-0.81 (m, 4H), 0.69-0.52 (m,4H). MS (m/z): 378.88 [M−H−HCl]⁻.

Example 45N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2,6-difluorobenzamidehydrochloride

Following the general procedure-1,N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-2,6-difluorobenzamide(71 mg) was prepared from 2,6-difluorobenzoic acid (126 mg, 0.799 mmol)and intermediate 30 (120 mg, 0.5 mmol) as a brown solid and dissolved inTHF. Saturated HCl in diethyl ether was added to this solution at 0° C.and stirred for 15 min. Solid that separated out was filtered and driedto give the title compound (69 mg) as a brown solid. M. P. 196-201° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.16 (s, 1H), 8.72 (d, J 2.3, 1H),8.26 (dd, J 2.5, 8.9, 1H), 7.75 (d, J 8.8, 1H), 7.65-7.60 (m, 1H), 7.27(t, J 8.0, 2H), 5.82 (s, 1H), 2.69-2.60 (m, 1H), 1.90-1.82 (m, 1H),0.94-0.82 (m, 4H), 0.70-0.59 (m, 4H). MS (m/z): [M+H−HCl]⁺.

Example 46N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]nicotinamidedihydrochloride

Following the general procedure-1,N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]nicotinamide (82mg) was prepared from intermediate 30 (120 mg, 0.5 mmol) and nicotinicacid (98 mg, 0.65 mmol) as a yellow solid and dissolved in THF.Saturated HCl in diethyl ether was added to this solution at 0° C. andstirred for 15 min. Solid that separated out was filtered and dried togive the title compound (80 mg) as an yellow solid. M.P.: 164.6-169.5°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.19 (s, 1H), 9.36 (s, 1H), 8.95(d, J 5.2, 1H), 8.88 (d, J 2.5, 1H), 8.75 (d, J 8, 1H), 8.36 (dd, J 2.5,8.9, 1H), 7.92 (dd, J 5.3, 8, 1H), 7.77 (d, J 8.9, 1H), 5.83 (s, 1H),2.71-2.61 (m, 1H), 1.91-1.81 (m, 1H), 0.95-0.82 (m, 4H), 0.70-0.55 (m,4H). MS (m/z): 346.27 [M−2HCl]⁻.

Example 47N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]isonicotinamidedihydrochloride

Following the general procedure-1,N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]isonicotinamide(220 mg) from intermediate 30 (200 mg, 0.83 mmol) and isonicotinic acid(163 mg, 1.3 mmol) as a pale-yellow solid and dissolved in THF.Saturated HCl in diethyl ether was added to this solution at 0° C. andstirred for 15 min. Solid that separated out was filtered and dried togive the title compound (190 mg) as a pale-yellow solid. M.P.:200.3-202.4° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.26 (s, 1H), 8.99(t, J 5.4, 2H), 8.88 (s, 1H), 8.35 (dd, J 2.6, 6.3, 1H), 8.30-8.25 (m,21H), 7.78 (d, J 8.9, 1H), 5.83 (s, 1H), 2.72-2.62 (m, 1H), 1.90-1.81(m, 1H), 0.94-0.82 (m, 4H), 0.70-0.59 (m, 4H). MS (m/z): 346.13[M+H−2HCl]⁺.

Example 48N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-3-fluoroisonicotinamide

Following the general procedure-1, the title compound (97 mg) wasprepared from intermediate 30 (120 mg, 0.5 mmol) and3-fluoroisonicotinic acid (112 mg, 0.8 mmol) as a brown solid. M.P.:192.3-195.4° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.00 (s, 1H), 8.79(s, 1H), 8.74 (d, J 2.5, 1H), 8.61 (d, J 4.8, 1H), 8.26 (dd, J 2.8, 8.9,1H), 7.78-7.72 (m, 2H), 5.83 (s, 1H), 2.61-2.51 (m, 1H), 1.90-1.80 (m,1H), 0.94-0.82 (m, 4H), 0.70-0.58 (m, 4H). MS (m/z): 364.19 [M+H]⁺.

Example 493,5-dichloro-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}isonicotinamide

Following the general procedure-2, the title compound (60 mg) wasprepared from 3,5-dichloroisonicotinoyl chloride (313 mg, 1.5 mmol) andintermediate 31 (200 mg, 0.75 mmol) as a white solid. M.P.: 182-184° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.21 (s, 1H), 8.82 (s, 2H), 7.85 (d,J 8.8, 2H), 7.65 (d, J 8.8, 2H), 6.62 (s, 1H), 1.90-1.80 (m, 1H),1.00-0.91 (m, 2H), 0.78-0.85 (m, 2H). MS (m/z): 371.76 [M−H−2Cl]⁻.

Example 503,5-dichloro-N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]isonicotinamidehydrochloride

Following the generalprocedure-2,3,5-dichloro-N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]isonicotinamide(24 mg) was prepared from 3,5-dichloroisonicotinoyl chloride (313 mg,1.5 mmol) and intermediate 30 (200 mg, 0.75 mmol) as a white solid anddissolved in THF. Saturated HCl in diethyl ether was added to thissolution at 0° C. and stirred for 15 min. Solid that separated out wasfiltered and dried to give the title compound (7 mg) as a pale-yellowsolid. M.P.: 193-195° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.34 (s,1H), 8.82 (s, 2H), 8.69 (d, J 2.4, 1H), 8.24 (dd, J 2.6, 8.9, 1H), 7.78(d, J 8.9, 1H), 5.83 (s, 1H), 2.72-2.64 (m, 1H), 1.80-1.70 (m, 1H),0.92-0.82 (m, 4H), 0.70-0.58 (m, 4H). MS (m/z): 413.40 [M−H−HCl]⁺.

Example 51N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-4-methylpyrimidine-5-carboxamidehydrochloride

Following the general procedure-1,N-[6-(3,5-dicyclopropyl-1H-pyrazol-1-yl)pyridin-3-yl]-4-methylpyrimidine-5-carboxamide(230 mg) from intermediate 30 (200 mg, 0.83 mmol) and intermediate 53(350 mg, 2.49 mmol) as a pale yellow solid and dissolved in THF.Saturated HCl in diethyl ether was added to this solution at 0° C. andstirred for 15 min. Solid that separated out was filtered and dried togive the title compound (120 mg) as a yellow solid. M.P.: 192-197° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.92 (s, 1H), 9.16 (s, 1H), 8.94 (s,1H), 8.75 (d, J 2.5, 1H), 8.27 (dd, J 2.6, 8.8, 1H), 7.76 (d, J 8.8,1H), 5.82 (s, 1H), 2.70-2.62 (m, 1H), 2.61 (s, 3H), 1.92-1.84 (m, 1H),0.95-0.85 (m, 4H), 0.70-0.58 (m, 4H). MS (m/z): 360.97 [M+H−HCl]⁺.

Example 52N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methyl-1,2,3-thiadiazole-5-carboxamide

Following the general procedure-2, the title compound (15 mg) wasprepared from 4-methyl-1,2,3-thiadiazole-5-carbonyl chloride (80 mg,0.49 mmol) and intermediate 31 (120 mg, 0.45 mmol) as a white solid. M.P. 84-89° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.95 (s, 1H), 7.87 (d, J8.8, 2H), 7.66 (d, J 8.8, 2H), 6.62 (s, 1H), 2.82 (s, 3H), 1.85-1.81 (m,1H), 0.99-0.94 (m, 2H), 0.86-0.79 (m, 2H). MS (m/z): 392.08 [M−H]⁻.

Example 53N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide

Following the general procedure-2, the title compound (20 mg) wasprepared from 4-methylthiazole-5-carbonyl chloride (78 mg) andintermediate 31 (120 mg, 0.45 mmol) as brown solid. M. P. 137-141° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.47 (s, 1H), 9.14 (s, 1H), 7.87 (d,J 8.8, 2H), 7.62 (d, J 8.8, 2H), 6.61 (s, 1H), 2.62 (s, 3H), 1.85-1.81(m, 1H), 0.99-0.94 (m, 2H), 0.88-0.83 (m, 2H). MS (m/z): 391.15 [M−H]⁻.

Example 54N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-N,4-dimethylthiazole-5-carboxamide

N-{4-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide(500 mg, 1.27 mmol) was dissolved in THF, cooled to 0° C. and addedsodium hydride (61 mg, 2.54 mmol) and stirred the mixture for 30 mins atthe same temperature. Methyl Iodide (210 mg, 1.52 mmol) was added andheated the reaction mixture to rt. After 3h, reaction mixture quenchedwith water. Work up(H₂O/AcOEt) and purification afforded the titlecompound (150 mg) as a gummy liquid. ¹H-NMR (δ ppm, CDCl₃, 400 MHz):8.59 (s, 1H), 7.63 (d, J 8.6, 2H), 7.27 (d, J 8.6, 2H), 6.26 (s, 1H),3.53 (s, 3H), 2.56 (s, 3H), 1.82-1.72 (m, 1H), 1.10-1.00 (m, 2H),0.81-0.75 (m, 2H). MS (m/z): 406.96 [M+H]⁺.

Example 55N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2,4-dimethylthiazole-5-carboxamide

Following the general procedure-1, the title compound (58 mg) wasprepared from 2,4-dimethylthiazole-5-carboxylic acid (77 mg, 0.49 mmol)and intermediate 31 (120 mg, 0.45 mmol) as an off-white solid. M. P.117-122° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.32 (s, 1H), 7.85 (d, J8.8, 2H), 7.61 (d, J 8.8, 2H), 6.61 (s, 1H), 2.66 (s, 3H), 2.55 (s, 3H),1.84-1.79 (m, 1H), 0.97-0.94 (m, 2H), 0.83-0.79 (m, 2H). MS (m/z):405.17 [M−H]⁻.

Example 56N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-5-methylisoxazole-4-carboxamide

Following the general procedure-2, title compound (50 mg) was preparedfrom 5-methylisoxazole-4-carbonyl chloride (71 mg, 0.489 mmol) andintermediate 31 (120 mg, 0.45 mmol) as a brown solid. M. P. 90-95° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.44 (s, 1H), 8.76 (s, 1H), 7.88 (d,J 8.8, 2H), 7.63 (d, J 9.5, 2H), 6.61 (s, 1H), 2.63 (s, 3H), 1.85-1.80(m, 1H), 0.99-0.93 (m, 2H), 0.84-0.79 (m, 2H). MS (m/z): 375.10 [M−H]⁻.

Example 57N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,5-dimethylisoxazole-4-carboxamide

Following the general procedure-2, the title compound (130 mg) wasprepared from 3,5-dimethylisoxazole-4-carbonyl chloride (85 mg, 0.54mmol) and intermediate 31 (120 mg, 0.45 mmol) as a pale-yellow solid.M.P.: 170-172° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.29 (s, 1H), 7.85(d, J 8.9, 2H), 7.62 (d, J 8.9, 2H), 6.61 (s, 1H), 2.56 (s, 3H), 2.34(s, 3H), 1.90-1.80 (m, 1H), 1.01-0.94 (m, 2H), 0.86-0.78 (m, 2H). MS(m/z): 388.61 [M−H]⁻.

Example 58N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-1-methyl-1H-imidazole-2-carboxamide

Following the general procedure-1, the title compound (25 mg) wasprepared from intermediate 31 (220 mg, 0.79 mmol) and1-methyl-1H-imidazole-2-carboxylic acid (100 mg, 0.79 mmol) as a whitesolid. M.P.: 132.1-134.5° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.63 (s,1H), 8.03 (d, J 8.9, 2H), 7.59 (d, J 8.9, 2H), 7.46 (s, 1H), 7.10 (s,1H), 6.60 (s, 1H), 4.00 (s, 3H), 1.86-1.80 (m, 1H), 0.99-0.92 (m, 2H),0.85-0.78 (m, 2H). MS (nm/z): 376.09 [M+H]⁺.

Example 59N-{4-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methyl-1H-imidazole-5-carboxamide

Following the general procedure-1, the title compound (150 mg) wasprepared from intermediate 31 (150 mg, 0.56 mmol) and4-methyl-1H-imidazole-5-carboxylic acid (85 mg, 0.67 mmol) as anoff-white solid. M.P.: 245-250° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz):12.46 (bs, 1H), 9.99 (s, 1H), 8.02 (d, J 8.9, 2H), 7.67 (s, 1H), 7.54(d, J 8.9, 2H), 6.59 (s, 1H), 2.48 (s, 3H), 1.86-1.76 (m, 1H), 1.00-0.92(m, 2H), 0.82-0.74 (m, 2H). MS (m/z): 374.04 [M−H]⁻.

Example 60N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-methylbenzamide

Following the general procedure-1, the title compound (80 mg) wasprepared from intermediate 31 (200 mg, 0.75 mmol) and o-toluic acid (163mg, 1.2 mmol) as an off-white solid. M.P.: 143.2-145.8° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): 10.56 (s, 1H), 7.93 (d, J 8.8, 2H), 7.60 (d, J8.8, 2H), 7.48 (d, J 7.6, 1H), 7.42-7.38 (m, 1H), 7.32-7.29 (m, 2H),6.61 (s, 1H), 2.39 (s, 3H), 1.88-1.78 (m, 1H), 1.00-0.92 (m, 2H),0.84-0.76 (m, 2H). MS (nm/z): 383.62 [M−H]⁻.

Example 61N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2,3-difluorobenzamide

The title compound (28 mg) was prepared from 2,3-difluorobenzoic acid(71 mg, 0.45 mmol) and intermediate 31 (100 mg, 0.374 mmol) as a whitesolid. M. P. 147-152° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.80 (s,1H), 7.90 (d, J 8.7, 2H), 7.64 (d, J 8.7, 2H), 7.53-7.50 (m, 1H),7.37-7.34 (m, 2H), 6.62 (s, 1H), 1.83-1.82 (m, 1H), 0.83-0.79 (m, 2H),0.99-0.94 (m, 2H). MS (m/z): 406.05 [M−H]⁻.

Example 62N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2,6-difluorobenzamide

Following the general procedure-1, the title compound (20 mg) wasprepared from 2,6-difluorobenzoic acid (142 mg, 0.89 mmol) andintermediate 31 (100 mg, 0.374 mmol) as a pale yellow solid. M. P.188-191° C. ¹H-NMR (S ppm, DMSO-d₆, 400 MHz): 11.06 (s, 1H), 7.87 (d, J8.8, 2H), 7.64 (d, J 8.8, 2H), 7.63-7.59 (m, 1H), 7.29-7.25 (m, 2H),6.62 (s, 1H), 1.85-1.82 (m, 1H), 0.99-0.94 (m, 2H), 0.83-0.79 (m, 2H).MS (m/z): 406.05 [M−H]⁻.

Example 63N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-(methylsulfonyl)benzamide

Following the general procedure-2, the title compound (43 mg) wasprepared from 3-(methylsulfonyl)benzoyl chloride (108 mg, 0.49 mmol) andintermediate 31 (100 mg, 0.45 mmol) as a white solid. M. P. 178-184° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.76 (s, 1H), 8.49 (s, 1H), 8.31 (d,J 7.5, 1H), 8.15 (d, J 7.5, 1H), 7.98 (d, J 8.6, 2H), 7.84 (t, J 7.8,1H), 7.66 (d, J 8.6, 2H), 6.62 (s, 1H), 3.21 (s, 3H), 1.98-1.82 (m, 1H),1.07-0.94 (m, 2H), 0.90-0.75 (m, 2H). MS (m/z): 448.22 [M−H]⁻.

Example 642-chloro-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-5-(methylthio)benzamide

Following the general procedure-1, the title compound (63 mg) wasprepared from 2-chloro-5-(methylthio)benzoic acid (100 mg, 0.49 mmol)and intermediate 31 (120 mg, 0.45 mmol) as a white solid. M.P.: 172-177°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.78 (s, 1H), 7.90 (d, J 8.8,2H),7.63 (d, J 8.8, 2H), 7.50-7.47 (m, 2H), 7.39 (dd, J, 2.4, 8.4, 1H),6.61 (s, 1H), 2.52 (s, 3H), 1.86-1.79 (m, 1H), 0.99-0.94 (m, 2H),0.84-0.79 (m, 2H). MS (m/z): 449.96 [M−H]⁻.

Example 652-chloro-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-5-(methylsulfonyl)benzamide

2-chloro-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-5-(methylthio)benzamide(40 mg, 0.08 mmols) was dissolved in a 5 mL mixture of H₂O and acetone(1:1) at 0° C. and added Oxone (108 mg, 0.16 mmols). The mixture wasstirred at ambient temperature for one hour. The reaction mixture wasfiltered to remove oxone and filtrate was worked up (AcOEt: H₂O). Titlecompound (38 mg) was obtained as a white solid. M. P. 132-135° C. ¹H-NMR(δ ppm, DMSO-d₆, 400 MHz): 10.97 (s, 1H), 8.19 (d, J 2.2, 1H), 8.04 (dd,J 8.4, 2.2, 1H), 7.89 (d, J 8.6, 3H), 7.65 (d, J 8.8, 2H), 6.62 (s, 1H),3.30 (s, 3H), 1.97-1.81 (m, 1H), 0.99-0.94 (m, 2H), 0.86-0.79 (m, 2H).MS (m/z): 481.85 [M−H]⁻.

Example 66N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}pyridine-4-carboxamidehydrochloride

Following general procedure-1,N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}pyridine-4-carboxamide(120 mg) was prepared from pyridine-4-carboxylic acid (66 mg, 0.54 mmol)and intermediate 31 (120 mg, 0.45 mmol) as a pale yellow solid anddissolved in THF. Saturated HCl in diethyl ether was added at 0° C. toit and stirred for 15 min. Solid that separated out was filtered anddried to give the title compound (70 mg) as a yellow solid. M. P.210-215° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.90 (s, 1H), 8.90 (d, J5.40, 2H), 8.07 (d, J 5.40, 2H), 7.99 (d, J 8.8, 2H), 7.66 (d, J 8.8,2H), 6.62 (s, 1H), 1.86-1.82 (m, 1H), 0.99-0.95 (m, 2H), 0.83-0.79 (m,2H). MS (m/z): 406.89 [M−H]⁻.

Example 67N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-fluoroisonicotinamide

Following the general procedure-1, the title compound (160 mg) wasprepared from intermediate 31 (200 mg, 0.75 mmol) and3-fluoroisonicotinic acid (168 mg, 1.2 mmol) as a brown solid. M.P.:143.2-145.9° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.95 (s, 1H), 8.78(d, J 1, 1H), 8.60 (dd, J 1, 4.8, 1H), 7.89 (d, J 8.9, 2H), 7.73 (d, J5.3, 1H), 7.66 (d, J 8.9, 2H), 6.62 (s, 1H), 1.88-1.79 (m, 1H),1.00-0.93 (m, 2H), 0.85-0.78 (m, 2H). MS (m/z): 391.14 [M+H]⁺.

Example 68N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methylpyrimidine-5-carboxamide

Following the general procedure-1, the title compound (17 mg) wasprepared from intermediate 31 (200 mg, 0.75 mmol) and intermediate 53(123 mg, 0.89 mmol) as an off-white solid. M.P.: 163.4-165.5° C. ¹H-NMR(δ ppm, DMSO-d₆, 400 MHz): 10.87 (s, 1H), 9.16 (s, 1H), 8.92 (s, 1H),7.91 (d, J 8.8, 2H), 7.65 (d, J 8.8, 2H), 6.62 (s, 1H), 2.60 (s, 3H),1.90-1.78 (m, 1H), 1.00-0.92 (m, 2H), 0.85-0.76 (m, 2H). MS (m/z):387.36 [M+H]⁺.

Example 69N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2,4-dimethylpyrimidine-5-carboxamide

Following the general procedure-1, the title compound (150 mg) wasprepared from intermediate 31 (150 mg, 0.56 mmol) and intermediate 55(170 mg, 1.12 mmol) as a pale-yellow solid. M.P.: 144.8-146.8° C. ¹H-NMR(δ ppm, DMSO-d₆, 400 MHz): 10.78 (s, 1H), 8.80 (s, 1H), 7.90 (d, J 8,2H), 7.64 (d, J 8, 2H), 6.63 (s, 1H), 2.63 (s, 3H), 2.55 (s, 3H),1.90-1.78 (m, 1H), 1.01-0.90 (m, 2H), 0.82-0.74 (m, 2H). MS (m/z):402.06 [M+H]⁺.

Example 70N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(4-fluorophenyl)acetamide

The title compound (14 mg) was prepared from 2-(4-fluorophenyl)aceticacid (83 mg, 0.54 mmol) and intermediate 31 (120 mg, 0.45 mmol) as apale yellow colour solid. M. P. 135-140° C. ¹H-NMR (δ ppm, DMSO-d₆, 400MHz): 10.42 (s, 1H), 7.77 (d, J 8.8, 2H), 7.56 (d, J 8.8, 2H), 7.38-7.35(m, 2H), 7.12 (t, J 8.8, 2H), 6.59 (s, 1H), 3.67 (s, 2H), 1.81-1.77 (m,1H), 0.96-0.91 (m, 2H), 0.86-0.77 (m, 2H). MS (m/z): 402.01 [M−H]⁻.

Example 71N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(pyridin-2-yl)acetamidehydrochloride

Following the general procedure-1,N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(pyridin-2-yl)acetamide(107 mg) was prepared from 2-pyridylacetic acid (124 mg, 0.71 mmol) andintermediate 31 (120 mg, 0.45 mmol) as a pale yellow solid and dissolvedin THF. Saturated HCl in diethyl ether was added to this solution at 0°C. and stirred for 15 min. Solid that separated out was filtered anddried to give the title compound (90 mg) as a pale yellow solid. M. P.210-215° C. ¹H-NMR (6 ppm, DMSO-d₆, 400 MHz): 10.80 (s, 1H), 8.79 (d, J4.8, 1H), 8.31 (t, J 7.2, 1H), 7.86 (d, J 7.4, 1H), 7.84-7.79 (m, 4H),7.59 (d, J 8.8, 2H), 6.60 (s, 1H), 4.20 (s, 2H), 1.85-1.75 (m, 1H),0.99-0.90 (m, 2H), 0.82-0.75 (m, 2H). MS (m/z): 420.89 [M−H]⁻.

Example 72N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(pyridin-3-yl)acetamidehydrochloride

Following the general procedure-1,N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(pyridin-3-yl)acetamide(140 mg) was prepared from 3-pyridylacetic acid (124 mg, 0.714 mmol) andintermediate 31 (120 mg, 0.45 mmol) as a white solid and dissolved inTHF. Saturated HCl in diethyl ether was added to this solution at 0° C.and stirred for 15 min. Solid that separated out was filtered and driedto give the title compound (101 mg) as a pale yellow solid. M. P.196-201° C. ¹H-NMR (6 ppm, DMSO-d₆, 400 MHz): 10.81 (s, 1H), 8.89 (s,1H), 8.81 (d, J 5.4, 1H), 8.48 (d, J 7.4, 1H) 8.00-7.97 (m, 1H), 7.80(d, J 8.7, 2H), 7.58 (d, J 8.7, 2H), 6.59 (s, 1H), 4.04 (s, 2H),1.84-1.75 (m, 1H), 0.97-0.91 (m, 2H), 0.80-0.75 (m, 2H). MS (nm/z):423.2 [M+H]⁺.

Example 73N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(pyridin-4-yl)acetamidehydrochloride

Following the general procedure-1,N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(pyridin-4-yl)acetamide(38 mg) was prepared from 2-(pyridin-4-yl)acetic acid (94 mg, 0.54 mmol)and intermediate 31 (120 mg, 0.45 mmol) as a pale-yellow solid anddissolved in THF. Saturated HCl in diethyl ether was added to thissolution at 0° C. and stirred for 15 min. Solid that separated out wasfiltered and dried to give the title compound (30 mg) as a brown solid.M. P. 135-139° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.93 (s, 1H), 8.85(d, J 5.8, 2H), 8.01 (d, J 5.8, 2H), 7.81 (d, J 8.6, 2H), 7.58 (d, J8.6, 2H), 6.59 (s, 1H), 4.13 (s, 2H), 1.83-1.74 (m, 1H), 0.99-0.91 (m,2H), 0.83-0.76 (m, 2H). MS (m/z): 387.27 [M+H−HCl]⁺.

Example 744-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-[(4-methylthiazol-5-yl)methyl]aniline

Intermediate 31 (600 mg, 2.24 mmol) was dissolved in THF, addedintermediate 58 (338 mg, 2.7 mmol), sodium triacetoxy borohydride (710mg, 3.4 mmol) and AcOH (0.12 ml, 2.24 mmol). The mixture was stirred atrt for 48 hrs. After completion of the reaction, THF was removed onrotavapour to obtain the residue. Work up (AcOEt/H₂O) and purificationon silicagel (60-120 mesh) using EA and Petether (25:75) afforded thetitle compound (31 mg) as a white solid. M.P.: 59.2-61.2° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): 8.84 (s, 1H), 7.28 (d, J 8.8, 2H), 6.71 (d, J8.8, 2H), 6.66 (t, J 5.7, 1H), 6.49 (s, 1H), 4.45 (d, J 5.7, 2H), 2.49(s, 3H), 1.79-1.69 (m, 1H), 0.98-0.90 (m, 2H), 0.80-0.74 (m, 2H). MS(m/z): 376.98 [M−H]⁻.

Example 751-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-(4-methyl-1,2,3-thiadiazol-5-yl)urea

4-methylthiadiazole-5-carboxylic acid (300 mg, 1.92 mmol) was dissolvedin acetone, water mixture (15 ml and 1.5 ml) and cooled to −5° C. Ethylchoroformate (0.32 ml, 2.3 mmol) was added slowly to this mixture andstirred at same temperature for 30 mins. At this stage sodium azide (250mg, 3.84 mmol) was added and stirred for 30 mins at the sametemperature. Water was added to the reaction mixture and extracted withEt₂O and ether was removed to obtain the crude. Crude was dissolved indioxane, intermediate 31 (90 mg, 0.33 mmol) was added and refluxed for30 mins. Work up (AcOEt:H₂O) followed by purification on 60-120 meshsilica gel using EA and Peteher (45:50) as eluent afforded the titlecompound (150 mg) as a white solid. M.P.: 124-128° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 10.27 (s, 1H), 9.45 (s, 1H), 7.68 (d, J 8.9, 2H),7.60 (d, J 8.9, 2H), 6.61 (s, 1H), 2.60 (s, 3H), 1.88-1.78 (m, 1H),1.00-0.92 (m, 2H), 0.84-0.76 (m, 2H). MS (m/z): 394. [M−H]⁻. MS (m/z):407.01 [M−H]⁻.

Example 761-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-(4-methylthiazol-5-yl)urea

4-methylthiazole-5-carboxylic acid (1 g, 6.99 mmol) was dissolved inacetone, water mixture (50 ml and 5 ml) and cooled to −5° C. Ethylchoroformate was added slowly to this mixture and stirred at sametemperature for 30 mins. At this stage sodium azide (0.9 g, 13.8 mmol)was added and stirred for 30 mins at the same temperature. Water wasadded to the reaction mixture and extracted with Et₂CO and ether wasremoved to obtain the crude. Crude was dissolved in dioxane,intermediate 31 was added and refluxed for 30 mins. Work up (AcOEt:H₂O)followed by purification on 60-120 mesh silica gel using EA and Peteher(45:50) as eluent afforded the title compound (2.1 g) as a pale yellowsolid. M.P.: 124-126° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 9.17 (s, 1H),9.15 (s, 1H), 8.50 (s, 1H), 7.64 (d, J 8.9, 2H), 7.55 (d, J 8.9, 2H),6.59 (s, 1H), 2.32 (s, 3H), 1.84-1.74 (m, 1H), 1.02-0.92 (m, 2H),0.82-0.74 (m, 2H). MS (m/z): 405.49 [M−H]⁻.

Example 771-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-(4-methylpyrimidin-5-yl)urea

4-methylpyrimidine-5-carbonyl azide (450 mg, 2.43 mmol) and intermediate31 (649 mg, 2.43 mmol) were dissolved in dioxane and refluxed for 30mins. Work up (AcOEt:H₂O) followed by purification on 60-120 mesh silicagel using EA and Peteher (10:90) as eluent afforded the title compound(200 mg) as a pale yellow solid. M. P.: 190-192° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 9.23 (s, 1H), 8.78 (s, 1H), 8.69 (s, 1H), 7.86 (s,1H), 7.50 (dd, J 2, 6.9, 4H), 6.10 (s, 1H), 2.44 (s, 3H), 1.74-1.66 (m,1H), 0.97-0.91 (m, 2H), 0.75-0.65 (m, 2H). MS (m/z): 401.27 [M−H]⁻.

Example 784-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-methylthiazol-5-yl)benzamide

Following the general procedure-1, the title compound (40 mg) wasprepared from intermediate 47 (98 mg, 0.86 mmol) and intermediate 59(170 mg, 0.57 mmol) as an off-white solid M.P.: 125-128° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): 10.83 (s, 1H), 8.70 (s, 1H), 8.15 (d, J 8.4,2H), 7.86 (d, J 8.4, 2H), 6.72 (s, 1H), 2.42 (s, 3H), 1.99-1.88 (m, 1H),1.05-0.97 (m, 2H), 0.89-0.79 (m, 2H). MS (m/z): 392.84 [M+H]⁺.

Example 794-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,6-difluorophenyl)benzamide

Following the general procedure-2, the title compound (8 mg) wasprepared from intermediate 47 (150 mg, 0.53 mmol) and2,6-difluoroaniline (194 mg, 0.63 mmol) as a white solid. M.P.:145.2-147.3° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.33 (s, 1H), 8.18(d, J 8.6, 2H), 7.86 (d, J 8.6, 2H), 7.44-7.40 (m, 1H), 7.23 (t, J 8.1,2H), 6.72 (s, 1H), 2.00-1.90 (m, 1H), 1.03-0.97 (m, 2H), 0.90-0.80 (m,2H). MS (m/z): 405.70 [M−H]⁻.

Example 80N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide

Following the general procedure-2, the title compound (71 mg) wasprepared from 4-methylthiazole-5-carbonyl chloride (70 mg, 0.44 mmol)and intermediate 32 (120 mg, 0.4 mmol) as a white solid. M.P.: 161-164°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.47 (s, 1H), 9.14 (s, 1H), 7.86(d, J 8.7, 2H), 7.63 (d, J 8.7, 2H), 3.29 (s, 3H), 2.01-1.94 (m, 1H),0.90-0.86 (m, 2H), 0.65-0.61 (m, 2H). MS (m/z): 425.08 [M−H]⁻.

Example 81N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-(pyridin-2-yl)acetamidehydrochloride

Following the general procedure-1, the title compound (32 mg) wasprepared from 2-(pyridin-2-yl)acetic acid acid (80 mg, 0.47 mmol) andintermediate 32 (120 mg, 0.40 mmol) as a white solid. M.P.: 215-219° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.82 (s, 1H), 8.78 (d, J 5, 2H), 8.31(t, J 7, 1H), 7.86 (d, J 7.8, 1H), 7.81-7.73 (m, 3H), 7.59 (d, J 8.7,1H), 4.20 (s, 2H), 2.00-1.91 (m, 1H), 0.90-0.81 (m, 2H), 0.63-0.54 (m,2H). MS (m/z): 421.23 [M+H−HCl]⁺.

Example 82N-{⁴-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methyl-1,2,3-thiadiazole-5-carboxamide

Following the general procedure-2, the title compound (33 mg) wasprepared from 4-methyl-1,2,3-thiadiazole-5-carbonyl chloride (147 mg,0.76 mmol) and intermediate 33 (200 mg, 0.76 mmol) as a white solid.M.P.: 105-112° C. ¹H-NMR (6 ppm, DMSO-d₆, 400 MHz): 11.17 (s, 1H), 7.93(d, J 12.2, 1H), 7.72-7.60 (m, 2H), 6.6 (s, 1H), 3.31 (s, 3H), 1.66-1.58(m, 1H), 0.94-0.84 (m, 2H), 0.8-0.72 (m, 2H). MS (m/z): 410.09 [M−H]⁻.

Example 83N-{⁴-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methylthiazole-5-carboxamide

Following the general procedure-2, the title compound (37 mg) wasprepared from 4-methylthiazole-5-carbonyl chloride (60 mg, 0.37 mmol)and intermediate 33 (100 mg, 0.37 mmol) as a white solid. M.P.: 95-97.6°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.66 (s, 1H), 9.17 (s, 1H), 7.92(d, J 12.5, 1H), 7.64 (d, J 2.4, 2H), 6.61 (s, 1H), 2.63 (s, 3H),1.70-1.56 (m, 1H), 1.00-0.89 (m, 2H), 0.80-0.72 (m, 2H). MS (m/z):408.98 [M−H]⁻.

Example 84N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-5-methylisoxazole-4-carboxamide

Following the general procedure-2, the title compound (37 mg) wasprepared from 5-methylisoxazole-4-carbonyl chloride (73 mg, 0.50 mmol)and intermediate 33 (120 mg, 0.42 mmol) as a white solid. M.P.: 125-128°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.47 (s, 1H), 9.08 (s, 1H), 7.95(dd, J 2, 12.9, 1H), 7.68-7.60 (m, 2H), 6.62 (s, 1H), 2.69 (s, 3H),1.67-1.58 (m, 1H), 0.95-0.85 (m, 2H), 0.80-0.72 (m, 2H). MS (m/z):392.61 [M−H]⁻.

Example 85N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-3,5-dimethylisoxazole-4-carboxamide

Following the general procedure-2, the title compound (54 mg) wasprepared from intermediate 33 (200 mg, 0.70 mmol) and3,5-dimethylisoxazole-4-carboxylic acid (120 mg, 0.85 mmol) as a whitesolid. M.P.: 163-165° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.50 (s,1H), 7.91 (dd, J 2, 12.6, 1H), 7.65 (t, J 8.6, 1H), 7.57 (dd, J 2, 8.8,1H), 6.61 (s, 1H), 2.56 (s, 3H), 2.34 (s, 3H), 1.94-1.87 (m, 1H),0.94-0.86 (m, 2H), 0.80-0.72 (m, 2H). MS (m/z): 409.04 [M+H]⁺.

Example 86N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2-methylbenzamide

Following the general procedure-1, the title compound (24 mg) wasprepared from intermediate 33 (200 mg, 0.7 mmol) and o-toluic acid (153mg, 1.1 mmol) as a pale-yellow solid. M.P.: 141.6-143.7° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): 10.78 (s, 1H), 8.01-7.98 (m, 1H), 7.69-7.60 (m,2H), 7.50 (d, J 7.6, 1H), 7.44-7.40 (m, 1H), 7.33 (d, J 7.5, 2H), 6.61(s, 1H), 2.39 (s, 3H), 1.69-1.60 (m, 1H), 0.94-0.88 (m, 2H), 0.80-0.72(m, 2H). MS (m/z): 401.54 [M−H]⁻.

Example 87N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2,3-difluorobenzamide

Following the general procedure-2, the title compound (156 mg) wasprepared from intermediate 33 (200 mg, 0.70 mmol) and2,3-difluorobenzoic acid (150 mg, 0.95 mmol) as a white solid. M.P.:132-135° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.03 (s, 1H), 7.96 (dd, J1.9, 12.7, 1H), 7.71-7.61 (m, 3H), 7.56-7.51 (m, 1H), 7.42-7.34 (m, 1H),6.62 (s, 1H), 1.67-1.58 (m, 1H), 0.94-0.86 (m, 2H), 0.79-0.72 (m, 2H).MS (m/z): 424.02 [M−H]⁻.

Example 88N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2,6-difluorobenzamide

Following the general procedure-1, the title compound (195 mg) wasprepared from intermediate 33 (200 mg, 0.75 mmol) and2,6-difluorobenzoic acid (189 mg, 1.2 mmol) as a white solid. M.P.:193.1-196.4° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.30 (s, 1H), 7.92(dd, J 2, 12.3, 1H), 7.69-7.58 (m, 3H), 7.29 (t, J 8.1, 2H), 6.62 (s,1H), 1.70-1.60 (m, 1H), 0.95-0.88 (m, 2H), 0.80-0.74 (m, 2H). MS (m/z):423.51 [M−H]⁻.

Example 89N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}nicotinamidehydrochloride

Following the general procedure-1,N-{4-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}nicotinamide(30 mg) from intermediate 33 (200 mg, 0.7 mmol) and nicotinic acid (138mg, 1.12 mmol) as a pale yellow solid and dissolved in THF. SaturatedHCl in diethyl ether was added to this solution at 0° C. and stirred for15 min. Solid that separated out was filtered and dried to give thetitle compound (68 mg) as an Off-white solid M.P.: 170-172° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): 10.98 (s, 1H), 9.18 (d, J 1.4, 1H), 8.84 (d, J3.7, 1H), 8.42 (d, J 8, 1H), 8.04 (dd, J 2.1, 12.6, 1H), 7.77-7.74 (m,1H), 7.70-7.65 (m, 2H), 6.62 (s, 1H), 1.69-1.59 (m, 1H), 0.96-0.88 (m,2H), 0.76-0.70 (m, 2H). MS (m/z): 390.93 [M−H−HCl]⁺.

Example 90N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}isonicotinamidehydrochloride

Following the general procedure-1,N-{4-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}isonicotinamide(60 mg) prepared from intermediate 33 (200 mg, 0.7 mmol) andisonicotinic acid (138 mg, 1.12 mmol) as a pale yellow solid anddissolved in THF. Saturated HCl in diethyl ether was added to thissolution at 0° C. and stirred for 15 min. Solid that separated out wasfiltered and dried to give the title compound (53 mg) as a pale-yellowsolid. M.P.: 148-153° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.12 (s,1H), 8.90 (d, J 1.9, 2H), 8.07-8.03 (m, 3H), 7.77 (dd, J 1.9, 8.8, 1H),7.68 (t, J 8.6, 1H), 6.63 (s, 1H), 1.78-1.68 (m, 1H), 0.95-0.85 (m, 2H),0.80-0.73 (m, 2H). MS (nm/z): 390.93 [M−H−HCl]⁻.

Example 91N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-3-fluoroisonicotinamide

Following the general procedure-1, the title compound (25 mg) wasprepared from intermediate 33 (200 mg, 0.7 mmol) and 3-fluoronicotinicacid (158 mg, 1.1 mmol) as a black solid. M.P.: 161-165° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): 11.17 (s, 1H), 8.80 (s, 1H), 8.61 (d, J 4.8,1H), 7.94 (d, J 11.8, 1H), 7.75 (t, J 5.2, 1H), 7.68 (t, J 8.2, 1H),7.62 (d, J 9.1, 1H), 6.62 (s, 1H), 1.70-1.58 (m, 1H), 0.96-0.88 (m, 2H),0.80-0.72 (m, 2H). MS (m/z): 408.32 [M+H]⁺.

Example 923,5-dichloro-N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}isonicotinamide

Following the general procedure-2, the title compound (86 mg) wasprepared from intermediate 33 (150 mg, 0.55 mmol) and3,5-dichloroisonicotinoyl chloride (132 mg, 0.63 mmol) as a white solid.M.P.: 218-223° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.48 (s, 1H), 8.84(s, 2H), 7.89 (dd, J 2.2, 12.04, 1H), 7.70 (t, J 8.6, 1H), 7.56 (dd, J1.6, 8.6, 1H), 6.63 (s, 1H), 1.70-1.60 (m, 1H), 0.96-0.88 (m, 2H),0.80-0.72 (m, 2H). MS (m/z): 458.33 [M−H]⁻.

Example 93N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methylpyrimidine-5-carboxamide

Following the general procedure-1, the title compound (150 mg) wasprepared from intermediate 53 (130 mg, 0.67 mmol) and intermediate 33(150 mg, 0.57 mmol) as a pale-yellow solid. M.P.: 101-103° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): 11.08 (s, 1H), 9.17 (s, 1H), 8.94 (s, 1H), 7.97(d, J 12.2, 1H), 7.70-7.61 (m, 2H), 6.62 (s, 1H), 1.70-1.57 (m, 1H),0.98-0.90 (m, 2H), 0.80-0.72 (m, 2H). MS (m/z): 403.71 [M−H]⁻.

Example 94N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-N,4-dimethylpyrimidine-5-carboxamide

N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methylpyrimidine-5-carboxamide(300 mg, 0.74 mmol) was dissolved in THF, cooled to 0° C., added sodiumhydride (35 mg, 1.48 mmol) and stirred the mixture for 30 mins at thesame temperature. Methyl Iodide (120 mg, 0.84 mmol) was added and heatedthe reaction mixture to rt. After 3h, reaction mixture quenched withwater. Work up (H₂O/AcOEt) and purification afforded the title compound(120 mg) as a pale-yellow solid. ¹H-NMR (δ ppm, CDCl₃, 400 MHz): 8.99(s, 1H), 8.41 (s, 1H), 7.46 (t, J 8.1, 1H), 7.08-7.01 (m, 2H), 6.21 (s,1H), 3.53 (s, 3H), 2.58 (s, 3H), 1.60-1.51 (m, 1H), 0.98-0.88 (m, 2H),0.70-0.60 (m, 2H). MS (m/z): 418.35 [M−H]⁻.

Example 95N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methyl-1,2,3-thiadiazole-5-carboxamide

Following the general procedure-2, the title compound (120 mg) wasprepared from 4-methyl-1,2,3-thiadiazole-5-carbonyl chloride (150 mg,0.94 mmol) and intermediate 34 (150 g, 0.47 mmol) as a white solid.M.P.: 143-147° C. ¹H-NMR (8 ppm, DMSO-d₆, 400 MHz): 11.18 (s, 1H), 7.93(dd, J 1.8, 12.5, 1H), 7.72 (t, J 8.6, 1H), 7.62 (d, J 9, 1H), 2.82 (s,3H), 1.85-1.71 (m, 1H), 0.90-0.80 (m, 2H), 0.72-0.64 (m, 2H). MS (m/z):444.04 [M−H]⁻.

Example 96N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2-(pyridin-2-yl)acetamidehydrochloride

Following the general procedure-1,N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2-(pyridin-2-yl)acetamide(150 mg) was prepared from 2-(pyridin-2-yl)acetic acid (97 mg, 0.56mmol) and intermediate 34 (150 mg, 0.47 mmol) as a white solid anddissolved in THF. Saturated HCl in diethyl ether was added to thissolution at 0° C. and stirred for 15 min. Solid that separated out wasfiltered and dried to give the title compound (25 mg) as a white solid.M.P.: 169-171° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.03 (s, 1H), 8.75(d, J 3.9, 1H), 8.29-8.20 (m, 1H), 8.88 (d, J 12.6, 1H), 7.79 (d, J 7.4,1H), 7.73-7.69 (m, 1H), 7.67 (t, J 8.7, 1H), 7.51 (d, J 8.6, 1H), 4.17(s, 2H), 1.80-1.70 (m, 1H), 0.90-0.80 (m, 2H), 0.72-0.60 (m, 2H). MS(m/z): 439.15 [M+H−HCl]⁺.

Example 971-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-3-(4-methylpyrimidin-5-yl)urea

4-methylpyrimidine-5-carboxylic acid (500 mg, 3.62 mmol) was dissolvedin acetone, water mixture (20 ml and 2 ml) and cooled to −5° C. Ethylchoroformate (0.47 ml, 4.34 mmol) was added slowly to this mixture andstirred at same temperature for 30 mins. At this stage sodium azide (470mg, 7.24 mmol) was added and stirred for 30 mins at the sametemperature. Water was added to the reaction mixture and extracted withEt₂CO and ether was removed to obtain the crude. Crude was dissolved indioxane, intermediate 33 (764 mg, 2.68 mmol) was added and refluxed for30 mins. Work up (AcOEt:H₂O) followed by purification on 60-120 meshsilica gel using EA and Peteher (10:90) as eluent afforded the titlecompound (403 mg) as a pale yellow solid. M. P.: 197.8-202.4° C. ¹H-NMR(δ ppm, DMSO-d₆, 400 MHz): 9.63 (s, 1H), 9.04 (s, 1H), 8.75 (s, 1H),8.49 (s, 1H), 7.76 (dd, J 2.2, 12.8, 1H), 7.56 (t, J 8.7, 1H), 7.33 (dd,J 1.8, 8.7, 1H), 6.60 (s, 1H), 2.48 (s, 3H), 1.64-1.57 (m, 1H),0.94-0.86 (m, 2H), 0.78-0.72 (m, 2H). MS (m/z): 419.26 [M−H]⁻.

Example 98N-{4-[5)-cyclopropyl-3-(trifluromethyl)-1H-pyrazol-1-yl]3-flurophenyl}-2,6-dichlorobenzamide

Following the general procedure-2, the title compound (15 mg) wasprepared from intermediate 48 (220 mg, 0.74 mmol) and2,6-dichloroaniline (100 mg, 0.62 mmol) as a white solid. M.P.: 175-180°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.63 (s, 1H), 8.11-8.02 (m, 2H),7.91 (t, J 7.8, 1H), 7.62 (d, J 8.2, 2H), 7.41 (t, J 8, 1H), 6.70 (s,1H), 1.73-1.64 (m, 1H), 0.97-0.90 (m, 2H), 0.84-0.77 (m, 2H). MS (m/z):455.94 [M−H]⁻.

Example 994-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)-3-fluorobenzamide

Following the general procedure-2, the title compound (100 mg) wasprepared from intermediate 48 (200 mg, 0.67 mmol) and2,3-difluoroaniline (216 mg, 0.65 mmol) as a white solid. M.P.: 175-180°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.6 (s, 1H), 8.09 (d J 9.3, 1H),8.01 (d, J 8.5, 1H), 7.88 (t, J 7.8, 1H), 7.49-7.41 (m, 1H), 7.39-7.31(m, 1H), 7.29-7.22 (m, 1H), 6.70 (s, 1H), 1.71-1.62 (m, 1H), 0.99-0.91(m, 2H), 0.82-0.74 (m, 2H). MS (m/z): 424.23 [M−H]⁻.

Example 1004-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,6-difluorophenyl)-3-fluorobenzamide

Following the general procedure-2, the title compound (15 mg) wasprepared from intermediate 48 (150 mg, 0.55 mmol) and2,6-difluoroaniline (69 mg, 0.54 mmol) as a white solid. M.P.:168.2-170.2° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.46 (s, 1H), 8.09(d, J 8, 1H), 8.03 (d, J 8.3, 1H), 7.89 (t, J 7.9, 1H), 7.50-7.40 (m,1H), 7.24 (t, J 8.2, 2H), 6.70 (s, 1H), 1.75-1.65 (m, 1H), 0.98-0.90 (m,2H), 0.81-0.74 (m, 2H). MS (m/z): 425.79 [M+H]⁺.

Example 101N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-4-methyl-1,2,3-thiadiazole-5-carboxamide

Following the general procedure-1, title compound (18 mg) was preparedfrom 4-methyl-1,2,3-thiadiazole-5-carboxylic acid (102 mg, 0.71 mmol)and intermediate 36 (120 mg, 0.45 mmol) as a pale yellow solid. M. P.170-172° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.15 (s, 1H), 8.86 (d, J2.2, 1H), 8.36 (dd, J 2.4, 8.8, 1H), 7.85 (d, J 8.8, 1H), 6.66 (s, 1H),2.85 (s, 3H), 2.60-2.50 (m, 1H), 1.08-0.98 (m, 2H), 0.82-0.74 (m, 2H).MS (nm/z): 392.79 [M−H−HCl]⁻.

Example 102N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-4-methylthiazole-5-carboxamidehydrochloride

Following the general procedure-2,N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-4-methylthiazole-5-carboxamide(45 mg) was prepared from 4-methylthiazole-5-carbonyl chloride (132 mg,0.82 mmol) and intermediate 36 (200 mg, 0.75 mmol) as a white solid anddissolved in THF. Saturated HCl in diethyl ether was added to thissolution at 0° C. and stirred for 15 min. Solid that separated out wasfiltered and dried to give the title compound (69 mg) as a pale-yellowsolid. M. P. 180-183° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.68 (s,1H), 9.18 (s, 1H), 8.85 (d, J 2.4, 1H), 8.35 (dd, J 2.5, 8.8, 1H), 7.79(d, J 8.8, 1H), 6.64 (s, 1H), 2.64 (s, 3H), 2.51-2.40 (m, 1H), 1.10-0.95(m, 2H), 0.81-0.74 (m, 2H). MS (m/z): 394.23 [M+H]⁺.

Example 103N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3,5-dimethylisoxazole-4-carboxamide

Following the general procedure-1, the title compound (34 mg) wasprepared from 3,5-dimethylisoxazole-4-carboxylic acid (101 mg, 0.71mmol) and intermediate 36 (120 mg, 0.45 mmol) as a white solid M.P.:139-142° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.47 (s, 1H), 8.82 (d, J2.5, 1H), 8.33 (dd, J 2.5, 8.8, 1H), 7.80 (d, J 8.8, 1H), 6.64 (s, 1H),2.58 (s, 3H), 2.57-2.50 (m, 1H), 2.49 (s, 3H), 1.00-0.92 (m, 2H),0.80-0.74 (m, 2H). MS (m/z): 389.67 [M−H]⁻.

Example 104N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2-methylbenzamide

Following the general procedure-1, the title compound (19 mg) wasprepared from o-toluic acid acid (58 mg, 0.43 mmol) and intermediate 36(80 mg, 0.26 mmol) as a white solid M.P.: 134-138° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 10.76 (s, 1H), 8.88 (d, J 2.4, 1H), 8.43 (dd, J 2.4,8.9, 1H), 7.79 (d, J 8.8, 1H), 7.53 (d, J 7.3, 1H), 7.44-7.40 (m, 1H),7.34-7.31 (m, 2H), 6.63 (s, 1H), 2.41 (s, 3H), 2.55-2.45 (m, 1H),1.01-0.92 (m, 2H), 0.81-0.72 (m, 2H). MS (m/z): 384.63 [M−H]⁻.

Example 1052-chloro-N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}benzamidehydrochloride

Following the generalprocedure-2,2-chloro-N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}benzamide(65 mg) was prepared from 2-chlorobenzoyl chloride (107 mg, 0.61 mmol)and intermediate 36 (150 mg, 0.56 mmol) and dissolved in THF. SaturatedHCl in diethyl ether was added to this solution at 0° C. and stirred for15 min. Solid that separated out was filtered and dried to give thetitle compound (52 mg) as a pale-yellow solid. M. P. 145-148° C. ¹H-NMR(δ ppm, DMSO-d₆, 400 MHz): 10.99 (s, 1H), 8.86 (d, J 2, 1H), 8.41 (dd, J2, 8.7, 1H), 7.81 (d, J 8.8, 1H), 7.66 (d, J 7, 1H), 7.60 (d, J 7.8,1H), 7.54 (t, J 7.3, 1H), 7.48 (t, J 7.3, 1H), 6.64 (s, 1H), 2.60-2.48(m, 1H), 1.04-0.92 (m, 2H), 0.82-0.70 (m, 2H). MS (m/z): 405.13[M−H−HCl]⁻.

Example 106N-(6-(5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)pyridin-3-yl)-2-fluorobenzamide

Following the general procedure-1, the title compound (110 mg) wasprepared from 2-fluorobenzoic acid (112 mg, 0.80 mmol) and intermediate36 (150 mg, 0.50 mmol) as a white solid M.P.: 102-106° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 10.89 (s, 1H), 8.87 (d, J 2.4, 1H), 8.40 (dd, J 2.5,8.8, 1H), 7.81 (d, J 8.8, 1H), 7.73 (dt, J 1.6, 7.5, 1H), 7.67-7.59 (m,1H), 7.44-7.34 (m, 2H), 6.64 (s, 1H), 2.58-2.50 (m, 1H), 1.02-0.94 (m,2H), 0.82-0.74 (m, 2H). MS (m/z): 389.09 [M−H]⁻.

Example 107N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2,3-difluorobenzamide

Following the general procedure-1, the title compound (22 mg) wasprepared from 2,3-difluorobenzoic acid (113 mg, 0.70 mmol) andintermediate 36 (120 mg, 0.45 mmol) as a white solid. M.P.: 151-156° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.99 (s, 1H), 8.86 (s, 1H), 8.39 (d,J 8.7, 1H), 7.82 (d, J 8.7, 1H), 7.65 (q, J 8.6, 1H), 7.55 (t, J 6.4,1H), 7.42-7.34 (m, 1H), 6.63 (s, 1H), 2.51-2.40 (m, 1H), 1.02-0.94 (m,2H), 0.82-0.74 (m, 2H). MS (m/z): 406.94 [M−H]⁻.

Example 108N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2,6-difluorobenzamide

Following the general procedure-1, the title compound was prepared from2,6-difluorobenzoic acid (113 mg, 70 mmol) and intermediate 36 (120 mg,0.45 mmol) as a pale yellow solid. M. P. 157-162° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 11.30 (s, 1H), 8.83 (s, 1H), 8.39 (d, J 8.8, 1H),7.83 (d, J 8.8, 1H), 7.65-7.60 (m, 1H), 7.29 (t, J 8, 2H), 6.64 (s, 1H),2.58-2.48 (m, 1H), 1.00-0.94 (m, 2H), 0.81-0.75 (m, 2H). MS (m/z):406.87 [M−H]⁻.

Example 109N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}picolinamide

Following the general procedure-1, the title compound (200 mg) wasprepared from picolinic acid (146 mg, 1.2 mmol) and intermediate 36 (200mg, 0.75 mmol) as a white solid M.P.: 159-162° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 11.19 (s, 1H), 9.09 (d, J 2.4, 1H), 8.78 (d, J 4,1H), 8.62 (dd, J 2.6, 8.8, 1H), 8.19 (d, J 7.8, 1H), 8.10 (td, J 1.7,7.7, 1H), 7.80 (d, J 8.8, 1H), 7.73-7.70 (m, 1H), 6.63 (s, 1H),2.66-2.58 (m, 1H), 1.06-0.98 (m, 2H), 0.84-0.76 (m, 2H). MS (m/z):372.09 [M−H]⁻.

Example 110N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-methylpicolinamide

Following the general procedure-1, the title compound (140 mg) wasprepared from 3-methylpicolinic acid (163 mg, 1.2 mmol) and intermediate36 (200 mg, 0.75 mmol) as an off-white solid M.P.: 197-199° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): 11.05 (s, 1H), 9.00 (d, J 2.5, 1H), 8.58-8.53(m, 2H), 7.84 (d, J 7.8, 1H), 7.79 (d, J 8.8, 1H), 7.57-7.54 (m, 1H),6.63 (s, 1H), 2.60 (s, 3H), 2.55-2.45 (m, 1H), 1.04-0.94 (m, 2H),0.81-0.74 (m, 2H). MS (m/z): 385.53 [M−H]⁻.

Example 111N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}nicotinamidehydrochloride

Following the general procedure-1,N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}nicotinamide(200 mg) was prepared from nicotinic acid (132 mg, 1.2 mmol) andintermediate 36 (290 mg, 0.67 mmol) as a white solid and dissolved inTHF. Saturated HCl in diethyl ether was added to this solution at 0° C.and stirred for 15 min. Solid that separated out was filtered and driedto give the title compound (192 mg) as a white solid M.P.: 211-213° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.11 (s, 1H), 9.27 (d, J 2, 1H), 8.98(d, J 2, 1H), 8.89-8.86 (m, 1H), 8.59-8.51 (m, 1H), 8.48-8.46 (m, 1H),7.83 (d, J 8.8, 1H), 7.79-7.73 (m, 1H), 6.65 (s, 1H), 2.58-2.50 (m, 1H),1.04-0.94 (m, 2H), 0.81-0.74 (m, 2H). MS (m/z): 371.90 [M−H]⁻.

Example 112N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2-methylnicotinamide hydrochloride

Following the general procedure-1,N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2-methylnicotinamide(35 mg) was prepared from 2-methylnicotinic acid (110 mg, 0.80 mmol) andintermediate 36 (150 mg, 0.5 mmol) as a white solid and dissolved inTHF. Saturated HCl in diethyl ether was added to this solution at 0° C.and stirred for 15 min. Solid that separated out was filtered and driedto give the title compound (20 mg) as a white solid. M.P.: 241-245° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.15 (s, 1H), 8.89 (d, J 2.5, 1H),8.74 (d, J 4.1 1H), 8.42 (dd, J 2.6, 8.8, 1H), 8.32 (d, J 7.7, 1H), 7.83(d, J 8.8, 1H), 7.72-7.64 (m, 1H), 6.65 (s, 1H), 2.70 (s, 3H), 2.58-2.50(m, 1H), 1.00-0.95 (m, 2H), 0.81-0.76 (m, 2H). MS (m/z): 385.64[M−H−HCl]⁻.

Example 113N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}isonicotinamidehydrochloride

Following the general procedure-1,N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}isonicotinamide(160 mg) was prepared from isonicotinic acid (132 mg, 1.2 mmol) andintermediate 36 (290 mg, 0.67 mmol) as an off-white solid and dissolvedin THF. Saturated HCl in diethyl ether was added to this solution at 0°C. and stirred for 15 min. Solid that separated out was filtered anddried to give the title compound (137 mg) as an yellow solid M.P.:186-188° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.23 (s, 1H), 8.99 (d, J2.5, 1H), 8.94 (d, J 6.2, 2H), 8.47 (dd, J 2.5, 8.8, 1H), 8.14 (d, J6.2, 2H), 7.85 (d, J 8.8, 1H), 6.65 (s, 1H), 2.60-2.50 (m, 1H),1.04-0.94 (m, 2H), 0.80-0.73 (m, 2H). MS (m/z): 371.65 [M−H]⁻.

Example 114N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide

Following the general procedure-1, the title compound (90 mg) wasprepared from 3-fluoroisonicotinic acid (113 mg, 0.80 mmol) andintermediate 36 (150 mg, 0.5 mmol) as a brown solid M.P.: 162-164° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.16 (s, 1H), 8.86 (d, J 2.5, 1H),8.80 (d, J 1, 1H), 8.64-8.62 (m, 1H), 8.39 (dd, J 2.6, 8.8, 1H), 7.84(d, J 8.8, 1H), 7.76 (t, J 5.4, 1H), 6.65 (s, 1H), 2.592.50 (m, 1H),1.05-0.97 (m, 2H), 0.81-0.74 (m, 2H). MS (m/z): 389.60 [M−H]⁻.

Example 1153,5-dichloro-N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}isonicotinamide

Following the general procedure-2, the title compound (45 mg) wasprepared from intermediate 36 (200 mg, 0.75 mmol) and3,5-dichloroisonicotinic acid (390 mg, 1.56 mmol) as a pale-yellowsolid. M.P.: 223-225° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.49 (s,1H), 8.84 (s, 2H), 8.80 (d, J 2.6, 1H), 8.37 (dd, J 2.6, 8.8, 1H), 7.86(d, J 8.8, 1H), 6.65 (s, 1H), 2.60-2.52 (m, 1H), 1.02-0.94 (m, 2H),0.82-0.74 (m, 2H). MS (m/z): 441.94 [M−H]⁻.

Example 116N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-4-methylpyrimidine-5-carboxamide

Following the general procedure-1, the title compound (17 mg) wasprepared from intermediate 36 (200 mg, 0.75 mmol) and intermediate 53(123 mg, 0.89 mmol) as an off-white solid. M.P.: 159.2-160.3° C. ¹H-NMR(δ ppm, DMSO-d₆, 400 MHz): 11.08 (s, 1H), 9.17 (s, 1H), 8.96 (s, 1H),8.86 (s, 1H), 8.45-8.38 (m, 1H), 7.83 (d, J 6.9, 1H), 6.65 (s, 1H), 2.61(s, 3H), 2.50-2.40 (m, 1H), 1.02-0.90 (m, 2H), 0.86-0.70 (m, 2H). MS(m/z): 386.77 [M−H]⁻.

Example 117N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2-(pyridin-2-yl)acetamidehydrochloride

Following the general procedure-1,N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}2-(pyridin-2-yl)acetamide(200 mg) was prepared from 2-(pyridin-2-yl)acetic acid (207 mg, 1.2mmol) and intermediate 36 (200 mg, 0.75 mmol) as an off-white solid anddissolved in THF. Saturated HCl in diethyl ether was added to thissolution at 0° C. and stirred for 15 min. Solid that separated out wasfiltered and dried to give the title compound (210 mg) as an Off-whitesolid M.P.: 179-181° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.38 (s, 1H),8.90 (dd, J 0.8, 5.7, 1H), 8.82 (d, J 2.5, 1H), 8.54 (t, J 6.7, 1H) 8.30(dd, J 2.6, 8.8, 1H), 8.06 (d, J 8, 1H), 7.96 (t, J 6.7, 1H), 7.77 (d, J8.8, 1H), 6.63 (s, 1H), 4.41 (s, 2H), 2.50-2.41 (m, 1H), 1.00-0.91 (m,2H), 0.79-0.72 (m, 2H). MS (m/z): 385.60 [M−H−HCl]⁻.

Example 118N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2-(pyridin-4-yl)acetamidehydrochloride

Following the general procedure-1,N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-2-(pyridin-4-yl)acetamide(280 mg) was prepared from 4-(pyridin-4-yl)acetic acid (310 mg, 1.78mmol) and intermediate 36 (300 mg, 1.12 mmol) as an off-white solid anddissolved in THF. Saturated HCl in diethyl ether was added to thissolution at 0° C. and stirred for 15 min. Solid that separated out wasfiltered and dried to give the title compound (68 mg) as an Off-whitesolid M.P.: 185.2-188° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.26 (s,1H), 8.87 (d, J 6.6, 2H), 8.81 (d, J 2.5, 1H), 8.30 (dd, J 2.6, 8.8,1H), 8.06 (d, J 6.6, 2H), 7.76 (d, J 8.8, 1H), 6.62 (s, 1H), 4.19 (s,2H), 2.52-2.42 (s, 1H), 1.00-0.91 (m, 2H), 0.80-0.72 (m, 2H). MS (m/z):385.53 [M−H−HCl]⁻.

Example 119N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methylpyrimidine-5-carboxamide

Step-1: Intermediate 34 (1.83 g, 5.72 mmol) and t-Butylacetoacetate (1.9ml, 11.4 mmol) were dissolved in xylene (5 ml) and heated to 145° C. f°r 90 mins. Reaction mixture was cooled to rt to obtain a solid. Solidthat formed was filtered, washed with petether and dried to obtainN-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-oxobutanamide(1.6 g).

Step-2:N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3-oxobutanamide(1.6 g, 3.98 mmol) and N,N-Dimethylformamide dimethylacetal (2.6 g, 21.9mmol) were mixed and stirred at rt for overnight. Workup (AcOEt/H₂O)followed by purification on 60-120 mesh silicagel using AcOEt andPeteher (1:1) as eluent affordedN-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-[(dimethylamino)methylene]-3-oxobutanamide(1.3 g).

Step-3:N-{4-[4-chloro-5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-2-[(dimethylamino)methylene]-3-oxobutanamide(1.3 g, 2.8 mmol) and formamidine acetate (354 mg, 3.4 mmol) weredissolved in ethanol and added NaOEt (202 mg, 3.4 mmol). The abovemixture was refluxed for 3 h. Ethanol was removed on rotavapour andworked up (H2O/AcOEt) to obtain the crude. Crude was purified by columnon 60-120 mesh silica gel using AcOEt and Petether (35:65) as eluent toobtain the title compound (150 mg) as a pale-yellow solid. M.P.:183-185° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.11 (s, 1H), 9.17 (s,1H), 8.95 (s, 1H), 7.99 (dd, J 1.8, 12.4, 1H), 7.71 (t, J 8.7, 1H), 7.62(d, J 8.7, 1H), 2.60 (s, 3H), 1.81-1.72 (m, 1H), 0.89-0.81 (m, 2H),0.74-0.67 (m, 2H). MS (m/z): 405.89 [M+H−Cl]⁺.

Example 1201-{6-[3-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-(4-methylthiazol-5-yl)urea

4-methylthiazole-5-carboxylic acid (300 mg, 2.09 mmol) was dissolved inacetone, water mixture (15 ml and 1.5 ml) and cooled to −5° C. Ethylchoroformate (270 mg, 2.5 mmol) was added slowly to this mixture andstirred at same temperature for 30 mins. At this stage sodium azide (270mg, 4.2 mmol) was added and stirred for 30 mins at the same temperature.Water was added to the reaction mixture and extracted with Et₂CO andether was removed to obtain the crude. Crude was dissolved in dioxane,intermediate 36 (240 mg, 0.89 mmol) was added and refluxed for 30 mins.Work up (AcOEt:H₂O) followed by purification on 60-120 mesh silica gelusing EA and Peteher (45:50) as eluent afforded the title compound (200mg) as a pale yellow solid. M. P.: 244-247° C. ¹H-NMR (δ ppm, DMSO-d₆,400 MHz): 9.49 (s, 1H), 9.45 (s, 1H), 8.60-8.53 (m, 2H), 8.20 (m, 1H),7.70 (m, 1H), 6.60 (s, 1H), 2.30 (s, 3H), 1.84-1.74 (m, 1H), 1.06-0.96(m, 2H), 0.82-0.72 (m, 2H). MS (m/z): 409.06 [M+H]⁺.

Example 1216-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,3-difluorophenyl)nicotinamide

Following the general procedure-2, the title compound (100 mg) wasprepared from intermediate 50 (220 mg, 0.74 mmol) and2,3-difluoroaniline (100 mg, 0.77 mmol) as a white solid. M.P.: 155-160°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.66 (s, 1H), 9.10 (d, J 2.2, 1H),8.6 (dd, J 2.3, 8.6, 1H), 8.00 (d J 8.6, 1H), 7.47-7.44 (m, 1H),7.35-7.30 (m, 1H), 7.29-7.23 (m, 1H), 6.74 (s, 1H), 2.90-2.72 (m, 1H),1.10-1.00 (m, 2H), 0.90-0.81 (m, 2H). MS (m/z): 407.22[M−H]⁻.

Example 1226-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,6-difluorophenyl)nicotinamide

Following the general procedure-2, the title compound (36 mg) wasprepared from intermediate 50 (150 mg, 0.46 mmol) and2,6-difluoroaniline (61 mg, 0.46 mmol) as a white solid. M.P.: 192-194°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.52 (s, 1H), 9.11 (d, J 2.1, 1H),8.58 (dd, J 2.1, 8.6, 1H), 8.02 (d, J 8.4, 1H), 7.50-7.40 (m, 1H), 7.24(t, J 8.12, 2H), 6.75 (s, 1H), 2.80-2.70 (m, 1H), 1.09-1.00 (m, 2H),0.88-0.80 (m, 2H).

Example 123N-{6-[4-chloro-5-cyclopropyl-3-trifluoromethyl-1H-pyrazol-1-yl]pyridin-3-yl}-4-methylthiazole-5-carboxamide

Following the general procedure-2, the title compound (21 mg) wasprepared from 4-methylthiazole-5-carbonyl chloride (52 mg, 0.36 mmol)and intermediate 37 (100 mg, 0.36 mmol) as a white solid. M.P.: 144-149°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.68 (s, 1H), 9.17 (s, 1H), 8.87(s, 1H), 8.37 (d, J 7.32, 1H), 7.77 (d, J 8.2, 1H), 2.65 (s, 3H),2.21-2.08 (m, 1H), 1.93-1.84 (m, 2H), 1.71-1.60 (m, 2H). MS (m/z):425.95 [M−H]⁻.

Example 124N-{2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-5-yl}-2,6-difluorobenzamide

Following the general procedure-2, the title compound (31 mg) wasprepared from intermediate 38 (150 mg, 0.55 mmol) and2,6-difluoroaniline (98 mg, 0.46 mmol) as a white solid. M.P.:279.7-281.2° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.54 (s, 1H), 9.24(s, 2H), 7.71-7.62 (m, 1H), 7.31 (t, J 8.1, 2H), 6.67 (s, 1H), 2.60-2.50(m, 1H), 1.02-0.94 (m, 2H), 0.82-0.74 (m, 2H). MS (n/z): 409.90 [M+H]⁺.

Example 125N-{4-[5-(fluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide

Following the general procedure-1, the title compound (110 mg) wasprepared from 4-methylthiazole-5-carboxylic acid (165 mg, 1.15 mmol) andintermediate 39 (150 mg, 0.58 mmol) as an off-white solid M.P.:123.9-125.3° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.51 (s, 1H), 9.15(s, 1H), 7.88 (d, J 8.9, 21-), 7.57 (d, J 8.9, 2H), 7.23 (d, J 2.6, 1H),5.53 (d, J 48.04, 2H), 2.62 (s, 3H). MS (m/z): 382.86 [M−H]⁻.

Example 126N-{4-[5-(difluoromethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methylthiazole-5-carboxamide

Following the general procedure-1, the title compound (70 mg) wasprepared from 4-methylthiazole-5-carboxylic acid (132 mg, 0.9 mmol) andintermediate 40 (150 mg, 0.58 mmol) as a white solid M.P.: 124-126° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.53 (s, 1H), 9.15 (s, 1H), 7.88 (d,J 8.8, 2H), 7.59 (d, J 8.8, 2H), 7.42 (s, 1H), 7.26 (t, J 52.9, 1H),2.62 (s, 3H). MS (m/z): 400.58 [M−H]⁻.

Example 1273,5-dichloro-N-[4-(3,5-dicyclopropyl-1H-pyrazol-1-yl)-3-fluorophenyl]isonicotinamide

Following the general procedure-2, the title compound (21 mg) wasprepared from intermediate 28 (500 mg, 1.94 mmol) and2,6-dichloroisonicotinic acid (380 mg, 1.97 mmol) as a yellow solid.M.P.: 279.7-281.2° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.37 (s, 1H),8.83 (s, 2H), 7.81 (dd, J 2, 12.1, 1H), 7.58-7.48 (m, 2H), 5.76 (s, 1H),1.89-1.80 (m, 1H), 1.50-1.41 (m, 1H), 0.90-0.78 (m, 4H), 0.66-0.54 (m,4H). MS (m/z): 431.02 [M−H]⁻

Example 128N-(2-chloro-6-fluorophenyl)-4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorobenzamide

Following the general procedure-2, the title compound (21 mg) wasprepared from intermediate 48 (500 mg, 1.94 mmol) and2-Chloro-6-fluoroaniline (380 mg, 1.97 mmol) as a white solid. M.P.:148-152° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.51 (s, 1H), 8.09 (d, J10.7, 1H), 8.04 (d, J 8.1, 1H), 7.90 (t, J 7.8, 1H), 7.50-7.35 (m, 3H),6.70 (s, 1H), 1.73-1.65 (m, 1H), 0.97-0.90 (m, 2H), 0.80-0.73 (m, 2H).MS (m/z): 442.08 [M+H]⁺.

Example 129N-{2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-5-yl}-4-methylthiazole-5-carboxamide

Following the general procedure-2, the title compound (86 mg) wasprepared from intermediate 38 (100 mg, 0.37 mmol) and4-methylthiazole-5-carbonyl chloride (72 mg, 0.45 mmol) as a whitesolid, M.P.: 148-152° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.81 (s,1H), 9.23 (s, 2H), 9.20 (s, 1H), 6.67 (s, 1H), 2.66 (s, 3H), 2.55-2.46(m, 1H), 1.06-0.97 (m, 2H), 0.81-0.74 (m, 2H). MS (m/z): 395.04 [M+H]⁺.

Example 130N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-difluorophenyl}-4-methylpyrimidine-5-carboxamide

Step-1: Intermediate 35 (1 g, 3.3 mmol) and t-Butylacetoacetate (782 mg,4.94 mmol) were dissolved in xylene (3 ml) and heated to 145° C. for 90mins. Reaction mixture was cooled to rt to obtain a solid. Solid thatformed was filtered, washed with petether and dried to obtainN-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-difluorophenyl}-3-oxobutanamide(1.0 g).

Step-2:N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)-3,5-difluorophenyl)-3-oxobutanamide(1 g, 2.6 mmol) and N,N-Dimethylformamide dimethylacetal (1.7 g, 14.2mmol) were mixed and stirred at rt for overnight. Workup (AcOEt/H₂O)followed by purification on 60-120 mesh silicagel using AcOEt andPeteher (1:1) as eluent affordedN-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-difluorophenyl}-2-[(dimethylamino)methylene]-3-oxobutanamide(0.7 g).

Step-3:N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3,5-difluorophenyl}-2-[(dimethylamino)methylene]-3-oxobutanamide(700 mg, 1.6 mmol) and formamidine acetate (282 mg, 2.7 mmol) weredissolved in ethanol and added NaOEt (120 mg, 3.4 mmol). The abovemixture was refluxed for 3 hr. Ethanol was removed on rotavapour andworked up (H₂O/AcOEt) to obtain the crude. Crude was purified by columnon 60-120 mesh silica gel using AcOEt and Petether (35:65) as eluent toobtain the title compound (34 mg) as a pale-yellow solid. M.P.: 147-150°C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.25 (s, 1H), 9.18 (s, 1H), 8.96(s, 1H), 7.73 (d, J 9.9, 21H), 6.69 (s, 1H), 2.61 (s, 3H), 1.65-1.56 (m,1H), 0.95-0.86 (m, 2H), 0.80-0.72 (m, 2H). MS (m/z): 424.09 [M+H]⁺.

Example 131N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-1-phenylcyclobutanecarboxamide

Following the general procedure-2, the title compound (26 mg) wasprepared from intermediate 33 (100 mg, 0.37 mmol) and intermediate 61(72 mg, 0.45 mmol) as a white solid. M.P.: 72-76° C. ¹H-NMR (δ ppm,DMSO-d₆, 400 MHz): 9.85 (s, 1H), 7.89 (d, J 11.4, 1H), 7.62-7.51 (m,2H), 7.49-7.43 (m, 2H), 7.36 (t, J 7.8, 2H), 7.28-7.22 (m, 1H), 6.58 (s,1H), 2.91-2.80 (m, 2H), 1.90-1.78 (m, 2H), 1.60-1.50 (m, 1H), 0.90-0.80(m, 2H), 0.79-0.68 (m, 2H). 444.18 [M+H]⁺

Example 132N-{4-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-4-methyloxazole-5-carboxamide

Following the general procedure-2, the title compound (26 mg) wasprepared from intermediate 33 (100 mg, 0.37 mmol) and4-Methyloxazole-5-carboxylic acid (70 mg, 0.55 mmol) as a white solid.M.P.: 148-150° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.74 (s, 1H), 8.59(s, 1H), 8.0 (d, J 12.6, 1H), 7.77 (d, J 8.4, 1H), 7.63 (t, J 8.8, 1H),6.61 (s, 1H), 2.44 (s, 3H), 2.66-2.58 (m, 1H), 0.94-0.84 (m, 2H),0.80-0.71 (m, 2H). MS (m/z): 395.04 [M+H]⁺.

Example 133N-{2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-5-yl}-4-methylpyrimidine-5-carboxamide

Step-1: Intermediate 38 (1.1 g, 4.08 mmol) and t-Butylacetoacetate (1.29g, 8.17 mmol) were dissolved in xylene (2.9 ml) and heated to 145° C.for 90 mins. Reaction mixture was cooled to rt to obtain a solid. Solidthat formed was filtered, washed with petether and dried to obtainN-{2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-5-yl}-3-oxobutanamide(445 mg).

Step-2:N-{2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-5-yl}-3-oxobutanamide(445 mg, 1.3 mmol) and N,N-Dimethylformamide dimethylacetal (859 mg, 7.2mmol) were mixed and stirred at rt for overnight. Workup (AcOEt/H₂O)followed by purification on 60-120 mesh silicagel using AcOEt andPeteher (1:1) as eluent affordedN-{2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-5-yl}-2-[(dimethylamino)methylene]-3-oxobutanamide(0.3 g).

Step-3:N-{2-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyrimidin-5-yl}-2-[(dimethylamino)methylene]-3-oxobutanamide(0.3 g, 0.78 mmol) and formamidine acetate (98 mg, 0.94 mmol) weredissolved in ethanol and added NaOEt (60 mg, 0.94 mmol). The abovemixture was refluxed for 3 h. Ethanol was removed on rotavapour andworked up (H₂O/AcOEt) to obtain the crude. Crude was purified by columnon 60-120 mesh silica gel using AcOEt and Petether (1:1) as eluent toobtain the title compound (12 mg) as a brown solid. M.P.: 201-203° C.¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 11.29 (s, 1H), 9.26 (s, 2H), 9.19 (s,1H), 8.99 (s, 1H), 6.68 (s, 1H), 2.64 (s, 3H), 2.55-2.49 (m, 1H),1.02-0.94 (m, 2H), 0.83-0.75 (m, 2H). MS (m/z): 389.93 [M+H]⁺.

Example 1344-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-3-fluoro-N-(4-methylpyrimidin-5-yl)benzamide

Following the general procedure-2, the title compound (17 mg) wasprepared from intermediate 48 (120 mg, 0.41 mmol) and4-methylpyrimidin-5-amine (50 mg, 0.46 mmol) as a white solid. M.P.:150-152° C. ¹H-NMR (δ ppm, DMSO-d₆, 400 MHz): 10.52 (s, 1H), 8.94 (s,1H), 8.76 (s, 1H), 8.11 (dd, J 1.6, 10.7, 1H), 8.04 (d, J 8.1, 1H), 7.91(t, J 7.7, 1H), 6.70 (s, 1H), 2.48 (s, 3H), 1.70-1.62 (m, 1H), 0.95-0.88(m, 2H), 0.83-0.77 (m, 2H). MS (m/z): 406.03 [M+H]⁺.

Example 135N-{4-[3-cyclopropyl-5-(difluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2,6-difluorobenzamideandN-{4-[5-cyclopropyl-3-(difluoromethyl)-1H-pyrazol-1-yl]-3-fluorophenyl}-2,6-difluorobenzamide

Following the general procedure-2, the title compound (60 mg) wasprepared from intermediate 65 (90 mg, 0.36 mmol) and 2,6-difluorobenzoicacid (120 mg, 0.76 mmol) as a white solid. M.P.: 168-171° C. ¹H-NMR (δppm, DMSO-d₆, 400 MHz): 11.28 (s, 0.64H), 11.26 (s, 0.36H), 7.92 (d, J12.4, 0.64H), 7.85 (d, J 12.4, 0.36H), 7.66-7.53 (m, 3H), 7.29 (t, J8.2, 1.28H), 7.19 (t, J 8.2, 0.72H), 7.00 (t, J 53.3, 0.36H), 6.97 (t, J53.3, 0.64H), 6.57 (s, 0.36H), 6.38 (s, 0.64H), 2.0-1.94 (m, 0.36H),1.64-1.56 (m, 0.64H), 0.96-0.86 (m, 2H), 0.75-0.69 (m, 2H). MS (m/z):408.20 [M+H]+.

BIOLOGICAL ASSAYS

The properties of the compounds of this invention may be confirmed by anumber of biological/pharmacological assays. Thebiological/pharmacological assay which can be been carried out with thecompounds according to the invention and/or their pharmaceuticallyacceptable salts is exemplified below. Similarly the compounds of thepresent invention may also be tested using other assays, such ascytokine (IL-2, IL-4, IL-5, IL-10, IL-12, TNF alpha, interferon gammaetc.) estimation in Jurkat as well as human PBMCs The compounds of theinvention may also be tested in various aminal models to establish thevarious therapeutic potential of of the compounds of this invention.

1. In-Vitro CRAC Channel Inhibition Assays

1A. In-Vitro CRAC Channel Inhibition Assay in Jurkat Cells

Inhibition of CRAC channels was determined following thapsigargin(Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkatcells. (see Yasurio Yonetoky et. al Bio. & Med Chem. 14 (2006)4750-4760). Cells were centrifuged and re-suspended in equal volumes ofCa²⁺ and Mg²⁺ free Hanks buffer and Fluo-8 NW dye (ABD Bioquest, Inc.,Sunnyvale, Calif.) loading solution at 2×10⁵ cells/100 μl/well in96-well black plate. Plate is incubated at 37° C./5% CO₂ for 30 minfollowed by further 15 min incubation at room temperature. Testcompounds (DMSO stocks diluted in Ca²⁺ and Mg²⁺ free Hanks buffer) atdesired concentrations were added to the wells and incubated for 15 min.Thapsigargin (1 μM final concentration) was added to the wells andincubated for 15 min to inhibit the Sarco-endoplasmic reticulum Ca²⁺ATPase pump thereby depleting endoplasmic calcium and raising cytosoliccalcium concentrations. Store-operated calcium entry was initiated byadding extracellular Ca²⁺ to a final concentration of 1.8 mM.Fluorescence was monitored over 5 min on a plate reader (BMG Labtech.,Germany) with excitation at 485 nm and an emission wavelength at 520 nm.Data were analyzed using GraphPad Prism. IC₅₀ for each compound wasdetermined based on the percent inhibition of thapsigargin-inducedcalcium influx into cells. The results are as provided in Table 1A.

TABLE 1A % inhibition IC50 Compound (1 uM) (nM) Example 1 99 62.44Example 2 100 206.7 Example 3 72.16 — Example 4 100 256.1 Example 548.52 — Example 6 41.31 — Example 7 98.98 36.35 Example 8 100 — Example9 98.6 — Example 10 49.47 — Example 11 71.86 — Example 12 90.8 — Example13 37.20 — Example 14 25.94 — Example 15 94.00 141.3 Example 16 92.85243.9 Example 17 87.50 129.6 Example 18 82.81 — Example 19 73.52 456.6Example 20 70.2 — Example 21 78.41 — Example 22 73.44 968.1 Example 2353.75 — Example 24 38.0 — Example 25 28.97 — Example 26 42.97 — Example27 91.16 — Example 28 100 60.31 Example 29 100 — Example 30 35.12 —Example 31 76.97 — Example 32 63.62 — Example 33 93.11 145.1 Example 3421.51 — Example 35 100 184.6 Example 36 68.18 223.5 Example 37 82.24181.1 Example 38 52.71 Example 39 41.26 851.4 Example 40 12.62 — Example41 0 — Example 42 26.19 — Example 43 9.34 — Example 44 63.44 — Example45 72.26 436.1 Example 46 0.26 — Example 47 10.38 — Example 48 12.34 —Example 49 100 65.49 Example 50 29.77 — Example 51 0 — Example 52 100183.6 Example 53 99.42 72.03 Example 54 0 — Example 55 100 — Example 56100 63.17 Example 57 83.77 124.5 Example 58 40.53 — Example 59 0.57 —Example 60 83.73 119.7 Example 61 100 — Example 62 100 — Example 6339.07 — Example 64 100 — Example 65 97.89 — Example 66 100 254.7 Example67 100 20.37 Example 68 61.47 — Example 69 74.57 — Example 70 68.9 —Example 71 100 604.3 Example 72 100 48.22 Example 73 67.98 — Example 74100 48.02 Example 75 0 — Example 76 92.31 269.0 Example 77 44.02 —Example 78 100 34.11 Example 79 100 123.8 Example 80 81.63 194 Example81 56.06 — Example 82 100 35.72 Example 83 100 48.17 Example 84 10020.79 Example 85 76.61 — Example 86 86.64 147.2 Example 87 91.57 32.59Example 88 100 98.58 Example 89 100 205.7 Example 90 100 232.0 Example91 100 159.1 Example 92 95.79 159.3 Example 93 90 81.25 Example 94 45.44— Example 95 100 — Example 96 18 — Example 97 97.01 600.3 Example 9885.63 — Example 99 56.18 — Example 100 86.73 99.71 Example 101 93.01149.6 Example 102 34.90 — Example 103 19.35 — Example 104 100 22.96Example 105 71.23 Example 106 100 60.0 Example 107 96.96 70.32 Example108 96.16 50.58 Example 109 6.18 — Example 110 78.40 — Example 111 10047.21 Example 112 36.44 — Example 113 100 62.56 Example 114 88.65 37.58Example 115 51.28 — Example 116 15.37 — Example 117 0 — Example 11820.95 — Example 119 40.49 — Example 120 0 — Example 121 23.12 — Example122 100 72.11 Example 123 31.0 — Example 124 86.16 295.4 Example 125 100373.4 Example 126 100 52.62 Example 127 66.27 — Example 128 100 —Example 129 28.28 — Example 130 5.31 — Example 131 0 — Example 132 85.15— Example 133 5.62 — Example 134 18.59 — Example 135 100 —1B. In-Vitro CRAC Channel Inhibition Assay in NCI-H460 Cancer Cell Line

Inhibition of CRAC channels was determined following thapsigargin(Sigma, Cat # T9033) induced endoplasmic calcium release in NCI-H460cells (National Centre For Cell Science (NCCS), Pune).

Cells (30,000 per well) were plated overnight in complete RPMI medium.Medium was substituted with Ca²⁺ and Mg²⁺ free Hanks buffer and Fluo-8NW dye (ABD Bioquest, Inc., Sunnyvale, Calif.) loading solution in96-well black plate. Plate was incubated at 37° C./5% CO₂ for 30 minfollowed by further 15 min incubation at room temperature. Testcompounds (DMSO stocks diluted in Ca²⁺ and Mg²⁺ free Hanks buffer) atdesired concentrations were added to the wells and incubated for 15 min.Thapsigargin (1 μM final concentration) was added to the wells andincubated for 15 min to inhibit the Sarco-endoplasmic reticulum Ca²⁺ATPase pump thereby depleting endoplasmic calcium and raising cytosoliccalcium concentrations. Store-operated calcium entry was initiated byadding extracellular Ca²⁺ to a final concentration of 2.5 mM.Fluorescence was monitored over 30 min on a plate reader (BMG Labtech.,Germany) with excitation at 485 nm and an emission wavelength at 520 nm.Data were analyzed using GraphPad Prism. IC₅₀ for each compound wasdetermined based on the percent inhibition of Thapsigargin-inducedcalcium influx into cells. The results are as provided in Table 2.

1C. In-Vitro Cell Proliferation Assay in NCI-H460 Cancer Cell Line(Anticancer Activity)

Growth inhibition assays were carried out using 10% FBS supplementedmedia. Cells were seeded at a concentration of 5000 cells/well in a96-well plate. Test compound at a concentration range from 0.01 to 10000nM were added after 24 h. Growth was assessed using the3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) dyereduction test at 0 h (prior to the addition of the test compound) and48 h after the addition of test compound. Absorbance was read on aFluostar Optima (BMG Labtech, Germany) at a wave length of 450 nm. Datawere analysed using GraphPad Prism. IC-50 for each compound wasdetermined based on the % inhibition due to the test compound comparedto the control. The results are as provided in Table 2.

For methods of cell proliferation assay, see, for example, Mosmann. T.,Journal of Immunological Methods, 65 (1-2), 55-63, (1983).

TABLE 2 NCI-H460 Cell Ca assay NCI-H460 Cell line assay % inhibition %inhibition Compound @ 1 μM IC 50 nM @ 10 μM G1 50 nM Example 1 93.18 —31 — Example 2 100 — — 197.3 Example 6 85.96 — 35 — Example 9 86.85 — 14— Example 21 — — 41 — Example 52 78.23 — 34 — Example 53 84.58 — 22 —Example 55 100 — — 613.4 Example 90 — — 90.73 304.9 Example 91 — — 92.711365 Example 92 — — 100 —2. In Vitro Inhibition of Cytokine Release in Jurkat Cells, Human WholeBlood and Peripheral Blood Mononuclear Cells (PBMC).

Inhibition of cytokine IL-2, IL-4, IL-5 and TNF a was determined asdescribed below.

a. Inhibition of IL-2 in Jurkat cells: Cells were incubated with desiredconcentrations of the inhibitor for 15 min. Cytokine release was inducedby the addition of Concanavalin A (25 μg/ml)+Phorbol Myristate Acetate(50 ng/ml) for IL-2 & TNFα or with Phytohemagglutinin (5 μg/ml) for IL-4& IL-5 and incubated at 37° C. in an atmosphere containing 95% CO₂.Supernatant was collected after 20 h (IL-2 & TNFα) or 48 h (IL-4 & IL-5)for estimation of cytokines by ELISA. Data were analysed using GraphPadPrism, IC₅₀ values for each compound were determined based on thepercent inhibition due to the test compound compared to the control.

b. Inhibition of cytokine release in Human Whole Blood (HWB): Freshlycollected HWB was diluted with RPMI medium (1:4.5) and added to a96-well plate. Wells were incubated with desired concentrations of theinhibitor for 15 min. Cytokine release was induced by the addition ofConcanavalin A (25 μg/ml)+Phorbol Myristate Acetate (50 ng/ml) for IL-2& TNF or with Phytohemagglutinin (5 μg/ml) for IL-4 & IL-5 and incubatedat 37° C. in an atmosphere containing 95% CO₂. Supernatant was collectedafter 20 h (IL-2 & TNFα) or 48 h (IL-4 & IL-5) for estimation ofcytokines by ELISA. Data were analysed using GraphPad Prism. IC₅₀ valuesfor each compound were determined based on the percent inhibition due tothe test compound compared to the control.

c. Inhibition of cytokine release in PBMC: PBMC from freshly collectedHWB were isolated by density gradient using Histopaque and seeded in a96-well plate. Cells were incubated with desired concentrations of theinhibitor for 15 min. Cytokine release was induced by the addition ofConcanavalin A (25 μg/ml)+Phorbol Myristate Acetate (50 ng/ml) for IL-2& TNF or with Phytohemagglutinin (5 μg/ml) for IL-4 & IL-5 and incubatedat 37° C. in an atmosphere containing 95% CO₂. Supernatant was collectedafter 20 h (IL-2 & TNFα) or 48 h (IL-4 & IL-5) for estimation ofcytokines by ELISA. Data were analysed using GraphPad Prism. IC₅₀ valuesfor each compound were determined based on the percent inhibition due tothe test compound compared to the control. The results are as providedin Table 3.

TABLE 3 IC 50 Values in nM Jurkat Human Whole Blood PBMC Compound IL-2IL-2 TNFα IL-5 IL-4 IL-2 TNFα IL-5 IL-4 Prednisolone 35.48 77.25 — — — 3.72 — — — Example 1 — 338.5 1078   — — — — — — Example 28 — 600.446.28 54.27 197.5 Example 49 — 198.6 — — — — — — — Example 53 — 273.7125.4 61.83 21.33 121.1  146.2 79.92 Example 56 — 78.44 — — — — — — —Example 78 — 34.71 — — — 148.7  — — — Example 82 — 38.25 — — — 24.61 — —— Example 83 57.90 132.4 546.1 — — 15.69 86.82 352.5  Example 88 — 229.3— — 260.2 — — — — Example 93 140.40  65.10 147.9 172.9  141.8 52.9066.80 139.6 264.2  Example 100 — 77.81 — 56.42 256   31.42 — — — Example104 57.46 96.09 581.8 — — 66.66 21.08 — — Example 106 60.47 83.59 — — —11.50 104.6  — — Example 108 — 138  38.41 19.79 142.7 17.5  16.5   20.6555.83 Example 111 — 82.76 — — — — — — — Example 143 — 480.4 — — — — — —— Example 144 60.80 243.4 338.4 — 654.6 141.6  53.23 — 2338    Example156 131.1 — — — 39.0  — — —

Example I: Evaluation of Usefulness of CRAC Channel Modulators inVarious Anti-Inflammatory and Autoimmune Disorders Using In-Vivo AnimalModels

i. Concanavalin (Con) A induced Hepatitis in Female Balb/C mice: Con Ais often used to prepare experimental animals with high levels ofcytotoxic T-lymphocytes, because these cells are involved in thedevelopment of viral infections in humans. In this model, animals wereadministered test compounds orally 1 hour prior to intravenousadministration of Con A. Blood samples were collected after 24 hours fordetermination of Serum glutamic oxaloacetic transaminase (SGOT) andSerum glutamic pyruvic transaminase (SGPT) in serum.

Results indicated >85% reduction in serum SGOT & SGPT uponadministration of the test compound (example 69) at 10 mg/kg b.wt.

ii. TNCB induced contact hypersensitivity in female Balb/c mice: Contacthypersensitivity is a simple in vivo assay of cell-mediated immunefunction. In this procedure, exposure of epidermal cells to exogenoushaptens results in a delayed type hypersensitive reaction that can bemeasured and quantified. Briefly, 7% TNCB solution was applied to theabdominal region of 8 week old Balb/c mice. Ear thickness was measured 7days after TNCB sensitization. Compounds were administered orallyfollowed by an application of 1% TNCB to inside and outside of earpinnae. Ear thickness was measured 24 h after TNCB challenge Datademonstrated >70% reduction in ear inflammation upon administration ofthe test compound (example 69) at 10 mg/kg b.wt.

iii. Foot paw Delayed Type Hypersensitivity in male Balb/c mice: DTHswelling responses can be used to follow the activity ofimmunosuppressive molecules and/or suppressor T cells in vivo.Intradermal antigen (methylated BSA) injections were given to mice (atbase of tail) on day 0 and day 7. Compounds were administered once dailyfrom day 0 to day 10 Methylated BSA was injected into the right hindfootpad of animals on day 10. Weight difference induced by antigen wasdetermined by weighing the right and left hind paws 24 h after injectionof methylated BSA (day 11).

Daily treatment of test compound (example 69) at 10 mg/kg resultedin >40% reduction in antigen-induced paw inflammation in mice.

iv. OVA-Induced Asthma in Guinea Pigs: Pulmonary eosinophilia and airwayremodelling in conjunction with altered neural control of airway toneand airway epithelial desquamation contributes to AirwayHyper-responsiveness (AHR) in asthma. For determination of eosinophilreduction, animals were sensitized with OVA on d0, d7, and d14 followedby another round (0.1% w/v) through inhalation on d19 & d20. Compoundswere administered orally 1 h before OVA challenge (0.3%). BAL fluid wascollected on d22 for differential count and cytokine estimation. Fordetermination of change in respiratory parameters, animals weresubjected to whole body plethysmography immediately after ova challenge.Results indicated >70% reduction in blood eosinophils along with aconcurrent improvement in respiration upon administration of the testcompound (Example 69) at 10 mg/kg b.wt dose.

v. Collagen-induced arthritis in male DBA/1 Ola HSD mice: Collageninduced arthritis in rodent models have been widely used to illustrateand understand the development of the disease besides serving as asurrogate for validation of therapeutic targets for human rheumatoidarthritis. Mice were anesthetized with Isoflurane and given 150 μl ofBovine Type II collagen in Freund's complete adjuvant injections (day 0and day 21). Treatment was initiated on study day 0 and continued oncedaily, every day (po, qd). Starting on day 18, clinical scores weregiven daily for each of the paws (right front, left front, right rear,left rear) and continued till the day of sacrifice (day 34). Dailyadministration of the test compound (Example 69) at 10 mg/kg b.wtalleviated arthritic symptoms, disease progression, and incidence by 30%compared to the control animals.

Other in-vivo models wherein the effect of CRAC channel modulators invarious Anti-inflammatory and Autoimmune disorders can be tested includeChronic Experimental Autoimmune Encephalomyelitis in C57/B16J mice:Experimental Autoimmune Encephalomyelitis (EAE) is an inflammatorydisease of the central nervous system and widely used as an animal modelof Multiple Sclerosis. Animals are administered pertussis toxinintravenously and myelin oligodendrocyte glycoprotein (MOG)subcutaneously on day 0. Treatment is initiated at day 0 and continuedtill sacrifice. Development of EAE is observed between day 9 to day 42.At the end of the treatment period, animals are sacrificed forhistopathological analysis as well as cytokine estimation in plasma.

Although the invention herein has been described with reference toparticular embodiments, it is to be understood that these embodimentsare merely illustrative of the principles and applications of thepresent invention. It is therefore to be understood that numerousmodifications may be made to the illustrative embodiments and that otherarrangements may be devised without departing from the spirit and scopeof the present invention as described in the specification and theclaims.

All publications and patent and/or patent applications cited in thisapplication are herein incorporated by reference to the same extent asif each individual publication or patent application was specificallyand individually indicated to be incorporated herein by reference.

We claim:
 1. A method of treating an autoimmune disorder comprising thestep of administering to a subject in need thereof an effective amountof a compound of formula

or a pharmaceutically acceptable salt thereof, wherein Ring Hyrepresents

optionally substituted with R′″; R¹ and R² are the same or different andare independently selected from CH₃, CH₂F, CHF₂, CF₃, substituted orunsubstituted C₍₃₋₅₎cycloalkyl, CH₂—OR^(a), CH₂—NR^(a)R^(b), CN and COOHwith the proviso that: a) both R¹ and R² at the same time do notrepresent CF₃, b) both R¹ and R² at the same time do not represent CH₃,c) when R¹ is CF₃ then R² is not CH₃; and d) when R¹ is CH₃ then R² isnot CF₃; Ring Ar represents:

L₁ and L₂ together represent NH—C(═O)—; A is absent; R′″ is selectedfrom hydrogen, hydroxy, cyano, halogen, —OR^(a), —COOR^(a),—S(═O)_(q)—R^(a), —NR^(a)R^(b), C(═X)—R^(a), substituted orunsubstituted C₍₁₋₆₎ alkyl group, substituted or unsubstituted C₍₁₋₆₎alkenyl, substituted or unsubstituted C₍₁₋₆₎ alkynyl, and substituted orunsubstituted C₍₃₋₅₎cycloalkyl; each occurrence of X is independentlyselected from O, S and —NR^(a); Cy is selected from monocyclicsubstituted or unsubstituted cycloalkyl group, monocyclic substituted orunsubstituted aryl; and substituted or unsubstituted pyridyl; eachoccurrence of R^(a) and R^(b) are the same or different and areindependently selected from hydrogen, nitro, hydroxy, cyano, halogen,—OR^(c), —S(═O)_(q)—R^(c), —NR^(c)R^(d), —C(═Y)—R^(c),—CR^(c)R^(d)—C(═Y)—R^(c), —CR^(c)R^(d)—Y—CR^(c)R^(d)—,—C(═Y)—NR^(c)R^(d)—, —NRR^(d)—C(═Y)—NR^(c)R^(d)—,—S(═O)_(q)—NR^(c)R^(d)—, —NR^(c)R^(d)—S(═O)_(q)—NR^(c)R^(d)—,—NR^(c)R^(d)—NR^(c)R^(d)—, substituted or unsubstituted alkyl,substituted or unsubstituted alkenyl, substituted or unsubstitutedalkynyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted cycloalkylakyl, substituted or unsubstituted cycloalkenyl,substituted or unsubstituted heterocylyl, substituted or unsubstitutedheterocyclylalkyl, substituted or unsubstituted aryl, substituted orunsubstituted arylalkyl, substituted or unsubstituted heteroaryl, andsubstituted or unsubstituted heteroarylalkyl, or when R^(a) and R^(b)are directly bound to the same atom, they may be joined to form asubstituted or unsubstituted saturated or unsaturated 3-10 member ring,which may optionally include one or more heteroatoms which may be thesame or different and are selected from O, NR^(c) and S; each occurrenceof R^(c) and R^(d) may be same or different and are independentlyselected from hydrogen, nitro, hydroxy, cyano, halogen, substituted orunsubstituted alkyl, substituted or unsubstituted alkenyl, substitutedor unsubstituted alkynyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted cycloalkylakyl, substituted orunsubstituted cycloalkenyl, substituted or unsubstituted heterocyclicgroup, substituted or unsubstituted heterocyclylalkyl, or when two R^(c)and/or R^(d) substitutents are directly bound to the same atom, they maybe joined to form a substituted or unsubstituted saturated orunsaturated 3-10 member ring, which may optionally include one or moreheteroatoms which are the same or different and are selected from O, NHand S; each occurrence of Y is selected from O, S and —NR^(a); and eachoccurrence of q independently represents 0, 1 or 2; wherein theautoimmune disorder is chronic obstructive pulmonary disease,inflammatory bowel disease, allergic rhinitis, multiple sclerosis,psoriasis, Crohn's disease, colitis, ulcerative colitis, arthritis, bonediseases associated with increased bone resorption, or chronicobstructive airway disease.
 2. The method of claim 1, wherein theautoimmune disorder is multiple sclerosis, chronic obstructive pulmonarydisease, chronic obstructive airway disease, or psoriasis.
 3. The methodof claim 1, wherein the subject is a human subject.
 4. The method ofclaim 2, wherein the subject is a human subject.
 5. A method ofmodulating store-operated calcium (SOC) channel activity comprisingcontacting the SOC channel complex, or portion thereof, with a compoundN-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamideor a pharmaceutically acceptable salt thereof.
 6. A method of modulatingcalcium release activated calcium channel (CRAC) activity in a mammalcomprising administering to the mammal a compoundN-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamideor a pharmaceutically acceptable salt thereof.
 7. A method of inhibitingstore-operated calcium entry (SOCE) activation of nuclear factor ofactivated T cells (NFAT) in a mammal comprising administering to themammal a compoundN-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamideor a pharmaceutically acceptable salt thereof.
 8. A method of decreasingcytokine release by inhibiting the SOCE activation of NFAT in a mammalcomprising administering to the mammal a compoundN-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamideor a pharmaceutically acceptable salt thereof.
 9. A method of inhibitingimmune cell activation comprising administering to an immune cell acompoundN-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamideor a pharmaceutically acceptable salt thereof.
 10. A method ofinhibiting T-cell and/or B-cell proliferation in response to an antigen,comprising administering to a T-cell and/or B-cell cell a compoundN-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamideor a pharmaceutically acceptable salt thereof.
 11. A method ofinhibiting cytokine production in a cell comprising administering to thecell a compoundN-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamideor a pharmaceutically acceptable salt thereof.
 12. The method of claim11, wherein the cytokine is selected from IL-2, IL-4, IL-5, IL-13,GM-CSF, IFN-γ, TNFα, and combinations thereof.
 13. A method ofmodulating an ion channel in a cell, wherein the ion channel is involvedin immune cell activation, comprising administering to the cell acompoundN-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamideor a pharmaceutically acceptable salt thereof.
 14. The method of claim13, wherein the ion channel is a Ca²⁺-release-activated Ca²⁺ channel(CRAC).
 15. A method of reducing an inflammation in a subject in needthereof comprising administering to the subject an effective amount of acompoundN-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamideor a pharmaceutically acceptable salt thereof.
 16. A method of treatingan autoimmune disorder comprising the step of administering to a subjectin need thereof an effective amount of a compoundN-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamideor a pharmaceutically acceptable salt thereof, wherein the autoimmunedisorder is chronic obstructive pulmonary disease, inflammatory boweldisease, allergic rhinitis, asthma, multiple sclerosis, psoriasis,Crohn's disease, colitis, ulcerative colitis, arthritis, bone diseasesassociated with increased bone resorption, or chronic obstructive airwaydisease.
 17. The method of claim 16, wherein the autoimmune disorder ismultiple sclerosis, asthma, chronic obstructive pulmonary disease,chronic obstructive airway disease, or psoriasis.
 18. The method ofclaim 16, wherein the subject is a human subject.
 19. The method ofclaim 17, wherein the subject is a human subject.